

Publications 1972-2019

1. Edwards JA, Gale RP. Camptobrachydactyly: A new autosomal dominant trait with two probable homozygotes. *Am J Hum Genet* 1972;24:464-74.
2. Zigelboim J, Gale RP, Ossorio RC, Fahey JL. A sensitive in vitro microassay for detecting antibody-dependent cellular cytotoxicity. *Transplant* 1974;18:27-30.
3. Zigelboim J, Thieme T, Gale RP, Ossorio RC, Fahey JL. A sensitive method for detecting antibodies in human sera for tissue typing. *Transplant* 1974;18:180-5.
4. Zigelboim J, Gale RP, Chiu A, Bonavida B, Ossorio RC, Fahey JL. Antibody dependent cellular cytotoxicity: Cytotoxicity mediated by non T-lymphocytes. *Clin Immunol Immunopath* 1974;3:193-200.
5. Gale RP, Zigelboim J. Modulation of polymorphonuclear leukocyte-mediated antibody-dependent cellular cytotoxicity. *J Immunol* 1974;113:1793-1800.
6. Gale RP. Granulocyte transfusion therapy. In: *Granulocytes in human disease*. Cline MJ, moderator. *Ann Intern Med*. 1974;81:801-16.
7. Zigelboim J, Gale RP. Interspecies variability in antibody-dependent cellular cytotoxicity (ADCC). *J Immunol* 1974;113:1145-50.
8. Gale RP, Zigelboim J, Ossorio RC, Fahey JL. A comparison of human lymphoid cells in antibody-dependent cellular cytotoxicity (ADCC). *J Immunol*. 1975; 3:377-84.
9. Gale RP, Opelz G, Sparkes R, and the UCLA Bone Marrow Transplant Team. Bone marrow transplantation between mixed lymphocytes culture reactive individuals. *Transplant* 1975;20:194-7..
10. Gale RP, Zigelboim J, Ossorio RC, Fahey JL. A comparison of human lymphoid cells in antibody dependent cellular cytotoxicity. *J Immunol*. 1975;44:1047-51.
11. Gale RP, Opelz G, Sparkes R, Zigelboim J, Fahey JL, Cline MJ, Craddock C, Young LS, Feig SA, Smith J, Terasaki PI, Rupard N. Bone marrow transplantation between HLA-identical MLC-reactive siblings. *Transplant Proc*. 1975;7:833-9.
12. Gale RP. Bone marrow transplantation in aplastic anemia and leukemia. In: Cline MJ (moderator). *Bone marrow transplantation in man*. *Ann Intern Med*.1975; 83:691-709.
13. Gale RP, Opelz G, Kiuchi M, Golde DW. Thymus-dependent lymphocytes in human bone marrow. *J Clin Invest*. 1975; 56:1491-8.
14. Zigelboim J, Gale RP, Kedar E. Polymorphonuclear leukocyte Fc receptors in antibody-dependent cellular cytotoxicity (ADCC). *Transplant* 1976;21:524-6.
15. Durantez A, Zigelboim J, Gale RP. Leukemia-associated antigens detected by heterologous antisera. *J Natl Cancer Inst*. 1976; 56:1217-19.

16. Gale RP, Feig SA, Opelz G, Territo MC, Young LS, Sarna GP, Fahey JL, Cline MJ, and the UCLA Bone Marrow Transplant Team. Bone marrow transplant in acute leukemia using intensive chemoradiotherapy (SCARI-UCLA). *Transplant Pro.* 1976; 8:611-6.
17. Billing R, Rafizadeh B, Drew I, Hartman G, Gale RP, Terasaki P. Human B-lymphocyte antigens expressed by human lymphocyte and myelocytic leukemia cells. I. Detection by sera. *J Exp Med.* 1976;144:167-78.
18. Camitta BM, Thomas ED, Nathan DG, Santos G, Gordon-Smith EC, Gale RP, Rapoport JM, Storb R. Severe aplastic anemia: A prospective study of early marrow transplantation on acute mortality. *Blood* 1976;48:63-70.
19. Feig SA, Opelz G, Winter S, Falk PM, Neerhout RC, Sparkes RS, Gale RP, and the UCLA Bone Marrow Transplant Team. Successful bone marrow transplantation across mixed lymphocyte culture barrier. *Blood* 1976;48:385-91.
20. Gale RP, Cline MJ, Fahey JL, Feig SA, Opelz G, Young LS, Territo MC, Golde DW, Sparkes RS, Naeim N, Juillard G, Haskell C, Fawzy F, Sarna G, Falk P. Bone marrow transplantation in severe aplastic anemia. *Lancet* 1976;2:921-4.
21. Opelz G, Gale RP, and the UCLA Bone Marrow Transplant Team. Absence of specific mixed leukocyte culture reactivity during graft-versus-host disease and following bone marrow transplant rejection. *Transplant* 1976;22:474-7.
22. Feig SA, Falk PM, Neerhout RC, Sparkes RS, Gale RP, Opelz G, and the UCLA Bone Marrow Transplant Team. Experience with incompatible maternal donors for bone marrow transplantation. *Blut* 1977;34:1-10.
23. Gale RP, Opelz G, Golde DW. The effects of endotoxin on circulating lymphocytes in normal man. *Br J Haematol.* 1977;36:49-58.
24. Sparkes R, Crist ML, Gale RP, Feig SA, and the UCLA Bone Marrow Transplant Team. Gene markers in human bone marrow transplantation. *Vox Sang* 1977;33:202-5.
25. Sarna G, Feig S, Opelz G, Young L, Langdon E, Juillard G, Naiem F, Sparkes R, Golde D, Territo M, Haskell C, Smith G, Fawzy F, Falk P, Fahey J, Cline M, Gale RP. Bone marrow transplantation with intensive combination chemotherapy-radiation therapy (SCARI) in acute leukemia. *Ann Intern Med.* 1977;86:151-9.
26. Gale RP, Feig SA, Rippee C, Sparkes R, and the UCLA Bone Marrow Transplant Team. The ABO blood group system and bone marrow transplantation. *Blood* 1977;50:185-94.
27. Territo MC, Gale RP, Cline MJ, and the UCLA Bone Marrow Transplant Team. Neutrophil function in bone marrow transplant recipients. *Br J Haematol.* 1977; 35:245-50.
28. Yu DTY, Gale RP. Human lymphocyte subpopulations: Rabbit red blood cell rosettes. *J Immunol Meth.* 1977;16:283-98.

29. Gale RP, Sarna S, Feig SA, and the UCLA Bone Marrow Transplant Team. A cyto-reductive-conditioning program for bone marrow transplantation in resistant leukemia (SCARI). *Transplant Proc.* 1977; 9:177-80.
30. Gale RP, Rutkowsky C, Golde DW. Modulation of graft-versus-host disease in the rat. I. Effect of hydroxyurea in the mixed lymphocyte reaction and graft-versus-host reactivity. In: *Experimental Hematology Today*. Baum SJ, Ledney GD, eds. New York, Springer-Verlag, 1977, pp. 185-90.
31. Zebrowski A, Billing R, Mikulski SM, Gale RP, Terasaki PI. Human B-lymphocyte antigens expressed by lymphocytic and myelocytic leukemia cells: Lymphocyte-dependent antibody studies with rabbit antisera. *Leuk Res.* 1977; 1:13-8.
32. Opelz G, Territo MC, Gale RP, Sparkes RS, and the UCLA Bone Marrow Transplant Team. Sensitization against non-HLA antigens following bone marrow graft rejection. *Tissue Antigens* 1977; 9:209-19.
33. Opelz G, Gale RP, McClelland JD. Relationship between leukemia antigens and stimulation in mixed lymphocyte culture. *J Natl Cancer Inst.* 1977; 59:95-98.
34. Opelz G, Gale RP, and the UCLA Bone Marrow Transplant Team. Spontaneous uptake of ³H-thymidine by lymphocytes of bone marrow transplant recipients. *Transplant* 1977;23:293-4.
35. Gale RP, Cline MJ for the UCLA Acute Leukemia Study Group. High remission induction rate in acute myeloid leukemia. *Lancet* 1977;1:497-9.
36. Cline MJ, Gale RP, Golde DW. Discrete clusters of hematopoietic cells in the marrow cavity. *Blood* 1977;50:709-12.
37. Graze PR, Sparkes RS, Como R, Gale RP. Hematopoietic engraftment following transplantation of bone marrow cells carrying a Philadelphia (Ph['])-like chromosome. *Am J Hematol.* 1977;3:137-42.
38. Yu DTY, Gale RP, Karcena A, Pearson CM. Human lymphocyte subpopulations: Rosette formation with sheep, human, and horse red blood cells. *Immunol Comm.* 1977;6:455-71.
39. Gale RP, Feig S, Ho WG, Falk P, Winston D, Young LS, Opelz G, Tesler A, Sparkes R, Graze PR, Sarna G, Golde DW, Territo MC, Bryson Y, Gosset T, Naiem F, Fawzy F, Haskell C, Fahey JL, Cline MJ. Bone marrow transplantation in acute leukemia. *Lancet* 1977;2:1197-200.
40. Naiem F, Smith G, Gale RP, and the UCLA Bone Marrow Transplant Team. Morphologic aspects of bone marrow transplantation in patients in aplastic anemia. *Human Pathol.* 1978; 9:295-308.
41. Falk PM, Feig SA, Gitnick GL, Wilkinson RW, Gale RP, and the UCLA Bone Marrow Transplantation Team. Transplantation of hepatitis B surface antigen positive bone marrow. *Transfusion* 1978;18:242-243.
42. Gale RP, Fitchen JH, Cahan M, Opelz G, Cline MJ. Pretransplant lymphocytotoxins and bone marrow graft rejection. *Lancet* 1978;1:170-72.

43. Falk PM, Herzog P, Lubens R, Wimmer R, Sparkes R, Naiman JL, Gale RP, August C, Feig SA, and the UCLA Bone Marrow Transplantation Team. Bone marrow transplant between a histocompatible parent and child for acute leukemia. *Transplant* 1978;25:88-90.
44. Opelz G, Gale RP, Feig SA, Walker J, Terasaki PI, Saxon A. Significance of HLA and non-HLA antigens in bone marrow transplantation. *Transplant Proc.* 1978;10:43-46.
45. Gale RP, Opelz G, Mickey MR, Graze PR, Saxon A. Immunodeficiency following bone marrow transplant. *Transplant Proc.* 1978;10:223-28.
46. Gale RP. Approaches to leukemia relapse following bone marrow transplantation. *Transplant Proc.* 1978;10:167-72.
47. Winston DJ, Meyer DV, Gale RP, Young LS. Further experience with infections in bone marrow transplant recipients. *Transplant Proc.* 1978; 0:247-54.
48. Gale RP, Opelz G. Immunologic and clinical perspectives in human bone marrow transplantation. *Transplant Proc* 1978;10:265-70.
49. Graze PR, Gale RP. Autotransplantation for leukemia and solid tumors. *Transplant Proc.* 1978;10:177-86.
50. Gale RP. The role of cyclophosphamide and total body irradiation in marrow transplantation for aplastic anemia. In: *Experimental Hematology Today*. Baum SJ, Ledney GD, eds. New York, Springer-Verlag, 1978, pp. 157-61.
51. Opelz G, Kersey J, Glovsky MM, Gale RP. Autoreactivity between lymphocytes and thymus cells in myasthenia gravis. *Arch Neurol.* 1978; 35:413-415.
52. Gale RP, Sparkes RS, Golde DW. Bone marrow origin of hepatic macrophages (Kupffer cells) in man. *Science* 1978;201:937-38.
53. Drew SI, Carter BM, Terasaki PI, Naiem F, Nathanson DS, Abromowitz B, Gale RP. Cell surface antigens detected on mature and leukemic granulocyte populations by cytotoxicity testing. *Tissue Antigens* 1978;12:75-86.
54. Opelz G, Walker J, Gale RP. Detection of non-HLA antibodies in bone marrow transplant recipients. *Transplant Proc* 1978;10:963-64.
55. Wolff L, Zigelboim J, Gale RP. Paraplegia following intrathecal cytosine arabinoside. *Cancer* 1979;48:83-5.
56. Winston DJ, Gale RP, Young LS, Meyer DV, and the UCLA Bone Marrow Transplant Team. Infectious complications of human bone marrow transplantation. *Medicine* 1979;57:1-32.
57. Camitta BM, Thomas ED, Nathan DG, Gale RP, Kopecky KJ, Rappoport JM, Santos G, Gordon-Smith EC, Storb R. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. *Blood* 1979;53:504-14.

58. Graze PR, Wells JR, Ho W, Gale RP, Cline MJ. Successful engraftment of cryopreserved autologous bone marrow stem cells in man. *Transplant* 1979;27:142-5.
59. Opelz G, Gale RP, Feig S, Tesler A, Golde D, Ho W, Territo MC, Sarna GP, Gosset T, Naiem F, Winston D, Young L, Bryson Y, Fahey L, Sparkes RS, Graze P, Cline MJ. A phase II trial of fractionated total body irradiation in bone marrow transplantation for acute leukemia. *Transplant Proc* . 1979;11:205-9.
60. Sparkes RS, Sparkes MC, Gale RP, and the UCLA Bone Marrow Transplantation Team. Immunoglobulin synthesis following allogeneic bone marrow transplantation in man. *Transplantation* 1979;27:212-13.
61. Gosset T, Gale RP, Fleishman H, Austin G, Sparkes R, Taylor C. Immunoblastic sarcoma in donor cells following bone marrow transplantation. *N Engl J Med*. 1979; 300:904-907.
62. Graze PR, Gale RP. Chronic graft-versus-host disease: A syndrome of disordered immunity. *Am J Med*. 1979; 66:611-20.
63. Gale RP, Graze PR, Wells J, Ho WG, Hershko C, Lowenberg B, Feig SA, Cline MJ. Autologous bone marrow transplantation in patients with cancer. *Exp Hematol*. 1979; 7:351-359.
64. Wells J, Ho WG, Graze PR, Sullivan A, Gale RP, Cline MJ. Isolation, cryopreservation, and autotransplantation of human stem cells. *Exp Hematol*. 1979; 7:12-20.
65. Hershko C, Gale RP, Ho WG, Cline MJ. Cure of aplastic anemia in paroxysmal nocturnal hemoglobinuria by marrow transfusion of identical twin: Failure of pheresis leukocytes to correct marrow aplasia. *Lancet* 1979;1:164-69.
66. Gale RP. Advances in the treatment of acute myelogenous leukemia. *N Engl J Med*. 1979; 300:1189-99.
67. Wells JR, Billing R, Herzog P, Feig SA, Gale RP, Terasaki P, Cline MJ. Autotransplantation after in vitro immunotherapy of lymphoblastic leukemia. *Exp Hematol*. 1979;7:164-69.
68. Targan S, Brown D, Gale RP, Jondal M. Presence of spontaneous killer (SK) cells in human bone marrow. *J Clin Lab Immunol*. 1979;2:139-43.
69. Gale RP, Graze PR, Ho WG, Furst D, Clemments P, Austin GE. Chronic graft-versus-host disease in man: Immune studies. *J Clin Lab Immunol*. 1979; 2:177-79.
70. Graze PR, Gale RP. Bone marrow transplantation for aplastic anemia: Conditioning with cyclophosphamide plus low-dose total body irradiation. In: *Experimental Hematology Today III*. Baum SJ, Ledney GD, eds. Heidelberg, Springer-Verlag, 1979, pp. 185-191.
71. Foon KA, Naiem F, Yale C, Gale RP. Acute myelogenous leukemia: Morphologic classification and response to therapy. *Leuk Res*. 1979;3:171-73.
72. Furst DE, Clemments PJ, Graze PR, Gale RP, Roberts N. A syndrome resembling systematic sclerosis (PSS) following bone marrow transplantation: A model for PSS. *Arthritis Rheum*. 1979; 22:990-10.

73. Gale RP. Bone marrow transplantation for acute leukemia: Current status and future directions. In: *Modern Trends in Leukemia Research III*. Neth R, Gallo R, eds. Heidelberg, Springer-Verlag, 1979, pp. 71-78.
74. Mitsuyasu RT, Gale RP. Detection of non-HLA antigens: Effect of lymphocyte priming and amplification signals. *Transplant* 1979;28:207-11.
75. Young LS, Meyer BV, Winston DJ, Feig SA, Gale RP. Gram-negative rod bacteremia: Epidemiologic aspects of markedly neutropenic subjects and approaches to immune prophylaxis. In: *New Criteria for Anti-Microbial Therapy*. Van der Waaij D, Verhoef J, eds. Amsterdam, Excerpta Medica, 1979, pp. 30-40.
76. Drew SI, Carter BM, Giudera D, Kee KB, Sasaki M, Terasaki PI, Gale RP. Further aspects of microgranulocytotoxicity. *Transfusion* 1979;19:134-43.
77. Gale RP, Rutkowsky C. Immunity to human hematopoietic stem cells. *Nature* 1979;281:220-6.
78. Gale RP. Treatment of acute myeloid leukemia. In: Cline MJ (moderator). *Acute Leukemia: Biology and Treatment*. *Ann Intern Med.* 1979; 91:758-73.
79. Territo M, Gale RP, Cline M, Feig S, Gosset T, Graze P, Sarna G, Sparkes R, Teslar R, Winston D, Young L. The use of bone marrow grafting in the treatment of acute leukemia. In: *Advances in Medical Oncology, Research and Education: Leukemia and Non-Hodgkin Lymphoma*. Crowther DG, ed. New York, Pergamon Press, 1979, pp. 71-77.
80. Winston DJ, Schiffman G, Wang DC, Feig SA, Marso EL, Lin C, Ho WG, Young L, Gale RP. Pneumococcal infections after human bone marrow transplantation. *Ann Intern Med.* 1979; 91:835-42.
81. Gale RP. Current status of bone marrow transplantation in acute leukemia. *Transplant Proc.* 1979; 9:1920-23.
82. Gale RP, Mitsuyasu RT, Yale C. Immunologic function in aplastic anemia. In: *Aplastic Anemia*. Heimpel H, Gordon-Smith EC, Heit W, Kubanek B, eds. Heidelberg, Springer-Verlag, 1979, pp. 229-38.
83. Gale RP. Autologous bone marrow transplantation in patients with cancer. *J Am Med Assoc.* 1980; 243:540-3.
84. Hershko C, Gale RP, Ho WG, Fitch J. ABH antigens and bone marrow transplantation. *Br J Haematol.* 1980; 44:65-75.
85. Mitsuyasu RT, Gale RP. Bacterial pyomyositis in a patient with aplastic anemia. *Postgrad Med J.* 1980; 56:61-62.
86. Koeffler HP, Gale RP, Golde DW. Myeloid colony-forming cell kinetics in man. *Exp Hematol* 1980;9:271-7.
87. Fitch JH, Gale RP, Cline MJ. Serum inhibitors of in vitro hematopoiesis and graft outcome in bone marrow transplantation for aplastic anemia. *Transplant* 1980;29:223-27.
88. Golde DW, Hocking WG, Quan SG, Sparkes RE, Gale RP. Origin of human bone marrow fibroblasts. *Br J Haematol.* 1980; 44:183-87.

89. Gale RP. The diagnosis and treatment of acute leukemia. In: Practical Oncology. Sarna GP, ed. New York, Houghton-Mifflin, 1980, pp. 81-93.
90. Zigelboim J, Gale RP. Acute Leukemia. In: Cancer Treatment. Haskell CM, ed. Philadelphia, W.B. Saunders, 1980, pp. 802-32.
91. Winston DJ, Ho WG, Young LS, Gale RP. Prophylactic granulocyte transfusions during human bone marrow transplantation. *Am J Med.* 68:893-8, 1980.
92. Winston DJ, Lau WK, Gale RP, Young LS. Trimethoprim-sulphamethoxazole for the treatment of pneumocystis carinii pneumonia. *Ann Intern Med* 92:762-769, 1980.
93. Gale RP, Moran C. Modification of graft-versus-host disease by deletion of antigen reactive cells. *IRCS Medical Science.* 8:616-7, 1980.
94. Sparkes RS, Sparkes MC, Crist M, Yale C, Mickey MR, Gale RP. MNSS antigen and graft-versus-host disease following bone marrow transplantation. *Tissue Antigens* 15:212-5, 1980.
95. Foon KA, Yale C, Clodfelter K, Gale RP. Post-transfusion hepatitis in acute myelogenous leukemia: Effect on survival. *J Am Med Assoc.* 244:1806-1807, 1980.
96. Yanagihara E, Naiem F, Gale RP, Austin G, Waisman J. Acute lymphoblastic leukemia with giant intracytoplasmic inclusions. *Am J Clin Pathol* 74:345-350, 1980.
97. Niskanen E, Champlin RE, Cline MJ, Golde DW, Gale RP. Effect of humoral factors on hematopoietic cell proliferation from human fetal liver. In: *Fetal Liver Transplantation: Current Concepts and Future Directions.* Lucarelli G, Fliedner T, Gale RP, eds. Amsterdam, Elsevier, 1980, pp. 37-45.
98. Champlin RE, Niskanen E, Gale RP. Hematopoiesis and immune reactivity of human fetal liver cells. In: *Fetal Liver Transplantation: Current Concepts and Future Directions.* Lucarelli G, Fliedner T, Gale RP, eds. Amsterdam, Elsevier, 1980, pp. 117-126.
99. Champlin RE, Feig S, Gale RP. Bone marrow transplantation in aplastic anemia, acute leukemia and solid tumors. In: *Fetal Liver Transplantation: Current Concepts and Future Directions.* Lucarelli G, Fliedner T, Gale RP, eds. Amsterdam, Elsevier, 1980, pp. 210-224.
100. Gale RP. Concepts of fetal liver transplantation in man. In: *Fetal Liver Transplantation: Current Concepts and Future Directions.* Lucarelli G, Fliedner T, Gale RP, eds. Amsterdam, Elsevier, 1980, pp. 247-257.
101. Gale RP. Fetal liver transplantation in man. In: *Fetal Liver Transplantation: Current Concepts and Future Directions.* Lucarelli G, Fliedner T, Gale RP, eds. Amsterdam, Elsevier, 1980, pp. 268-276.
102. Gale RP. Clinical trials of bone marrow transplantation in leukemia. In: *Biology of Bone Marrow Transplantation.* Gale RP, Fox CF, eds. New York, Academic Press, 1980, pp. 11-29.
103. Hershko C, Gale RP. GVHD scoring system for predicting survival and specific mortality in bone marrow transplant recipients. In: *Biology of Bone Marrow Transplantation.* Gale RP, Fox CF, eds. New York, Academic Press, 1980, pp. 59-69.

104. Winston DJ, Bryson Y, Ho WG, Territo MC, Golde DW, Gale RP. Interstitial pneumonia and cytomegalovirus infection after bone marrow transplantation. In: *Biology of Bone Marrow Transplantation*. Gale RP, Fox CF, eds. New York, Academic Press, 1980, pp. 83-95.
105. Wells JR, Ho WG, Gale RP, Cline MJ. Hematopoietic stem cell procurement, separation and cryopreservation. In: *Biology of Bone Marrow Transplantation*. Gale RP, Fox CF, eds. New York, Academic Press, 1980, pp. 127-136.
106. Billing R, Wells JR, Gale RP, Foon K, Linker-Israel M, Deng C, Terasaki PI, Cline MJ. In vitro of bone marrow with hetero antisera prior to transplantation. In: *Biology of Bone Marrow treatment Transplantation*. Gale RP, Fox CF, eds. New York, Academic Press, 1980, pp. 167-75.
107. Foon KA, Fitchen JH, Billing RJ, Belzer MB, Wells JR, Golde DW, Gale RP, Cline MJ. Hematopoietic stem cell antigens. In: *Biology of Bone Marrow Transplantation*. Gale RP, Fox CF, eds. New York, Academic Press, 1980, pp. 477-491.
108. Winston DJ, Ho WG, Howell CL, Miller MJ, Mickey MR, Maryin WJ, Lin Ch, Gale RP. Cytomegalovirus infections associated with leukocyte transfusions. *Ann Intern Med*. 93:671-675, 1980.
109. Targan SR, Gale RP, Jondal M. Bone marrow modulation of spontaneous killer cellular cytotoxicity (SKCC) induction. *J Clin Exp Immunol*. 1980;4:1-6.
110. Hershko C, Gale RP. Bone marrow transplantation in aplastic anemia and leukemia. *Transplant Proc*. 1980;8:612-616.
111. Gale RP, Ho WG, Feig SA, Champlin RE, Tesler A, Arenson E, Ladish S, Young L, Winston D, Sparkes R, Fitchen J, Territo M, Sarna G, Wong L, Paik Y, Yvonne B, Golde DJ, Fahey J, Cline MJ. Prevention of graft rejection following bone marrow transplantation. *Blood*. 1981;57:9-12..
112. McIntyre R, Gale RP. Relationship between graft-versus-leukemia and graft-versus-host in man - UCLA experience. In: *Graft-Versus-Leukemia in Man and Animal Models*. Okunewick JP, Merideth RF, eds. Baton Rouge, CRC Press, 1981, pp. 1-10.
113. Bortin MM, Gale RP, Rimm AA. For the IBMTR Advis. Comm. Allogeneic bone marrow transplantation for 144 patients with severe aplastic anemia. *J Am Med Assoc*. 1981;245:1132-1139.
114. Whittaker JA, Reizenstein P, Callender ST, Cornwell GG, Delamore IW, Gale RP, Gobi M, Jacobs P, Lantz B, Maiolo AT, Rees JKH, Vanslyck EJ, Vuvan H. Long survival in acute myelogenous leukemia: An international collaborative study. *Br J Med*. 1981;82:1-10.
115. Foon KA, Naiem F, Saxon A, Stevens R, Gale RP. Leukemia of T-helper lymphocytes: Clinical and functional features. *Leuk Res*. 1981;5:1-10.
116. Harada M, Gale RP. Evaluation of antithymocyte globulin for human bone marrow transplantation. III. Effect of ATG treatment on T-cell precursors. *Transplantation*.. 31:233-237, 1981.
117. McIntyre RE, Magidson JD, Austin GE, Gale RP. Fatal veno-occlusive disease of the liver following high dose 1,3-bis(2-chloroethyl)-1 Nitrosourea (BCNU) and autologous bone marrow transplantation. *Am J Clin Pathol*. 1981;75:614-617.
118. Gale RP, Foon KA, Cline MJ, Zighelboim J. Intensive chemotherapy in acute myelogenous leukemia. *Ann Intern Med*. 1981;94:753-757.

119. Strauss RS, Connet JE, Gale RP, Bloomfield CD, Herzig GP, McCullough J, Maguire LC, Winston DJ, Ho WG, Stump DC, Miller WV, Koepke JA. A controlled trial of prophylactic granulocyte transfusions during initial induction chemotherapy for acute myelogenous leukemia. *N Engl J Med.* 1981;305:597-603.
120. Harada M, Gale RP. Effect of antithymocyte globulin on histocompatibility antigen recognition in man. *Transplantation.* 1981;31:101-105.
121. Foon Ka, Gale RP, Zigelboim J, Yale C. Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia. *Blood.* 1981;58:467-470.
122. Oriol R, Le Pendu J, Sparkes RS, Sparkes MC, Crist M, Gale RP, Terasaki PI, Bernoco M. Insights onto expression of ABH and Lewis antigens through human bone marrow transplantation. *AM J Hum Genet* 1981;33:551-560.
123. Niskanen E, Gale RP, Cline MJ, Golde DW. Culture of myeloid and erythroid colonies from human fetal liver in vivo and in vitro. In: *Experimental Hematology Today.* Baum S, Ledney GD, van Bekkum DW, eds. Basel, S. Karger, 1981, pp. 265-270.
124. Saxon A, McIntyre RE, Stevens RH, Gale RP. Lymphocyte dysfunction in chronic graft-versus-host disease. *Blood.* 1981;58:746-794.
125. Gale RP, Champlin RE, Feig SA, Fitch JH. Aplastic anemia: Biology and treatment. *Ann Intern Med.* 1981;95:477-494.
126. Foon KA, Filderman A, Gale RP. Histiocytic lymphoma following resolution of sarcoidosis. *Med Ped Oncol.* 1981;9:325-331.
127. Sparkes R, Gale RP, Yale C, Mickey MR, Sparkes RC, Crist M. Human bone marrow transplantation: Effect of genes other than those of the major histocompatibility complex. *Proceedings of International Congress of Genetics (Moscow) XIV. Problems in General Genetics II, Book I,* 1981, pp. 158-161.
128. Douer D, Champlin RE, Ho WG, Sarna GP, Wells JH, Graze PR, Cline MJ, Gale RP. High-dose combined modality therapy and autologous bone marrow transplantation in resistant cancer. *Am J Med.* 1981;71:973-976.
129. Koch RR, Gale RP. Acute leukemia. In: *Hematology for the Practicing Internist.* Figueroa WG, ed. New York, Houghton-Mifflin, 1981, pp. 197-219.
130. Koch RR, Gale RP. Chronic leukemia. In: *Hematology for the Practicing Internist.* Figueroa WG, ed. New York, Houghton-Mifflin, 1981, pp. 220-243.
131. Gale RP. Bone marrow transplantation in leukemia. *Ann Clin Res.* 1981;13:367-372.
132. Gale RP. Progress in acute myelogenous leukemia. *Cancer Treat Rep.* 1981;65(4):87-92.
133. Sarna G, Champlin RE, Wells J, Gale RP. Phase I study of high dose mitomycin with autologous bone marrow support. *Cancer Treat Rep.* 66:277-282, 1981.
134. Bortin M, Kay H, Gale RP, Rimm A. Factors associated with interstitial pneumonitis after bone marrow transplantation for acute leukemia. *Lancet.* 1981;1:437-440.

135. Ungerleider JT, Andrysiak T, Tashkin DP, Gale RP. Contamination of marijuana cigarettes with pathogenic bacteria-possible source of infection in cancer patients. *Cancer Treat Rep.* 1982;66:589-591.
136. Gale RP. Progress in bone marrow transplantation in man. *Surv Immunol Res.* 1982;1:40-66.
137. Winston D, Ho WG, Gale RP. Granulocyte transfusions. *African J Clin Exp Immunol.* 1982;3:129-137.
138. Gale RP, Foon KA, Yale C, Zigelboim J. Immunotherapy of acute myelogenous leukemia using *Corynebacterium parvum* and allogeneic cells. In: *Immunotherapy of Human Cancer.* Terry WD, Rosenberg SA, eds. New York, Excerpta Medica, 1982, pp. 39-43.
139. Gale RP. The present status of bone marrow transplantation in the United States of America. *J Jap Soc Blood Transfusion.* 1982;28:24-33.
140. Harada M, Gale RP. Evaluation of antithymocyte globulin (ATG) for human bone marrow transplantation: Antihemopoietic and immunosuppressive activity. *Transplantation.* 1982;33:625-30.
141. Foon KA, Gale RP. Controversies in the therapy of acute myelogenous leukemia. *Am J Med.* 1982;73:962-73.
142. Storch S, Feig SA, Gale RP. Bone marrow transplantation in children. *Ind J Ped.* 1982;49:317-24.
143. Gale RP. Transplantation of hematopoietic stem cells. In: *UCLA Forum in Medical Sciences: Symposium on Developmental Immunology: Clinical Problems of Aging.* Cooper E, Brazier M, eds. New York, Academic Press, 1982, pp. 161-9.
144. Winston DJ, Pollard RB, Ho WG, Gallagner JG, Rasmussen LE, Huang SNY, Lin CH, Gosset TG, Merigan TC, Gale RP. Cytomegalovirus immune plasma in bone marrow transplant recipients. *Ann Intern Med.* 1982;97:11-18.
145. Foon KA, Schroff RW, Gale RP. Surface markers on leukemia and lymphoma cells: Recent advances. *Blood.* 1982;60:1-19.
146. Champlin RE, Ho WG, Arenson E, Gale RP. Allogenic bone marrow transplantation in chronic myelogenous leukemia in the chronic or accelerated stage. *Blood.* 1982;60:1038-41.
147. Schroff RW, Gale RP, Fahey JL. Regeneration of T-cell subpopulations following bone marrow transplantation: Cytomegalovirus infection and lymphoid subset imbalance. *J Immunol.* 1982;129:1926-30.
148. Gale RP, Kay HEM, Rimm AA, Bortin MM. Bone marrow transplantation for acute leukemia in first remission. *Lancet.* 1982;2:1006-9.
149. Gale RP, Ho WG, Winston DJ. Current status of granulocyte transfusions. *J Jap Soc Blood Transfusions.* 1982;28:409-14.
150. Winston DJ, Ho WG, Gale RP. Therapeutic granulocyte transfusions for documented infections: A controlled trial of ninety-five infectious granulocytopenic episodes. *Ann Intern Med.* 1982;97:509-15.
151. Winston DJ, Ho WG, Young LS, Hewitt WL, Gale RP. Piperacillin plus amikacin versus carbenicillin plus amikacin therapy in febrile, granulocytopenic patients. *Arch Intern Med.* 1982;142:1663-7.

152. Winston DJ, Ho WG, Rasmussen LE, Li CH, Chu CL, Merigan TC, Gale RP. Use of intravenous immune globulin in patients receiving bone marrow transplants. *J Clin Immunol.* 1982;2:429-79.
153. Champlin RE, Ho WG, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia: A prospective randomized trial. *N Engl J Med.* 1982;308:113-8.
154. Bortin M, Gale RP, Kay HEM, Rimm AA. Bone marrow transplantation for 172 patients with acute myelogenous leukemia: Factors associated with early mortality. *J Am Med Ass.* 1982;249:1166-75.
155. Ho WG, Gale RP. Bone marrow transplantation. In: *Transplantation.* Chatterlee SN, ed. Baltimore, PSG Publishers, 1983, pp. 485-526.
156. Winston DJ, Dudnick DW, Chepin M, Ho WG, Gale RP, Martin WJ. Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy. *Arch Intern Med.* 1983;143:32-6.
157. Zeldis JB, Dienstag JL, Gale RP. Aplastic anemia and non-A, non-B hepatitis. *Am J Med.* 1983;74:64-8.
158. Lazarus HM, Gottfried MR, Herzig RH, Phillips GL, Weiner RS, Sarna G, Fay J, Wolff SN, Sudilovsky O, Gale RP, Herzig GP. Veno-occlusive disease of the liver after high dose mitomycin C therapy and autologous bone marrow transplantation. *Cancer* 1983;49:1789-95.
159. Champlin RE, Winston DJ, Ho WG, Feig SA, Gale RP. Allogeneic bone marrow transplantation for chronic myeloid leukemia in the chronic or accelerated phase. *Transplant Proceed* 1983;15:1401-4.
160. Foon KA, Gale RP. Therapy of acute myelogenous leukemia. In: *Cancer Chemotherapy.* Muggia FM, ed. Boston, Nijhoff, 1983, pp. 303-31.
161. Slavin S, Gale RP. Bone marrow transplantation: Experimental and clinical aspects. In: *T and B Cell Tumors.* Vitetta E, ed. New York, Academic Press, 1983, pp. 547-51.
162. Schroff RW, Gale RP, Fahey JL. Lymphoid immaturity and T subpopulation imbalances in human disease. In: *T and B Cell Tumors.* Vitetta E, ed. New York, Academic Press, 1983, pp. 285-91.
163. Gale RP, Levine A, Golde DW, Bloomfield C, Foon KA. Chronic Leukemias. In: *Hematology 1982.* American Society of Hematology, New Jersey, Charles B. Slack, 1982, pp. 8-14.
164. Niskanen E, Champlin RE, Oki A, Golde DW, Gale RP, Cline MJ. Humoral stimulation of hematopoietic progenitors from human fetal liver. *Stem Cells* 1983;2:246-52.
165. Gale RP. Acute leukemia. In: *Internal Medicine: A Systemic Approach.* Stein E, ed. Boston, Little, Brown and Company, 1983, pp. 1638-44.
166. Gale RP. Aplastic anemia: Bone marrow failure. In: *Internal Medicine: A Systemic Approach.* Stein E, ed. Boston, Little, Brown and Company, 1983, pp. 1575-84.
167. Foon KA, Gale RP. Chronic myeloproliferative disorders. In: *Internal Medicine: A Systemic Approach.* Stein E, ed. Boston, Little, Brown and Company, 1983, pp. 1632-8.

168. Bortin MM, Gale RP, Rimm AA. Factors associated with early mortality following allogeneic bone marrow transplantation in acute myelogenous leukemia. A report from the IBMTR. *Transplant Proceed.* 1983;15:1389-91.
169. Champlin RE, Ho WG, Winston DJ, Feig SA, Gale RP. Anti-thymocyte globulin treatment for aplastic anemia: A controlled randomized trial and comparison with marrow transplantation. *Transplant Proceed.* 1983;15:595-8.
170. Winston DJ, Territo MC, Ho WG, Miller MJ, Gale RP, Golde DW. Alveolar macrophage dysfunction in human bone marrow transplant recipients. *Am J Med* 1983;73:859-66.
171. Winston DJ, Ho WG, Schroff RW, Champlin RE, Gale RP. Safety and tolerance of recombinant leukocyte and interferon in bone marrow transplant recipients. *Antimicrob Agents Chemother* 1983;23:846-51.
172. Champlin RE, Gale RP. Aplastic anemia. In: *Current Therapy in Hematology/Oncology.* Brain MC, McCulloch PBM, eds. Philadelphia, B.C. Decker, 1983, pp. 1-6.
173. Gale RP, Kersey JH, Bortin MM, Dicke KA, Good RA, Zwaan FE, Rimm AA. Bone marrow transplantation for acute lymphoblastic leukemia. *Lancet.* 1983;2:663-7.
174. Feig SA, Champlin RE, Arenson E, Yale C, Ho WG, Tesler A, Gale RP. Improved survival following bone marrow transplantation for aplastic anemia. *Br J Haematol.* 1983;54:509-17.
175. Foon KA, Gale RP. Treatment of elderly patients with acute myelogenous leukemia. *Geriatric Med Today.* 1983;9:48-61.
176. Foon KA, Smalley RV, Riggs CW, Gale RP. The role of immunotherapy in acute myelogenous leukemia. *Arch Intern Med* 1983;143:1726-31.
177. Champlin RE, Mitsuyasu RT, Elashoff R, Gale RP. The role of bone marrow transplantation in the treatment of chronic myelogenous leukemia. In: *Recent Advances in Bone Marrow Transplantation.* Gale RP, ed. New York, Alan R. Liss, 1983, pp. 141-58.
178. Stitzel KA, Champlin RE, Gale RP. Fetal liver cell transplantation in dogs: A possible alternative source of hematopoietic stem cells for transplantation. In: *Recent Advances in Bone Marrow Transplantation.* Gale RP, ed. New York, Alan R. Liss, 1983, pp. 831-40.
179. Gale RP, Champlin RE. Bone marrow transplantation in leukemia: Critical analysis and controlled clinical trials. In: *Recent Advances in Bone Marrow Transplantation.* Gale RP, ed. New York, Alan R. Liss, 1983, pp. 71-94.
180. Mitsuyasu R, Champlin R, Ho WG, Wells J, Billing R, Territo M, Gale RP. Autologous bone marrow transplantation after in vitro treatment with anti-calla heteroantiserum and complement for adult acute lymphoblastic leukemia. In: *Recent Advances in Bone Marrow Transplantation.* Gale RP, ed. New York, Alan R. Liss, 1983, pp. 679-887.
818. Champlin RE, Ho WG, Winston D, Bayever E, Feig S, Gale RP. The treatment of severe aplastic anemia: A comparison of antithymocyte globulin and allogeneic bone marrow transplantation. In: *Recent Advances in Bone Marrow Transplantation.* Gale RP, ed. New York, Alan R. Liss, 1983, pp. 29-38.

182. Winston DJ, Ho WG, Champlin RE, Gale RP. Treatment and prevention of interstitial pneumonia associated with bone marrow transplantation. In: *Recent Advances in Bone Marrow Transplantation*. Gale RP, ed. New York, Alan R. Liss, 1983, pp. 425-44.
183. Stroch S, Gale RP, Champlin RE, Ho WG, Falk PM, Feig SA. Partially mismatched marrow transplantation for acute leukemia and aplastic anemia. In: *Recent Advances in Bone Marrow Transplantation*. Gale RP, ed. New York, Alan R. Liss, 1983, pp. 785-95.
184. Camitta B, O'Reilly R, Sensenbrenner L, Rapoport J, Champlin RE, Doney K, August C, Hoffman R, Kirkpatrick D, Stuart R, Santos G, Parkman R, Gale RP, Storb R, Nathan D. Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia. *Blood* 1983;62:883-8.
185. Gale RP, Levine A, Golde D, Bloomfield C, Foon K. Chronic leukemias. In: *Hematology 1982*. American Society of Hematology, New Jersey, Charles B. Slack, 1982, pp. 8-14.
186. Shavit Y, Lewis J, Terman G, Gale RP, Liebeskind J. Endogenous opioids may mediate the effects of stress on tumor growth and immune function. *Proc West Pharmacol Soc* 1983;26:53-6.
187. Lewis J, Shavit Y, Terman G, Nelson L, Gale RP, Liebeskind J. Apparent involvement of opioid peptides in stress-induced enhancement of tumor growth. *Peptides* 1983;4:635-8.
188. Douer D, Gale RP. Bone marrow autotransplantation in patients with cancer. In: *Supportive Care of the Cancer Patient*. Wiernik PL, ed. Mount Kisco, Futura, 1983, pp. 249-75.
189. Gale RP, Levine A, Champlin RE, Bloomfield C, Foon KA. Chronic leukemias. In: *Hematology 1983*. American Society of Hematology, New Jersey, Charles B. Slack, 1983, pp. 16-24.
190. Shavit Y, Lewis J, Terman G, Gale RP, Liebeskind J. Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity. *Science*. 1983;223:188-90.
191. Bonavida K, Kodo H, Colvin M, Brautbar H, Gale RP, Lebow L. Cyclophosphamide inhibits both the recognition and lethal hit stages of NK cell-mediated cytotoxicity. In: Hashino P, Koran HS, Ukida A, eds. Amsterdam, Excerpta Medica, 1984, pp. 283-9.
192. Winston DJ, Ho WG, Schiffman G, Champlin RE, Feig SA, Gale RP. Pneumococcal vaccination of recipients of bone marrow transplants. *Arch Intern Med*. 1983;143:1735-7.
193. Gale RP. Treatment of acute leukemia in adults. In: *Normal and Neoplastic Hematopoiesis*. Golde DW, Marks PM, eds. New York, Alan R. Liss, 1983, pp. 479-90.
194. Champlin RE, Gale RP. Role of bone marrow transplantation in the treatment of hematologic malignancies and solid tumors: Critical review of syngeneic, autologous, and allogeneic transplants. *Cancer Treat Rep*. 1983;68:145-61.
195. Champlin RE, Feig SA, Sparkes RS, Gale RP. Bone marrow transplantation from identical twins in the treatment of aplastic anemia: Implication for the pathogenesis of the disease. *Br J Haematol*. 1984;56:455-63.
196. Winston DJ, Ho WG, Lin CH, Budinger MD, Champlin RE, Gale RP. Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. *Am J Med*. 1984;76:128-33.

197. Canaani E, Gale RP, Steiner-Saltz S, Berrebi A, Agahi E, Januszewicz E. Altered transcription of an oncogene in chronic myeloid leukemia. *Lancet*. 1984;1:593-5.
198. Foon KA, Gale RP. Acute myelogenous leukemia: Recent advances in diagnosis and therapy. In: *Contemporary Hematology/ Oncology*. Gordon AS, Silber R, Muggia EM, Lobue, J, eds. New York, Plenum, 1984, pp. 171-214.
199. Winston DJ, Ho WG, Champlin RE, Gale RP. Infectious complications of bone marrow transplantation. *Exp Hematol*. 1984;12:205-15.
200. Champlin RE, Jacobs A, Gale RP, Elashoff R, Foon KA, Zigelboim J. Prolonged survival in acute myelogenous leukemia without maintenance chemotherapy. *Lancet*. 1984;1:894-5.
201. Kodo H, Gale RP, Saxon A. Antibody synthesis by bone marrow cells in vitro following primary and booster tetanus toxoid immunization in humans. *J Clin Invest*. 1984;73:1377-84.
202. Champlin RE, Ho WG, Bayever E, Winston D, Lenarsky C, Feig SA, Gale RP. Treatment of aplastic anemia: Results with bone marrow transplantation, antithymocyte globulin, and a monoclonal anti-T-cell antibody. In: *Aplastic Anemia: Stem Cell Biology and Treatment*. Young NS, Levine AS, Humphries RK, eds. New York, Alan R. Liss, 1984, pp. 227-38.
203. Foon KA, Mitsuyasu RT, Schroff RW, McIntyre RE, Champlin RE, Gale RP. Immunologic defects in young male patients with hepatitis-associated aplastic anemia. *Ann Intern Med*. 1984;100:657-62.
204. Champlin RE, Gale RP. The early complications of bone marrow transplantation. *Sem Hematol* 1984;21:101-8.
205. Ho WG, Champlin RE, Feig SA, Gale RP. Transplantation of ABH incompatible bone marrow gravity sedimentation of donor marrow. *Br J Haematol* 1984;57:155-162.
206. Lewis JW, Shavit Y, Terman GW, Gale RP, Liebeskind JC. Stress and morphine affect survival of rats challenged with mammary ascites tumor. *Natural Immun Cell Growth Reg*. 1984;3:43-50.
207. Boccia R, Zigelboim J, Champlin RE, Kim CC, Gale RP. AMSA: A phase II trial in resistant and recurrent acute myelogenous leukemia. *Med Ped Oncol*. 1984;178-9.
208. Suh JY, Choi MG, Seung KB, Park CW, Kim CC, Kim DJ, Gale RP. The effect of 4'-(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in the treatment of refractory adult myeloid leukemia. *Korean J Hematol* 1984;19:39-44.
209. Gale RP, Champlin RE. How does bone marrow transplantation cure leukemia? *Lancet*. 1984;28-30.
210. Ben-Bassat I, Gale RP. Hybrid acute leukemia. *Leuk Res*. 1984;8:929-36.
211. Champlin RE, Gale RP. Aplastic anemia. In: *Current Therapy in Internal Medicine*. Bayless TM, Brain MC, Cherniack RM, eds. Philadelphia, B.C. Decker, 1984, pp. 250-55.
212. Mitsuyasu RT, Champlin RE, Gale RP. Immune reconstitution post bone marrow transplantation: Implications for the treatment of the acquired immunodeficiency syndrome (AIDS). In: *Acquired Immune Deficiency Syndrome*. Gottlieb MS, Groopman JE, eds. New York, Alan R. Liss, 1984, pp. 395-408.

213. Gale RP. Cellular oncogenes and chemical carcinogens. *Immunol Hematol Research*. 1984;3:189-93.
214. Foon KA, Gale RP. Acute myelogenous leukemia: Current status of therapy in adults. In: *Recent Developments in Diagnosis and Therapy*. Thiel S, Thierfelder S, eds. Berlin, Springer-Verlag, 1984, pp. 216-39.
215. Gale RP, Canaani E. Transcription of *abl* in chronic myelogenous leukemia. In: *Genes and Cancer*. Bishop JM, Rowley JD, Greaves M, eds. New York, Alan R. Liss, 1984, pp. 435-48.
216. Gale RP. Progress in acute myelogenous leukemia. *Ann Intern Med*. 1984;101:702-5.
217. Champlin RE, Feig SA, Gale RP. Case problems in bone marrow transplantation. I. Graft failure in aplastic anemia: Its biology and treatment. *Exp Hematol*. 1984;12:728-33.
218. Gale RP, Canaani E. An 8-kilobase *abl* RNA transcript in chronic myelogenous leukemia. *Proc Natl Acad Sci USA*. 1984;81:5648-52.
219. Jacobs A, Schroff RW, Gale RP. Acute transformation of chronic lymphocytic leukemia. *Med Ped Oncol*. 1984;12:318-21.
220. Jacobs A, Gale RP. Acute myelogenous leukemia following radiation therapy and chemotherapy for osteogenic sarcoma. *Cancer Treat Rep*. 1984;68:909-11.
221. Jacobs AD, Gale RP. Recent advances in the biology and treatment of acute lymphoblastic leukemia in adults. *N Engl J Med*. 1984;311:1219-31.
222. Zigelboim J, Foon KA, Gale RP, Haskell CM. Acute myelogenous leukemia. In: *Cancer Treat Rep*. Haskell CM, ed. Philadelphia, W.B. Saunders, 1984, pp. 694-705.
223. Bereson JR, Zigelboim J, Gale RP. Acute lymphoblastic leukemia. In: *Cancer Treatment*. Haskell CM, ed. Philadelphia, W.B. Saunders, 1984, pp. 706-21.
224. Winston DJ, Barnes RC, Ho WG, Young LS, Champlin RE, Gale RP. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. *Am J Med*. 1984;77:442-50.
225. Gale RP. Bone marrow transplantation in leukemia. In: *New Trends in Experimental Hematology*. Peschle C, Rizzoli C, eds. Rome, Ares Serono Symposia, 1984, pp. 361-3.
226. Bayever E, Champlin R, Ho W, Lenarsky C, Storch S, Gale RP, Feig SA. Comparison between bone marrow transplantation and antithymocyte globulin in treatment of young patients with severe aplastic anemia. *J Pediatr*. 1983;105:920-5.
227. Winston DJ, Huang ES, Miller MJ, Lin CH, Ho WG, Gale RP, Champlin RE. Molecular epidemiology of cytomegalovirus infections associated with bone marrow transplantation. *Ann Intern Med*. 1985;102:16-20.
228. Ho WG, Winston DJ, Champlin RE, Gale RP. Cytomegalovirus infection and its prevention with specific immunoglobulins. In: *Transplantation and Blood Transfusion*. Sibinga CT, Das PC, Opelz G, eds. Boston, Martinus Nijhoff, 1984, pp 73-7.

229. Gale RP. Autologous bone marrow transplantation in patients with cancer. In: Bone Marrow and Organ Transplantation-Present State, Future Goals. Slavin S, ed. Amsterdam, Elsevier, 1984, pp 111-123.
230. Li S, Champlin RE, Fitchen JH, Gale RP. Abnormalities of myeloid progenitor cells following "successful" bone marrow transplantation. *J Clin Invest* .1985;75:234-41.
231. Weiner RS, Bortin MM, Gale RP, Gluckman E, Kay HEM , Kolb KH, Hartz AJ, Rimm AA. Risk factors associated with interstitial pneumonitis following allogeneic bone marrow transplantation for leukemia. *Transplant Proc*. 1984;17:470-4.
232. Mitsuyasu RT, Champlin RE, Ho WG, Winston D, Feig S, Wells J, Terasaki P, Billing R, Weaver M, Gale RP. Prospective randomized controlled trial of ex-vivo treatment of donor bone marrow with monoclonal anti-T cell antibody and complement for prevention of graft-versus-host disease: A preliminary report. *Transplant Proc*. 1985;17:482-5.
233. Champlin RE, Ho WG, Linarsky C, Winston D, Mitsuyasu RT, Feig SA, Gale RP. Successful second bone marrow transplants for treatment of acute myelogenous leukemia or acute lymphoblastic leukemia. *Transplant Proc*. 1985;17:496-9.
234. Winston DJ, Ho WG, Gale RP, Champlin RE. Interstitial pneumonia after bone marrow transplantation. In: Autologous Bone Marrow Transplantation. Dicke KA, Spitzer G, Zander AR, eds. Houston, University of Texas, 1985, pp. 481-7.
235. Gale RP. Bone marrow transplantation. *Crit Rev Hematol Oncol*. 1985;2:261-96.
236. Champlin RE, Ho WG, Gale RP, Winston D, Selch M, Mitsuyasu R, Lenarsky C, Elashoff R, Zigelboim J, Feig SA. Treatment of acute myelogenous leukemia; A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy. *Ann Intern Med*. 1985;102:285-91.
237. Gale RP, Hershko C. Bone marrow transplantation in leukemia. In: Bone Marrow and Organ Transplantation: Present State, Future Goals. Slavin S, ed. Amsterdam, Elsevier, 1984, pp. 67-93.
238. Gale RP. Antineoplastic chemotherapy myelosuppression: Mechanisms and new approaches. *Exp Hematol*. 1985;13:3-7.
239. Gale RP. Treatment of acute leukemia in adults. In: Leukemia and Lymphoma: Diagnosis and Therapy. Santoro G, ed. Milano, Casa Editrice Ambrosiana, 1985, pp. 231-37.
240. Champlin RE, Gale RP. Role of bone marrow transplantation in the treatment of hematologic malignancies and solid tumors: Critical review of syngeneic, autologous and allogeneic transplants. In: Leukemia and Lymphoma: Diagnosis and Therapy. Santoro G, ed. Milano, Casa Editrice Ambrosiana, 1985, pp. 351-73.
241. Kodo H, Bonavida B, Colvin M, Gale RP. Effects of 4-hydroperoxy-cyclophosphamide on human T and B cell function in vitro. *Int J Immunopharm* 1985;7:555-60.
242. Shtivelman E, Lifshitz B, Canaani E, Gale RP. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. *Nature* 1985;315:550-4.
243. Champlin RE, Ho WG, Feig S, Winston FJ, Lenarsky C, Gale RP. Do androgens enhance the response to antithymocyte globulin for treatment of aplastic anemia: A prospective randomized trial. *Blood*. 1985; 66:184-8.

244. Champlin R, Jacobs A, Gale RP, Ho W, Selch M, Lenarsky C, Feig SA. High dose cytarabine in consolidation chemotherapy or with bone marrow transplantation for patients with leukemia: Preliminary results. *Sem Oncol* .1985;12:190-5.
245. Gale RP, Foon KA. Chronic lymphocytic leukemia: Recent advances in biology and treatment. *Ann Intern Med*. 1985;103:101-20.
246. Shavit Y, Terman GW, Martin F, Lewis JW, Liebeskind JC, Gale RP. Stress, opioid peptides, the immune system, and cancer. *J Immunol*. 1985;135:834s-837s.
247. Gale RP, Cananni E. The molecular biology of chronic myelogenous leukemia. *Br J Haematol*. 1985;60: 395-408.
248. Lewis JW, Shavit Y, Terman GW, Nelson LR, Martin FC, Gale RP, Liebeskind JC. Involvement of opioid peptides in analgesic, immunosuppressive, and tumor-enhancing effects of stress. *Psychopharm Bull* 1985;21:479-84.
249. Canaani E, Shtivelman E, Lifshitz B, Gale RP. An abl-bcr hybrid RNA in chronic myelogenous leukemia. In: *Leukemia: Recent Advances in Biology and Treatment*. Gale RP, Golde DW, eds. New York, Alan R. Liss, 1985, pp. 29-40.
250. Jacobs AD, Gale RP. Treatment of acute lymphoblastic leukemia in adults. In: *Leukemia: Recent Advances in Biology and Treatment*. Gale RP, Golde DW, eds. New York, Alan R. Liss, 1985, pp. 597-607.
251. Gale RP, Foon KA. Therapy of acute myelogenous leukemia. In: *Leukemia: Recent Advances in Biology and Treatment*. Gale RP, Golde DW, eds. New York, Alan R. Liss, 1985, pp.609-49.
252. Gale RP. Fetal liver transplantation in hematologic disorders. In: *Recent Advances in Fetal Liver Transplantation*. RP Gale, Touraine J-L, Lucarelli G, eds. New York, Alan R. Liss, 1985, pp. 293-98.
253. Gale RP. Immune development in human fetal liver. In: *Recent Advances in Fetal Liver Transplantation*. Gale RP, Touraine J-L, Lucarelli G, eds. New York, Alan R. Liss, 1985, pp.73-88.
254. Champlin RE, Cain G, Stitzel KA, Gale RP. Fetal liver cell transplantation in dogs: Results with DLA-compatible and incompatible grafts. In: *Recent Advances in Fetal Liver Transplantation*. Gale RP, Touraine J-L, Lucareli G, eds. New York, Alan R. Liss, 1985, pp.195-204.
255. Champlin RE, Mitsuyasu RT, Gale RP. Transplantation of T-lymphocyte depleted bone marrow to prevent graft-versus-host disease: Its implications for fetal liver transplantation. In: *Recent Advances in Fetal Liver Transplantation*. Gale RP, Touraine J-L, Lucarelli G, eds. New York, Alan R. Liss, 1985, pp. 315-26.
256. Gale RP, Champlin RE, Jacobs AD. Treatment of acute leukemia. In: *Hematology 1985*. American Society of Hematology. New Jersey, Charles B. Slack, 1985, pp. 8-15.
257. Weiner RS, Bortin MM, Gale RP, Gluckman E, Kay HEM, Kolb H-J, Hartz AJ, Rimm AA. Interstitial pneumonitis after bone marrow transplantation. *Ann Intern Med*. 1986;104:168-174.
258. Cain GR, Cardinet III GH, Cuddon PA, Gale RP, Champlin RE. Myasthenia gravis and polymyositis in a dog following fetal hematopoietic cell transplantation. *Transplant*. 1986;41:21-25.

259. Gale RP. Graft-versus-host disease. *Immunol Rev.* 1986;88:193-214.
260. Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, Champlin RE. Use of polyvalent intravenous immune globulin or cytomegalovirus-specific hyperimmune globulin for modification of cytomegalovirus infection and prevention of interstitial pneumonia after bone marrow transplantation. *Immunitat and Infektion* 1986;13:296-301.
261. Lowenberg B, Gale RP. Aplastic anemia. In: *Bone Marrow Transplantation: Biological Mechanisms and Clinical Practice.* van Bekkum DW, Lowenberg B, eds. New York, Marcel Dekker, 1985, pp 409-34.
262. Jacobs AD, Gale RP. Acute lymphoblastic leukemia in adults. In: *Leukemia Treatment.* Gale RP, ed. Oxford, Blackwell Scientific, 1985, pp 71-98.
263. Gale RP, Foon K. Acute myelogenous leukemia. In: *Leukemia Treatment.* Gale, RP, ed. Oxford, Blackwell Scientific, 1985, pp 99-146.
264. Foon K, Gale RP. Principles of leukemia treatment. In: *Leukemia Treatment.* Gale RP, ed. Oxford, Blackwell Scientific, 1985, pp 1-24.
265. Winston DJ, Ho WG, Gale RP, Champlin RE. Prevention and treatment of infection in leukemia patients. In: *Leukemia Treatment.* Gale RP, ed. Oxford, Blackwell Scientific, 1985, pp 213-38.
266. Foon K, Gale RP. Chronic lymphocytic leukemia. In: *Leukemia Treatment.* Gale RP, ed. Oxford, Blackwell Scientific, 1985, pp 165-80.
267. Kosmo MJ, Gale RP. Plasma cell leukemia. In: *Leukemia Treatment.* Gale RP, ed. Oxford, Blackwell Scientific, 1985, pp 249-60.
268. Gale RP. Treatment of aplastic anemia. *Tokai J Exp Clin Med.* 1985;10:117-26.
269. Gale RP. Fetal liver transplantation in man. *Tokai J Exp Clin Med.* 1985;10:215-23.
270. Gale RP, Canaani E. Oncogenes in chronic myelogenous leukemia. In: *Experimental Hematology Today.* Baum SJ, Pluznik DH, Rozenszajn LA, eds. Berlin, Springer-Verlag, 1986, pp.102-5.
271. Gale RP. Minimal residual disease in leukemia. In: *Minimal Residual Disease in Leukemia.* Lowenberg B, Hagenbeek A, eds. Boston, Martinus Nijhoff, 1986, pp. 386-88.
272. Gale RP. Chromosomes, oncogenes, and retroviruses in the chronic leukemias. In: *Chronic Leukemias: Oncogenes, Chromosomes, and Advances in Therapy.* Champlin R, moderator. *Ann Intern Med.* 1986;104:671-88.
273. Shavit Y, Terman GW, Lewis JW, Zane CJ, Gale RP, Liebeskind JC. Effects of footshock stress and morphine on natural killer lymphocytes in rats: Studies of tolerance and cross-tolerance. *Brain Res.* 1986;372:382-5.
274. Gale RP. The analysis of bone marrow transplantation data in man. *Bone Marrow Transplant.* 1986;1:3-9.
275. Winston DJ, Ho WG, Champlin RE, Gale RP, Busuttill RW. Ureidopenicillins, aztreonam, and thienamycin: Efficacy as single-drug therapy of severe infections and potential as components of combined therapy. *J Antimicrob Chemother* 1986;17:55-66.

276. Winston DJ, Ho WG, Gale RP, Champlin RE. Treatment of herpes zoster infection in immunosuppressed patients. In: *Biology of the Interferon System*. Stewart II WE, Schellekens H, eds. Amsterdam, Elsevier, 1986, pp. 479-84.
277. Winston DJ, Ho WG, Nakao SL, Gale RP, Champlin RE. Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. *Am J Med*. 1986;80:884-90.
278. Gale RP, Reisner Y. Graft rejection and graft-versus-host disease: Mirror images. *Lancet* 1986;1:1468-70.
279. Mitsuyasu RT, Champlin RE, Gale RP, Ho WG, Lenarsky C, Winston D, Selch M, Elashoff R, Giorgis J, Wells J, Terasaki P, Billing R, Feig S. Treatment of donor bone marrow with monoclonal anti-T cell antibody and complement for the prevention of graft-versus-host disease: A prospective randomized double blind trial. *Ann Intern Med*. 1986;105:20-6.
280. Silver RT, Gale RP. Chronic myeloid leukemia. *Am J Med*. 1986;80:1137-48.
281. Gale RP. Leukemia. *Sem Hematol*. 1986;23:188.
282. Gale RP. Potential utilization of a national HLA-typed donor pool for bone marrow transplantation. *Transplantation*. 1986;42:54-8.
283. Zeldis JB, Mugashima H, Steinberg HN, Nir E, Gale RP. In vitro hepatitis B infection of human bone marrow cells. *J Clin Invest*. 1986;78:411-17.
284. Gale RP. Clinical trials of bone marrow transplantation. *Isr J Med Sci*. 1986;22:260-63.
285. Gale RP. Chernobyl: Biomedical consequences. *Issues Sci Technol*. 3:14-20, 1986.
286. Ho WG, Winston DJ, Champlin RE, Gale RP. Prophylactic use of immunoglobulin in bone marrow transplantation. *Intl J Cell Cloning*. 1986;4 (Suppl 1):174-80.
287. Butturini A, Seeger RC, Gale RP. Recipient immune-competent T lymphocytes can survive intensive conditioning for bone marrow transplantation. *Blood*. 1986;68:954-6.
288. Saxon A, Mitsuyasu R, Stevens R, Champlin RE, Kimata H, Gale RP. Designed transfer of specific immune responses with bone marrow transplantation. *J Clin Invest*. 1986;78:959-67.
289. Foon KA, Gale RP, Todd RF. Recent advances in the immunologic classification of leukemia. *Sem Hematol*. 1986;23:257-83.
290. Gale RP, Hoffbrand VA. Acute leukaemias: Biology and treatment. *Clin Hematol*. 1986;15:567-71.
291. Gale RP, Foon KA. Acute myeloid leukemia: Recent advances in therapy. *Clin Hematol*. 1986;15:781-810.
292. Gale RP, Champlin RE. Bone marrow transplantation in acute leukaemia. *Clin Hematol*. 1986;15:851-72.

293. Lewis JW, Shavit Y, Martin FC, Terman GW, Gale RP, Liebeskind JC. Effects of stress and morphine on natural killer cell activity and on mammary tumor development. In: Enkephalins and Endorphins: Stress and the Immune System. Plotnikoff N, Faith RE, Murgu AJ, Good RA, eds. Plenum Press, New York, 1986, pp 101-8.
294. Shavit Y, Depaulis A, Martin FC, Terman GW, Pechnick RN, Zane CJ, Gale RP, Liebeskind JC. Involvement of brain opiate receptors in the immune-suppressive effect of morphine. Proc Natl Acad Sci USA. 1986;83:7114-17.
295. Armitage JO, Gale RP. Bone marrow autotransplantation in man: Report of an international cooperative study. Lancet. 1986;2:960-6.
296. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNA's transcribed from the human abl gene and from of the bcr-abl fused gene. Cell. 1986;47:277-84.
297. Mitsuyasu RT, Li S, Champlin RE, Gale RP. Abnormal T-lymphocyte colonies cells (CFU-TL) following bone marrow transplantation. Exp Hematol. 1986;14:1049-55.
298. Gale RP. Chernobyl. Issues Sci Technol 1986;3:6-7.
299. Cassileth PA, Gale RP. Amsacrine: A review. Leuk Res. 1986;10:1257-65.
300. Gale RP. Acute myelogenous leukemia: Recent advances in therapy. In: Current Hematology and Oncology. Fairbanks VF, ed. Chicago, Year Book Medical Publishers, 1987, pp. 1-44.
301. Gale RP. Bone marrow failure. In: Internal Medicine. Stein JH, ed. Boston, Little, Brown and Company, 1987, pp. 1063-9.
302. Gale RP. T-cells, bone marrow transplantation, and immunotherapy: Use of monoclonal antibodies. In: Immune Interventions in Disease. Fahey JL, moderator. Ann Intern Med. 1987;106:257-74.
303. Hoelzer D, Gale RP. Acute lymphoblastic leukemia in adults: Recent progress, future directions. Sem Hematol. 1987;24:27-39.
304. Gale RP, Foon KA. Therapy of acute myelogenous leukemia. Sem Hematol. 1987;24:40-54.
305. Champlin RE, Gale RP. Bone marrow transplantation for acute leukemia: Recent advances and comparison with alternative therapies. Sem Hematol. 1987;24:55-67.
306. Bortin MM, Gale RP. Current status of allogeneic bone marrow transplantation: A report from the International Bone Marrow Transplant Registry. In: Clinical Transplants 1986. Terasaki PI, ed. Los Angeles, UCLA Tissue Typing Laboratory, 1987, pp. 17-30.
307. Shtivelman E, Gale RP, Drazzen O, Berrebi A, Zaizov R, Miyoshi I, Canaani E. bcr-abl in RNA in patients with chronic myelogenous leukemia. Blood. 1987;69:971-3.
308. Butturini A, Rivera GK, Bortin MM, Gale RP. Which treatment for childhood acute lymphoblastic leukemia in second remission? Lancet. 1987;1:429-32.

309. Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, Champlin RE. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. *Ann Intern Med* 1987;106:12-18.
310. Foon KA, Gale RP. Principles of leukaemia treatment. In: *Leukaemia*. Whittaker JA, Delamore IW, eds. Oxford, Blackwell Scientific Publications, 1987, pp 270-285.
311. Herzig RH, Barrett AJ, Gluckman E, Jacobsen SJ, Masaoka T, Ramsay NKC, Ringdon O, Zwaan FE, Bortin MM, Blume KG, Horowitz MM, Marmont A, Prentice HG, Rimm AA, Speck B, Gale RP. Bone-marrow transplantation in high-risk lymphoblastic leukaemia in first and second remission. *Lancet* 1987;1:786-88.
312. Gale RP, Ben-Bassat I. Hybrid acute leukemia. *Br J Haematol* 1987;65:261-4.
313. Gale RP, Touraine JL, Kochupillai V. Synopsis and perspectives on fetal liver transplantation. *Thymus* 1987;10:1-4.
314. Champlin RE, Cain G, Stitzel K, Gale RP. Sustained recovery of hematopoiesis and immunity following transplantation of fetal liver cells in dogs. *Thymus*. 1987;10:13-18.
315. Gale RP. Fetal liver transplantation in aplastic anemia and leukemia. *Thymus*. 1987;10:89-94.
316. Gale RP. Development of the immune system in human fetal liver. *Thymus*. 1987;10:45-56.
317. Champlin RE, Gale RP. Acute myelogenous leukemia: Recent advances. *Blood*. 1987;69:1551-62.
318. Champlin RE, Ho W, Winston D, Decker R, Greenberg P, Burnison M, Holley G, Gale RP. Treatment of adults with acute myelogenous leukemia prospective evaluation of high dose cytarabine in consolidation chemotherapy and with bone marrow transplantation. *Sem Oncol* 1987;14(Suppl 1):1-6.
319. Vaughan WP, Weisenburger DD, Sanger W, Gale RP, Armitage JO. Early leukemic recurrence of non-Hodgkin lymphoma after high-dose anti-neoplastic therapy with autologous marrow rescue. *Bone Marrow Transplant*. 1987;1:373-8.
320. Gale RP. The role of bone marrow transplantation in acute myelogenous leukemia. In: *Progress in Bone Marrow Transplantation*. Gale RP, Champlin RE, eds. New York, Alan R. Liss, 1987, pp 55-75.
321. Sallerfors B, Gale RP. A critical analysis of acute graft-versus-host disease in twins. In: *Progress in Bone Marrow Transplantation*. Gale RP, Champlin RE, eds. New York, Alan R. Liss, 1987, pp. 281-93.
322. Franceschini F, Butturini A, Gale RP. Clinical trials of T-cell depletion in bone marrow transplantation. In: *Progress in Bone Marrow Transplantation*. Gale RP, Champlin RE, eds. New York, Alan R. Liss, 1987, pp. 323-35.
323. Franceschini F, Gale RP. Immune reconstitution following bone marrow transplantation in man. In: *Progress in Bone Marrow Transplantation*. Gale RP, Champlin RE, eds. New York, Alan R. Liss, 1987, pp 607-22.
324. Champlin RE, Gale RP. Aplastic anemia. *Medicine Intl*. 1987;2:1748-51.
325. Kosmo M, Gale RP. Plasma cell leukemia. *Sem Hematol*. 1987;24:202-8.

326. Gale RP. The role of bone marrow transplantation following nuclear accidents. *Bone Marrow Transplant.* 1987;2:1-6.
327. Butturini A, Bortin MM, Seeger RC, Gale RP. Graft vs. leukemia following bone marrow transplantation: A model of immunotherapy in man. In: *Cellular Immunotherapy of Cancer.* Truitt RL, Gale RP, Bortin MM, eds. New York, Alan R. Liss, 1986, pp 371-90.
328. Vaughan WP, Weisenburger DD, Sanger W, Gale RP, Armitage JO. Early leukemia recurrence of non-Hodgkin lymphoma after high dose antineoplastic therapy with autologous marrow rescue. In: *Bone Marrow Transplantation: Recent Progress, Future Directions.* Gale RP, Champlin RE, eds. New York, Alan R. Liss, 1986, pp. 787-96.
329. Dreazen O, Klisak I, Rassool F, Goldman JM, Sparkes RS, Gale RP. Do oncogenes determine clinical features in chronic myeloid leukemia? *Lancet.* 1987;1:1402-5.
330. Foon KA, Gale RP. Immunologic classification of lymphoma and lymphoid leukemia. *Blood Rev.* 1987;1:77-88.
331. Gale RP. Medical consequences of nuclear energy: Lessons from Chernobyl. *Bone Marrow Transplant.* 1987;2 (Suppl 1):91-5.
332. Winston DJ, Ho WG, Gale RP, Champlin RE. Treatment and prevention of interstitial pneumonia after bone marrow transplantation. In: *Progress in Bone Marrow Transplantation.* Gale RP, Champlin RE, eds. New York, Alan R. Liss, 1987, pp 524-44.
333. Cain GR, Gale RP, Champlin RE. Fetal liver cell transplantation in dogs: Results with compatible and incompatible cells. In: *Progress in Bone Marrow Transplantation.* Gale RP, Champlin RE, eds. New York, Alan R. Liss, 1987, pp 689-94.
334. Armitage JO, Gale RP. Bone marrow autotransplantation: Results from an international cooperative study. In: *Progress in Bone Marrow Transplantation.* Gale RP, Champlin RE, eds. New York, Alan R. Liss, 1987, pp. 697-709.
335. Gale RP, Foon KA. Biology of chronic lymphocytic leukemia. *Sem Hematol.* 1987;24:209-29.
336. Foon KA, Gale RP. Staging and therapy of chronic lymphocytic leukemia. *Sem Hematol.* 1987;24:264-74.
337. Gale RP. Immediate medical consequences of nuclear accidents: Lessons from Chernobyl. *JAMA.* 1987;258:625-8.
338. Bolwell BJ, Cassileth PA, Gale RP. Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: A review. *Leukemia.* 1987;1:575-9.
339. Gale RP. Bone marrow purging: Current status, future directions. *Bone Marrow Transplant.* 1987. 2(Suppl 2):107-15.
340. Foon KA, Gale RP. Chemotherapy of chronic lymphocytic leukemia. In: *Chronic Lymphocytic Leukemia: Recent Progress and Future Directions.* Gale RP, Rai K, eds. New York, Alan R. Liss, 1987, pp 307-16.

341. Foon KA, Roth MS, Gale RP. Biological therapy of chronic lymphocytic leukemia and other lymphoproliferative disorders. In: Chronic Lymphocytic Leukemia: Recent Progress and Future Directions. Gale RP, Rai K., eds. New York, Alan R. Liss, 1987, pp 353-66.
342. Gale RP. A review of disordered immunity and hypogammaglobulinemia in chronic lymphocytic leukemia. In: Chronic Lymphocytic Leukemia: Recent Progress and Future Direction. Gale RP, Rai K, eds. New York, Alan R. Liss, 1987, pp 411-18.
343. Rai KR, Gale RP. Chronic lymphocytic leukemia: Future directions. In: Chronic Lymphocytic Leukemia: Recent Progress and Future Direction. Gale RP, Rai K, eds. New York, Alan R. Liss, 1987, pp 419-24.
344. Ho WG, Champlin RE, Winston DJ, Feig SA, Gale RP. Bone marrow transplantation in patients with leukemia previously transfused with blood products from family members. *Br J Haematol.* 67:67-70, 1987.
345. Lifshitz B, Fainstein E, Shtivelman E, Gale RP, Canaani E. bcr-related genes in the human genome. In: Recent Advances in Leukemia and Lymphoma. Gale RP, Golde DW, eds. New York, Alan R. Liss, 1987, pp 83-94.
346. Clements PJ, Furst DE, Ho WG, Gale RP. Progressive systemic sclerosis-like disease following bone marrow transplantation. In: Systemic Sclerosis. Black CM, Myers AR, eds. London, Gower, 1985, pp 376-81.
347. Gale RP. Use in chronic lymphocytic leukemia. In: Intravenous immunoglobulins as therapeutic agents. Steihm ER, moderator. *Ann Intern Med.* 1987;107:367-82.
348. Champlin RE, Ho WG, Mitsuyasu RT, Burnison M, Greenberg P, Holly G, Winston DJ, Feig SA, Gale RP. Graft rejection and leukemia relapse following T-lymphocyte depleted bone marrow transplants: Effect of intensification of immunosuppressive conditioning. *Transplant Proceed.* 1987;19:2616-19.
349. Gale RP, Rai KR. New insights into chronic lymphocytic leukemia. *Leukemia.* 1987;1:677-9.
350. Emerson SG, Gale RP. The regulation of hematopoiesis following bone marrow transplantation. *Intl J Cell Cloning.* 1987;5:432-49.
351. Gale RP. Calculating risk: Radiation and Chernobyl. *J Comm.* 1987;37:68-79.
352. Dreazen O, Klisak I, Goldman JM, Ho W, Sparkes RS, Gale RP. Rearrangement of bcr and c-abl genes in acute lymphoblastic leukemia and chronic myelogenous leukemia. In: Recent Advances in Leukemia and Lymphoma. Gale RP, Golde DW, eds. New York, Alan R. Liss, 1987, pp 103-17.
353. Gale RP. Leukemia chemotherapy. In: Recent Advances in Leukemia and Lymphoma. Gale RP, Golde DW, eds. New York, Alan R. Liss, 1987, pp 459-63.
354. Feig SA, Dreazen O, Wiley F, Gale RP. Post transplant leukemic relapse in cells of donor origin. In: Recent Advances in Leukemia and Lymphoma. Gale RP, Golde DW, eds. New York, Alan R. Liss, 1987, pp 545-9.
355. Gale RP. The role of bone marrow transplantation in acute myelogenous leukemia. In: Acute Leukemias: Prognostic Factors and Treatment Strategies. Buchner T, Schellong G, Hiddemann W, Urbanitz D, Ritter J, eds. Berlin, Springer-Verlag, 1987, pp 197-203.

356. Cevreska L, Gale RP. Prognostic factors in acute myelogenous leukemia. In: Acute Leukemias: Prognostic Factors and Treatment Strategies. Buchner T, Schellong G, Hiddemann W, Urbanitz D, Ritter J, eds. Berlin, Springer-Verlag, 1987, pp 376-9.
357. Dreazen O, Klisak I, Jones G, Ho WG, Sparkes RS, Gale RP. Multiple molecular abnormalities in Ph' chromosome positive acute lymphoblastic leukemia. *Br J Haematol.* 1987;67:319-24.
358. Fainstein E, Marcelle C, Rosner A, Canaani E, Gale RP, Dreazen O, Smith SD, Croce CM. A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukemia. *Nature.* 1987;330:386-8.
359. Butturini A, Bortin MM, Gale RP. Graft-vs-leukemia following bone marrow transplantation. *Bone Marrow Transplant.* 1987;2:233-42.
360. Butturini A, Gale RP. The role of T-cells in preventing relapse in chronic myelogenous leukemia. *Bone Marrow Transplant.* 1987;2:351-4.
361. Kosmo M, Gale RP. Trisomy 12 in Burkitt-like lymphoma associated with Acquired Immunodeficiency Syndrome. *Cytogenet.* 1987;29:245-51.
362. Dreazen O, Canaani E, Gale RP. Molecular biology of chronic myelogenous leukemia. *Sem Hematol.* 1988;25:35-48.
363. Champlin RE, Goldman JM, Gale RP. Bone marrow transplantation in chronic myelogenous leukemia. *Sem Hematol.* 1988;25:74-80.
364. Feig SA, Dreazen O, Simon M, Wiley F, Schreck R, Gale RP. B-cell acute lymphoblastic leukemia (ALL) in donor cells following bone marrow transplantation for T-cell ALL. *Bone Marrow Transplantat.* 1988;3:331-7.
365. Atkinson K, Horowitz MM, Biggs JC, Gale RP, Rimm AA, Bortin MM. The clinical diagnosis of acute graft-versus-host disease: A diversity of views amongst marrow transplant centers. *Bone Marrow Transplant.* 1988;3:5-10.
366. Gale RP, Goldman JM. How can results of bone marrow transplantation be improved? *Bone Marrow Transplantation.* 1988;3:1-4.
367. Gale RP, Bortin MM, van Bekkum DW, Biggs JC, Dicke KA, Gluckman E, Good RA, Hoffmann RG, Kay HEM, Kersey JH, Marmont A, Masaoka T, Rimm AA, van Rood JJ, Zwaan FE. Risk factors for acute graft-versus-host disease. *Br J Haematol.* 1987;67:397-406.
368. Dreazen O, Klisak I, Rassool F, Goldman JM, Sparkes RS, Gale RP. The bcr gene is joined to c-abl in Ph1 chromosome negative chronic myelogenous leukemia. *Oncogene Res.* 1988;2:167-75.
369. Butturini A, Shtivelman E, Canaani E, Gale RP. Oncogenes in human leukemias. *Acta Haemat.* 1987;78 (Suppl. 1): 2-10.
370. Cain G, Stitzel K, Gale RP, Champlin R. Transplantation of DLA-compatible and incompatible fetal liver hematopoietic cells in dogs. *Transplantation.* 1987;44:742-7.
371. Butturini A, Gale RP. Oncogenes and human leukemias. *Intl J Cell Cloning.* 1988; 6:2-24.
372. Bolwell BJ, Cassileth PA, Gale RP. High dose cytarabine: A review. *Leukemia.* 1987;1:575-9.

373. Champlin RE, Gale RP. Bone marrow transplantation: Its biology and role as treatment for acute and chronic leukemias. In: Ann NY Acad Sci. Peschle C, ed. New York, New York Academy of Science, 1988, pp 447-58.
374. Jacobs AD, Gale RP. Acute lymphoblastic leukemia in adults. In: Current Therapy in Hematology-Oncology-3. Brain MC, Carbone PP, eds. Toronto, B.C. Decker, 1988, pp 61-62.
375. Butturini A, Gale RP. Oncogenes in chronic lymphocytic leukemia. Leuk Res.1988;12:89-92.
376. Dreazen O, Berman M, Gale RP. Molecular abnormalities of bcr and c-abl in chronic myelogenous leukemia associated with a long chronic phase. Blood 1988;71:797-99.
377. Emerson S, Gale RP. Hemapoietic engraftment and differentiation after bone marrow transplantation. In: Hematopoiesis: Long-Term Effects of Chemotherapy and Radiation. Testa NG, Gale RP, eds. New York, Marcel Decker, 1988, pp 339-55.
378. Kedar E, Rezai AR, Giorgi J, Gale RP, Champlin RE, Mitsuyasu RT, Heitjan D, Fahey JL. Immunomodulating effects in vitro of interleukin-2 and interferon-gamma on the human blood and bone marrow mononuclear leukocytes. Natl Immun Cell Growth Regul 1988;7:13-30.
379. Gale RP, Reisner Y. The role of bone marrow transplants after nuclear accidents. Lancet. 1988;1:923-6.
380. Gale RP. Myelosuppressive effects of antineoplastic chemotherapy. In: Hematopoiesis: Effects of Chemotherapy and Radiation. Testa NG, Gale RP, eds. New York, Marcel Dekker, 1988, pp 63-73.
381. Gale RP, Butturini A. Oncogenes in acute myelogenous leukemia. In: Bone Marrow Transplantation: Experimental Hematology Today 1987. Baum SJ, Santos G, eds. New York, Springer-Verlag, 1987, pp 49-52.
382. Gale RP. Bone marrow transplantation following nuclear accidents. In: Recent Advances and Future Directions in Bone Marrow Transplantation: Experimental Hematology Today 1987. Baum SJ, Santos G, Takaku F, eds. New York, Springer-Verlag, 1987, pp 195-99.
383. Testa NG, Gale RP. Bone marrow function: Recent progress and future directions. In: Hematopoiesis: Effects of Chemotherapy and Radiation. Testa NG, Gale RP, eds. New York, Marcel Dekker, 1988, pp 403-6.
384. Butturini A, Gale RP. T-cell depletion in bone marrow transplantation: Current results, future directions. Bone Marrow Transplant. 1988;3:185-92.
385. Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Sem Hematol. 1988;25:140-58.
386. Gale RP, Foon KA. Daunorubicin or doxorubicin in acute myelogenous leukemia. Leukemia. 1988;2:209-10.
387. Antman K, Gale RP. Advanced breast cancer: High dose chemotherapy and bone marrow autotransplants. Ann Intern Med. 1988;108:570-4.
388. Lifshitz B, Fainstein E, Marcelle C, Shtivelman E, Amson R, Gale RP, Canaani E. bcr genes and transcripts. Oncogene. 1988;2:113-7.

389. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk of relapse associated with T-cell depletion. *Ann Intern Med.* 1988;108:806-14.
390. Kosmo MA, Gale RP. Plasma cell leukemia with IgA paraproteinemia and hyperviscosity. *Am J Hematol.* 1988;28:113-5.
391. Apperley JF, Mauro FR, Goldman JM, Gregory W, Arthur CK, Hows J, Arcese W, Papa G, Mandelli F, Wardle D, Gravett P, Franklin IM, Bandini G, Ricci P, Tura S, Iacone A, Torlantino G, Heit W, Champlin RE, Gale RP. Bone marrow transplantation for chronic myeloid leukemia in first chronic phase: Importance of a graft-versus-leukemia effect. *Br J Haematol.* 1988;69:239-45.
392. Gale RP. Perspective: The medical response to radiation and nuclear accidents: Lessons for the future. *J Natl Cancer Inst* 1988;80:995-8.
393. Winston D, Ho WG, Bartoni K, Holland GN, Mitsuyasu RT, Gale RP, Busuttill RW, Champlin RE. Gancyclovir therapy of cytomegalovirus infections in bone marrow transplants and other immunosuppressed patients. In: *Reviews of Infectious Diseases* 1988;10(Suppl 3):547-53.
394. Antman K, Gale RP. High dose chemotherapy and bone marrow autotransplants for breast cancer. In: *Breast Cancer.* Di Martinoi L, ed. Cagliari, Ettore Gasperini Editore, 1988, pp. 167-73.
395. Gale RP, Goldman JM. Rapid progress in chronic myelogenous leukemia. *Leukemia.* 1988;2:321-4.
396. Butturini A, Shtivelman E, Canaani E, Gale RP. Oncogenes in human leukemias. *Cancer Investigation* .1988;6:305-315.
397. Butturini A, De Souza PC, Gale RP, Cordiero JM, Lopes DM, Neto C, Cunha CB, De Souza CEP, Ho WG, Tabak DG, Sanpai JM, Burla A, & Navy Hospital Radiation Team. Use of recombinant granulocyte-macrophage colony stimulating factor in the Brazil radiation accident. *Lancet.* 1988;2:471-4.
398. Winston D, Ho WG, Bruckner DA, Gale RP, Champlin RE. Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients. *Am J Med.* 1988;85(Suppl 1A): 21-30.
399. Bunch C, Chapel HM, Dicato M, Lee M, Gale RP & the Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: A randomized, controlled clinical trial. *N Engl J Med.* 1988;319:902-7.
400. Ben-Bassat I, Gale RP. New and evolving concepts in leukemia. *Leukemia.* 1988;2:704-7.
401. Gale RP. Chronic myelogenous leukaemia: a model for human cancers. In: *Bailliere's Clin Hematol* 1987;1:869-886.
402. Gale RP. Medical response to nuclear reactor accidents. In: *Radiation accidents, nuclear energy and nuclear war: Medical consequences and therapy.* Champlin RE, moderator. *Ann Intern Med.* 1988;109(9): 730-44.
403. Gale RP. Short term medical consequences of the Chernobyl nuclear accident: Lessons for the future. *Can Family Phys.* 1988;34:2565-70.

404. Gale RP, Butturini A. Acute lymphoblastic leukemia: Chemotherapy versus transplantation. In: Bone Marrow Transplantation: Current Controversies. Gale RP, Champlin RE, eds. New York, Alan R. Liss, pp 66-74, 1988.
405. Foon KA, Gale RP. Chemotherapy of acute myelogenous leukemia. In: Bone Marrow Transplantation: Current Controversies. Gale RP, Champlin RE, eds. New York, Alan R. Liss, pp. 75-94, 1988.
406. Armitage JO, Gale RP. Bone marrow autotransplants- A new direction in cancer therapy?. In: Bone Marrow Transplantation: Current Controversies. Gale RP, Champlin RE, eds. New York, Alan R. Liss, pp 229-35, 1988.
407. Antman K, Gale RP, et al. High dose chemotherapy and autologous bone marrow support for breast cancer. In: Bone Marrow Transplantation: Current Controversies. Gale RP, Champlin RE, eds. New York, Alan R. Liss, pp 253-63, 1988.
408. Butturini A, Gale RP. Clinical trials of T-cell depletion. In: Bone Marrow Transplantation: Current Controversies. Gale RP, Champlin RE, eds. New York, Alan R. Liss, pp 495-509, 1988.
409. Gale RP. Medical response to nuclear accidents. In: Bone Marrow Transplantation: Current Controversies. Gale RP, Champlin RE, eds. New York, Alan R. Liss, pp 671-80, 1988.
410. Bortin MM, Horowitz MM, Gale RP. Current status of bone marrow transplantation in humans: A report from the International Bone Marrow Transplant Registry. In: Practical Bone Marrow Transplantation. Kato S, ed. Tokyo, Nihon-Igakukan Press, pp 295-6, 1988.
411. Gale RP. Recent radiation accidents. *Alabama J Med Sci.* 1988;25:439-44.
412. Winston D, Ho W, Gale RP, Champlin R. Prophylaxis of infection in bone marrow transplants. *Eur J Cancer Clin Oncol.* 1988;24(Suppl 1): 815-23.
413. Gale RP. Current issues in chronic lymphocytic leukemia. In: *Nou Rev Francaise d'Hematol.* 1988;30:263-5.
414. Foon KA, Gale RP. Clinical transformation of chronic lymphocytic leukemia. In: *Nou Rev Francaise d'Hematol.* 1988;30:385-8.
415. Wormsley SB, Rai KR, Gale RP. Analysis of treatment response in chronic lymphocytic leukemia. In: *Nou Rev Francaise d'Hemato.l* 1988;30:413-17.
416. Bortin MM, Horowitz MM, Gale RP. Current status of bone marrow transplantation in humans: Report from the International Bone Marrow Transplant Registry. *Natrl Immun Cell Growth Regul* 1988;7:334-50.
417. Bortin MM, Gale RP. Current status of allogeneic bone marrow transplantation in Leukemia: A report from the International Bone Marrow Transplant Registry. In: *Clinical Transplants 1987.* Terasaki PI, ed. Los Angeles, UCLA Tissue Typing Laboratory, pp. 127-40.
418. Foon KA, Gale RP. Chronic lymphocytic leukemia and related diseases. In: *Recent Advances in Haematology 5.* Hoffbrand AV, ed. Edinburgh, 1988, Churchill Livingstone, pp. 179-209.
419. Armitage JO, Gale RP. Bone marrow autotransplantation. *Am J Med.* 1989;86:203-6.

420. Gale RP, Butturini A. The role of hematopoietic growth factors in nuclear and radiation accidents. In: *Experimental Hematology Today*. Baum S, Dicke K, Lotzova E, Pluznik D, eds. New York, Springer-Verlag, 1988, pp 179-82.
421. Butturini A, Franceschini F, Gale RP. Critical analysis of T-cell depletion in man. In: *T-Cell Depletion in Allogeneic Bone-Marrow Transplantation*. Grignani R, Reisner Y, Martelli F, eds. Rome, Aies-Serono Symposia, 1988, pp 1-13.
422. Binet JL, Catovsky D, Dighiero H, Gale RP, Montserrat E, Rai KR, Rozman C, Sawitsky C. Chronic lymphocytic leukemia: Recommendations for diagnosis, staging and response criteria. *Ann Intern Med*. 1989;110:236-7.
423. Champlin RE, Horowitz MM, van Bekkum DW, Camitta BM, Elfenbein GE, Gale RP, Gluckman E, Good RA, Rimm AA, Rozman C, Speck B, Bortin MM. Graft failure following bone marrow transplantation for severe aplastic anemia: Risk factors and treatment results. *Blood* 1989;73:606-13.
424. Foon KA, Gale RP. Interferon therapy of chronic lymphocytic leukemia and viral infections in leukemia patients. In: *Clinical Aspects of Interferon*. Revel M, ed. Massachusetts, Kluwer, 1989, pp 141-8.
425. Gale RP. Bone marrow transplantation in leukemia. *Labmedica* 1989;6:23-29.
426. Horowitz MM, Gale RP, Barrett J, et al. Effect of methotrexate on relapse after bone marrow transplantation for acute lymphoblastic leukemia. *Lancet*. 1989;1:535-7.
427. Goldman JM, Rassool F, Dreazen O, Klisak I, Gale RP. Ph-negative chronic myeloid leukaemia: molecular similarity but clinical deviation from Ph-1 positive disease. In: *T-Cell Depletion in Allogeneic Bone-Marrow Transplantation*. Grignani R, Reisner Y, Martelli F, eds. Rome, Aies-Serono Symposia, 1988, pp 27-36.
428. Bunch CR, Chapel H, Gale RP. Infectious complications in chronic lymphocytic leukemia. In: *Chronic Lymphocytic Leukemia*. Polliak A, Catovsky D. Chur Switzerland, Harwood Academic Publishers, 1989, pp. 249-62.
429. Foon KA, Gale RP, Todd RF. Immunologic approaches to the classification and therapy of lymphomas and lymphoid leukemias. In: *Lymphomas/Leukemias III: Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias*. Bennett JM, Foon KA, eds. Boston, Martinus Nijhoff, 1989, pp 1-30.
430. Kuriyama K, Gale RP, Tomonaga M, Ikeda S, Yao E, Klisak I, Whelan K, Yakir H, Ichimaru M, Sparkes RS, Dreazen O. CML-T1: A cell line derived from T-lymphocyte acute phase of chronic myelogenous leukemia. *Blood*. 1989;74:1381-87.
431. Baranov AE, Gale RP, Guskova AK, Pyatkin EK, Champlin R, Selidovkin GD, Muravyova LI, Terasaki P, Reisner Y, Danilova NB, Evseeva LV, Petrosyan LN, Pushkareva SG, Konchalovsky MV, Gordeeva AA, Toporkova TD, Protasova TG, Suvorova LA. Transplantation of bone marrow after total irradiation in victims of the breakdown at the Chernobyl atomic power plant. *Hematology and Transfusion (USSR)*, Issue 3:3-16, 1989.
432. Weiner RS, Horowitz MM, Gale RP, van Bekkum DW, Dicke KA, Marmont AM, Masaoka T, Ramsay NKC, Rimm AA, Rozman C, Bortin MM. Risk factors for interstitial pneumonia following bone marrow transplantation for severe aplastic anemia. *Br J Haematol*. 1989;71:535-43.

433. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. *Bone Marrow Transplant.* 1989;4:247-54.
434. Gale RP, Armitage JO, Butturini A. Is there a role for autotransplants in acute leukemia. *Bone Marrow Transplant.* 1989;4:217-19.
435. Butturini A, Gale RP. Chemotherapy versus transplantation: I. Acute myelogenous leukemia. *Haematologica.* 1989;74:1-4.
436. Butturini A, Gale RP. Chemotherapy versus transplantation in acute leukemia. *Br J Haematol.* 1989;72:1-8.
437. Gale RP, Horowitz MM, Biggs JC, Herzig RH, Kersey JH, Marmont AM, Masaoka T, Rimm AA, Speck B, Weiner RS, Zwaan FE, Bortin MM for the Advisory Committee of the International Bone Marrow Transplant Registry. Transplant or chemotherapy in acute myelogenous leukemia. *Lancet.* 1989;1:119-22.
438. Gale RP, Gluckman E, Horowitz M, Champlin R, Bortin MM for the Advisory Committee of the International Bone Marrow Transplant Registry. Graft-failure following transplants for aplastic anemia: Evidence for an immune mechanism. *Bone Marrow Transplant.* 1989;4:115.
439. Gale RP, Marmont A, Horowitz M, Bortin MM, for the Advisory Committee of the International Bone Marrow Transplant Registry. T-cell depletion to prevent graft-versus-host disease: Preliminary univariate analysis of the IBMTR. *Bone Marrow Transplant.* 1989;4:121.
440. Gale RP. Current status of autotransplants in acute leukemia. In: *Autologous Bone Marrow Transplantation: Proceeding of the Fourth International Symposium.* Dicke KA, Spitzer G, Jagannath S, Evinger-Hodges MJ, eds. Houston, University of Texas M.D. Anderson Cancer Center 1989, pp 813-17.
441. Champlin RE, Gale RP. Acute lymphoblastic leukemia: Recent advances in biology and therapy. *Blood.* 1989;73:2051-66.
442. Marmont AM, Gale RP, Butturini A, Goldman JM, Martelli MF, Prentice HG, Slavin S, Storb R, Truitt RL, Van Bekkum D. T-cell depletion in allogeneic bone marrow transplantation: progress and problems. *Hematologica.* 1989;74:235-48.
443. Baranov A, Gale RP, Guskova A, Piatkin E, Selidovkin G, Muravyova LI, Champlin RE, Danilova N, Yevseeva L, Petrosyan L, Pushkareva S, Konchalovsky M, Gordeeva A, Protasova T, Reisner Y, Mickey MR, Terasaki PI. Bone marrow transplantation following the Chernobyl nuclear accident. *N Engl J Med.* 1989;321:205-13.
444. Barrett AJ, Lucarelli G, Gale RP, Sobocinski A, Horowitz M, Bortin MM. Bone marrow transplantation for thalassemia - a preliminary report from the International Bone Marrow Transplant Registry. In: *Advances and Controversies in Thalassemia Therapy: Bone Marrow Transplantation and Other Approaches.* Buckner G, Gale RP, Lucarelli G, eds. New York, Alan R. Liss, 1989, pp 173-87.
445. Gale RP. Prospects for correction of thalassemia by genetic engineering. In: *Advances and Controversies in Thalassemia Therapy: Bone Marrow Transplantation and Other Approaches* Buckner G, Gale RP, Lucarelli G, eds. New York, Alan R. Liss, 1989, pp 141-63.
446. Gale RP, Butturini A. Is transplantation in first remission AML more effective than in advanced leukemia? *Leuk Res.* 1989;12:1035-38.

447. Barrett AJ, Horowitz MM, Gale RP, Biggs JC, Blume KG, Camitta BM, Dicke KA, Gluckman E, Good RA, Herzig RH, Lee MB, Marmont AL, Masaoka T, Ramsay NKC, Rimm AA, Speck B, Zwaan FE, Bortin MM. Marrow transplantation for acute lymphoblastic leukemia: Factors affecting relapse and survival. *Blood*. 1989;74:862-71.
448. Gale RP. Medical response to nuclear accidents. In: *New Aspects of Disaster Medicine. Proceedings of the Asian-Pacific Conference on Disaster Medicine*. Ohta M, Ukai T, Yamamoto Y, eds. Tokyo, Herusu Publishing, 1989, pp 7-9.
449. Gale RP, Butturini A. Autotransplants in leukemia. *Lancet*. 1989;2:315-17.
450. Gorin NC, Gale RP, Armitage JO for the Advisory Committee of the International Autologous Bone Marrow Transplant Registry. Autologous Bone Marrow Transplants: Different indications for transplantation in Europe and North America. *Lancet*. 1989;2:317-8.
451. Butturini A, Gale RP. How can we cure leukemia. *Br J Haematol*. 1989;72:479-85.
452. Shavit Y, Martin FC, Yirmiya R, Ben-Eliyahu S, Terman GW, Weiner H, Gale RP, Liebeskind JC. Effects of a single administration of morphine or footshock stress on natural killer cell cytotoxicity. *Brain Behavior and Immunity*. 1987;1:318-28.
453. Gale RP, Binet JL, Catovsky D, Dighiero G, Montserrat E, Rai K, Rozman C, Sawitsky A. 4th International Workshop on CLL. *Leuk Res*. 1989;13:505-11.
454. Gale RP, Hoelzer D. Acute lymphoblastic leukemia: Current controversies, future directions. *Leukemia* 1989;3:681-6.
455. Stadtmauer EA, Cassileth PA, Gale RP. Etoposide in leukemia, lymphoma and bone marrow transplantation. *Leuk Res*. 1989;13:639-50.
456. Beilin Benzion B, Martin FC, Shavit Y, Gale RP, Liebeskind JC. Suppression of natural killer cell activity by high dose narcotic anesthesia in rats. *Brain Behavior and Immunity*. 1989;3:129-37.
457. Maitreyan V, Gale RP. What is hybrid acute leukemia. *Leuk Res* 1989;13:725-8.
458. Butturini A, Gale RP. Age of onset and type of leukemia. *Lancet*.. 1989;2:789-91.
459. Gale RP, Buchner Th. Acute leukemia: prognostic factors and treatment strategies. *Leukemia*. 1989;3:758-61.
460. Butturini A, Gale RP. Chemotherapy versus transplantation: II Acute lymphoblastic leukemia. *Hematologica*. 1989;74:337-9.
461. Li W, Dreazen O, Kloetzer W, Gale RP, Arlinghaus, RB. Characterization of bcr gene products in hematopoietic cells. *Oncogene*. 1989;4:127-38.
462. Gale RP, Butturini A. Controversies in the biology and therapy of acute lymphoblastic leukemia. In: *Acute Lymphoblastic Leukemia: Current Controversies*. Gale RP, Hoelzer D, eds. New York, Alan R. Liss, 1989, pp 299-308.
463. Foon KA, Champlin RE, Gale RP. Therapy of Acute lymphoblastic leukemia. In: *Acute Lymphoblastic Leukemia: Current Controversies*. Gale RP, Hoelzer D, eds. New York, Alan R. Liss, 1989, pp 157-96.

464. Gale RP. Short term medical consequences of the Chernobyl nuclear accident: Lessons for the future. In: Horizons in Medicine. Bunch CR, ed. London, Bailliere-Tindall Ltd., 1989, pp 256-62.
465. Fainstein E, Einat M, Gokkel E, Marcellle C, Croce C, Gale RP, Canaani E. Nucleotide sequence analysis of human abl and bcr-abl cDNAs. *Oncogene* 1989;4:1477-81.
466. Gale RP and Foon KA. Chronic leukemias. In: *Conn's Current Therapy*. Rakel RE, ed. Philadelphia, W.B. Saunders, pp 376-384, 1990.
467. Gale RP and Butturini A. Bone marrow transplants in acute lymphoblastic leukemia. In: *Bone Marrow Transplantation: Advances in Biology and Clinical Applications*. Champlin R, ed. New York, Kluwer Academic Press 1990, pp 223-33.
468. Foon KA, Gale RP, Todd RF III. Immunologic advances in the classification of leukemia. In: *The Biology of Human Leukemia*. Mauer AM, ed. Baltimore, Johns Hopkins University Press, pp 44-93, 1990
469. van Damm J, Farraye FA, Gale RP, Zeldis JB. Fulminant hepatic failure following bone marrow transplantation for hepatitis associated aplastic anemia. *Bone Marrow Transplant*. 1990;5:57-69.
470. Bortin MM, Atkinson K, van Bekkum DW, Biggs JC, Dicke KA, Gale RP, et al. Factors influencing the risk of acute and chronic graft-versus-host disease in humans: a preliminary report from the IBMTR. *Bone Marrow Transplant*. 1990;4(Suppl 1): 222-4.
471. Bernstein R, Gale RP. Do chromosome abnormalities determine the type of acute leukemia that develops in CML? *Leukemia*. 1990;4:65-8.
472. Berkman S, Lee M, Gale RP. Clinical uses of intravenous immunoglobulins. *Ann Intern Med*. 1990;112:278-86.
473. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H-J, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin M. Graft-versus-leukemia reactions after bone marrow transplantations. *Blood*. 1990; 75:555-62.
474. Gale RP, Horowitz M, Bortin M. IBMTR analysis of bone marrow transplants in acute leukemia. *Bone Marrow Transplant*. 1990;4:83-5.
475. Gale RP, Butturini A. Emergency response to nuclear and radiation accidents. *Bone Marrow Transplant*. 1989;4(Suppl 4): 2-3.
476. Gale RP. USSR: Follow-up after Chernobyl. *Lancet*. 1990;335:401-2.
477. Butturini A, Gale RP. Oncogenes and human leukemias. *Leukemia*. 1990;4:138-60.
478. Gale RP, Butturini A. Treatment strategies for acute lymphoblastic leukemia. In: *Acute Leukemia*. Buchner TH, Schellong G, Hiddemann W, Ritter J, eds. Berlin, Springer Verlag, pp. 684-7, 1990.
479. Gale RP. Bone marrow failure. In: *Internal Medicine, Third Edition*. Stein JH, ed. Boston, Little, Brown and Company, pp. 1109-14, 1990.
480. Gale RP, Lee ML. Do different therapies of AML produce different outcomes. *Leuk Res*. 1990;14:207-8.

481. Butturini A, Gale RP. T-cell depletion in bone marrow transplantation. *Clin Transplant*. 1989;3:122-8.
482. Gale RP, Butturini A. Ph1-chromosome positive ALL and lymphoid acute phase of CML: One or two diseases. Two. *Leuk Res*. 1990;14:295-7.
483. Sun G, Sparkes RS, Wormsley S, Naeim F, Champlin R, Gale RP. Are some cases of acute leukemia with t(8;21) hybrid leukemias? *Cancer Genet and Cytogenet*. 1990;49:177-84.
484. Butturini A, Keating A, Goldman JM, Gale RP. Autotransplants in chronic myelogenous leukemia: Strategies and results. *Lancet*. 1990;1:1255-7.
485. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ, Sawitsky AA, Stass S, Weinstein H, Wood WA. Report of the NCI-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. *J Clin Oncol*. 1990;8:813-9.
486. Gale RP, Horowitz MM for the Advisory Committee of the International Bone Marrow Transplant Registry. Graft versus leukemia in bone marrow transplantation. *Bone Marrow Transplant*. 1990; 6(suppl 1): 94-7.
487. Berenson J, Gale RP. Acute lymphoblastic leukemia. In: *Cancer Treatment*. Haskell CM, ed. Philadelphia, W.B. Saunders, 1990, pp 606-20.
488. Foon KA, Gale RP, Champlin RE. Acute myelogenous leukemia: In: *Cancer Treatment*. Haskell CM, ed. Philadelphia, W.B. Saunders, 1990, pp 589-606.
489. Sun G, Koeffler HP, Gale RP, Sparkes RS, Schreck RR. Use of conditioned media in cell culture can mask cytogenetic abnormalities in acute leukemia. *Cancer Genet Cytogenet*. 1990;46:107-13.
490. Gale RP, Butturini A. Transplants of blood-derived hematopoietic stem cells. *Bone Marrow Transplant*. 1990;5(suppl 1):2-4.
491. Gale RP, Butturini A. Xenophobia. T-cells and a journey to a foreign land. *Thymus*. 1990;16:1-5.
492. Gale RP. Chernobyl today. *Bulletin of the Atomic Scientist.s* 1990;46:19-24.
493. Marcelle C, Gale RP, Prokocimer M, Merle-Beral H, Canaani E. Analysis of bcr-abl mRNA in chronic myelogenous leukemia patients and the identification of a new bcr-related sequence in human DNA. *Genes, Chromosomes and Cancer*. 1989;1:172-9.
494. Gale RP, Butturini A. The role of hematopoietic growth factors in nuclear and radiation accidents. *Exp Hematol*. 1990;18:958-64.
495. Gale RP. Acute myelogenous leukemia. Progress and controversies. *Leukemia*. 1990;4:529-31.
496. Aurer I, Ribas A, Gale RP. What is the role of recombinant colony stimulating factors in bone marrow transplantation. *Bone Marrow Transplantation* 1990;6:79-87.
497. Gale RP. Long-term impact from Chernobyl in USSR. *Forum for App Res Publ Pol*, Fall 1990;93-4.
498. Keating A, Gale RP. Evaluating therapy of AML. In: *Acute Myelogenous Leukemia: Progress and Controversies*. Gale RP, ed. New York: Alan R. Liss, 1990, pp. 163-4.

499. Foon KA, Gale RP. Alternate first-line treatment for acute myelogenous leukemia. In: Acute Myelogenous Leukemia: Progress and Controversies. Gale RP, ed. New York: Alan R. Liss, 1990, pp. 353-61.
500. Gale RP, Butturini A. Strategies to treat acute myelogenous leukemia. In: Acute Myelogenous Leukemia: Progress and Controversies. Gale RP, ed. New York: Alan R. Liss, 1990, pp. 375-9.
501. Gale, RP. Acute myelogenous leukemia: Progress and controversies. In: Acute Myelogenous Leukemia: Progress and Controversies. Gale RP, ed. New York: Alan R. Liss, 1990, pp. 493-500.
502. Santucci T, Butturini A, Gale RP. Can long term bone marrow culture eliminate leukemia cells? *Leukemia and Lymphoma*. 1990;3:87-91.
503. Butturini A, Santucci MA, Gale RP, Perocco P, Tura S. GM-CSF incubation prior to treatment with cytarabine or doxorubicin enhances drug activity against AML cells in vitro. A model for leukemia chemotherapy. *Leuk Res*. 1990;14:743-9.
504. Foon KA, Rai KR, Gale RP. Chronic lymphocytic leukemia: New insights into biology and therapy. *Ann Intern Med*. 1990;113:525-39.
505. Goldman J, Grosveld G, Baltimore D, Gale RP. Chronic myelogenous leukemia: the unfolding saga. *Leukemia*. 1990;4:163-7.
506. Butturini A, Gale RP. New strategies in T-cell depletion. *Bone Marrow Transplant*. 1990;6:225-7.
507. Canaani E, Gale RP, Marcelle C, Fainstein E, Prokocimer M, Berrebi A. *acr-abl* in CML and AML. In: *Chronic Myelogenous Leukemia Molecular Approaches to Research and Therapy*. Deisseroth A, Arlinghaus RB, eds. New York, Marcel Dekker, 1990, pp. 217-41.
508. Butturini A, Gale RP, Graft-versus-leukemia in chronic myelogenous leukemia. In: *Chronic Myelogenous Leukemia Molecular Approaches to Research and Therapy*. Deisseroth A, Arlinghaus RB, eds. New York, Marcel Dekker, 1990, pp 377-87.
509. Butturini A, Gale RP. Role of hematopoietic growth factors in radiation victims. In: *Treatment of Radiation Injuries*. Browne D, Weiss J, MacVittie TJ, Pillai M, eds. New York, Plenum, 1991, pp 127-32.
510. Gale RP, Butturini A. How do bone marrow transplants cure leukemia. In: *New Strategies in Bone Marrow Transplantation*. Gale RP, Champlin R, eds. New York: Wiley/Liss, 1991, pp 109-18.
511. Butturini A, Gale RP. New strategies for T-cell depletion. In: *New Strategies in Bone Marrow Transplantation*. Gale RP, Champlin R, eds. New York: Wiley/Liss, 1991, pp 267-74.
512. Horowitz MM, Gale RP. Graft-versus-leukemia. In: *New Strategies in Bone Marrow Transplantation*. Gale RP, Champlin R, eds. New York: Wiley/Liss, 1991, pp 275-80.
513. Foon K, Gale RP. The chronic leukemias. In: *Conn's Current Therapy*. Rakel RE, ed. Philadelphia, W.B. Saunders, 1991, pp 363-73.
514. Gale RP, Butturini A. Use of hematopoietic growth factors in radiation accidents. *Intl J Rad Oncol Biol and Phys*. 1990;19:1291-5.

515. Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Ofloxacin versus vancomycin/polymixin for prevention of infections in granulocytopenic patients. *Am J Med.* 1990;88:36-42.
516. Gale RP, Ben-Bassat I. Is remission in acute leukemia reestablishing a preleukemia phase. *Leuk Res.* 1990;14:825-39.
517. Gale RP, Horowitz MM. How best to analyze new strategies in bone marrow transplantation. *Bone Marrow Transplant.* 1990;6:357-59.
518. Yirmiya R, Shavit Y, Ben-Eliyahu S, Gale RP, Liebeskind JC, Taylor AN, Weiner H. Modulation of immunity and neoplasia by neuropeptides released by stressors. In: *Stress, Neuropeptides and Systemic Disease.* Kaufmann PG, McCubbin JA, Nemeroff CB, eds. Academic Press, pp. 262-86.
519. Butturini AB, Gale RP. Relationship between clonality and transformation in acute leukemia. *Leuk Res.* 1991;15:1-7.
520. Gale RP, Butturini A, Bortin M. What does total body radiation do in bone marrow transplants for leukemia? *Intl J Rad Oncol Biol Phys.* 1991;20:631-4.
521. Gale RP, Armitage JA, Dicke KA. Meeting report. Autotransplants: now and in the future. *Bone Marrow Transplant.* 1991;7:153-7.
522. Henon PR, Butturini A, Gale RP. Blood derived hematopoietic cell transplants: Blood to blood. *Lancet.* 1991;337:961-3.
523. Aurer I, Gale RP. Review: Are new conditioning regimens in AML better? *Bone Marrow Transplant.* 1991;7:255-61.
524. Gale RP, Butturini A, Bortin MM. Bone marrow transplantation in children and adolescents with leukemia. In: *Childhood Cancer: Present Problems and Future Directions.* Akera T, Akatsuka K, Kobayashi N, eds. Tokyo, Medical Information Services, 1991, pp 179-83.
525. Butturini A, Gale RP. Detecting minimal residual leukemia. *Cancer Genet Cytogenet.* 1991; 52:19-26.
526. Gale RP. Will more intensive chemotherapy of leukemia increase cures. *Leuk Res.* 1991;15:185-7.
527. Gale RP, Butturini A. Strategies for acute myelogenous leukemia. *Bone Marrow Transplant (Suppl 2)* 1991;7:58.
528. Gale RP, Horowitz MM, Butturini AB, for the Advisory Committee of the IBMTR. Autotransplants in acute leukemia. *Br J Haematol.* 1991;78:135-7.
529. Sun G, Wormsley S, Sparkes RF, Naeim F, Gale RP. Hybrid leukemia and the 5q-abnormality. *Leuk Res.* 1991;15:351-6.
530. Gale RP, Butturini A. Perspective: Chernobyl and leukemia. *Leukemia.* 1991;5:441-2.
531. Gale RP, Horowitz M, Butturini A. Autotransplants in leukemia: Approaches to prevent leukemia relapse. In: *Autologous Bone Marrow Transplantation IV.* Dicke K, Armitage JO, Dicke-Evinger, MJK eds. University of Nebraska Press, pp 255-7, 1991.

532. Foon K, Champlin R, Gale RP. Therapy of acute lymphoblastic leukemia. In: Acute Lymphoblastic Leukemia. Gale RP, Hoelzer D, eds. Wiley-Liss, New York, pp 157-96, 1990.
533. Gale RP, Hoelzer D. Acute lymphoblastic leukemia: Current controversies, future directions. In: Acute Lymphoblastic Leukemia. Gale RP, Hoelzer D, eds. Wiley-Liss, New York, pp 309-22, 1990.
534. Gale RP, Butturini A. Controversies in the biology and therapy of acute lymphoblastic leukemia. In: Acute Lymphoblastic Leukemia. Gale RP, Hoelzer D, eds. Wiley-Liss, New York, pp 299-308, 1990.
535. Gale RP. Meeting report: Autotransplants: Now and in the future. In: Autologous Bone Marrow Transplantation IV. Dicke K, Armitage JO, Dicke-Evinger MJK, eds. University of Nebraska Press, pp 905-10, 1991 .
536. Surbone A, Armitage J, Gale RP. Autotransplantation in lymphoma: better therapy or healthier patients. *Ann Intern Med.* 1991;114:1059-60.
537. Gale RP. Chronic myelogenous leukemia: Molecule to man. *Henry Ford Hosp Med J* 1991;39:108-11.
538. Winston D, Gale RP. Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990's. *Bone Marrow Transplant.* 1991; 8:7-11.
539. Ash RC, Horowitz MM, Gale RP, van Bekkum DW, Casper JT, Gordon-Smith EC, Henslee PJ, Kolb H-J, Lowenberg R, Masaoka T, McGlave PB, Rimm AA, Ringden O, van Rood JJ, Sondel PM, Vowels MR, Bortin MM. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T-cell depletion. *Bone Marrow Transplant.*1991;7:443-52.
540. Aurer I, Ribas A, Gale RP. Hematopoietic growth factors in bone marrow transplantation: Current and future directions. *Haematologica,* 1991;76:85-8.
541. Horowitz MM, Messerer D, Hoelzer D, Gale RP, Neiss A, Atkinson K, Barrett AJ, Kolb H-J, Marmont AM, O'Reilly RJ, Rimm AA, Rozman C, Sobocinski KA, Speck B, Weisdorf DJ, Zwaan FE, Bortin MM. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. *Ann Intern Med* 1991;115:13-18.
542. Gale RP, Butturini A, Reizenstein P. Autotransplants in leukemia: current state, future progress. *Leuk Res.* 1991;15:781-4.
543. Gale RP, Butturini A, Horowitz M. Does more intensive chemotherapy increase cures in acute leukemia. *Sem Hematol.*1991;28 (Suppl 4):93-4.
544. Marmont AM, Horowitz MM, Gale RP, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA, Herzig RH, Hong R, Masaoka T, O'Reilly RJ, Prentice HG, Rimm AA, Ringden O, Speck B, Weiner RS, Bortin MM. T-cell depletion of HLA-identical transplants in leukemia. *Blood.* 1991; 78:2120-30.
545. Gale RP, Butturini A. Medical response to nuclear and radiation accidents. *State Art Rev Occ Med.* 1991;6:581-96.
546. Aurer I, Butturini A, Gale RP. BCR-ABL rearrangements in children with Philadelphia chromosome positive chronic myelogenous leukemia. *Blood.* 1991;78:2407-10.

547. Gale RP. Biologic features of CLL. *Leukemia and Lymphoma*. 1991; 5 (Suppl):3-5.
548. Butturini A, Gale RP. Maintenance chemotherapy and cure of childhood acute lymphoblastic leukemia. *Lancet*. 1991;338:1315-18.
549. Barlogie B, Gale RP. Multiple myeloma and chronic lymphocytic leukemia: commonalities and differences in biology and therapy. *Leukemia and Lymphoma*. 1991;5 (Suppl):27-32.
550. Gale RP, Butturini A. Stem cell clonality and leukemia. *Hematology and Transfusion (in Russian)*, 1026-30, 1991.
551. Fainstein E, Cimino G, Gale RP, Alimena G, Berthier R, Kishi KA, Goldman J, Zaccaria A, Berrebi A, Canaani E. p53 in chronic myelogenous leukemia in acute phase. *Proc Natl Acad Sci (USA)*, 1991;88:6293-7.
552. Aurer I, Canaani E, Gale RP. Hypothesis: Additional cytogenetic abnormalities and progression to acute phase in chronic myelogenous leukemia. *Leukemia*. 1991;5:1012-3.
553. Sun G, Wormsley S, Sparkes RS, Naeim F, Gale RP. Where does transformation occur in acute leukemia. *Leuk Res*. 1991;15:1183-9.
554. Ben-Eliyahu S, Yirmiya R, Liebeskind JC, Taylor A, Gale RP. Stress increases metastatic spread of a mammary tumor in rats: Evidence for mediation by the immune system. *Brain, Behavior and Immunity*. 1991;5:193-205.
555. Gluckman E, Horowitz MM, Champlin RE, Hows JM, Bacigalupo A, Biggs JC, Camitta BM, Gale RP, Gordon-Smith EC, Marmont AM, Masaoka T, Ramsay NKC, Rimm AA, Rozman C, Sobocinski MS, Speck B, Bortin MM. Bone marrow transplantation for severe aplastic anemia: Influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. *Blood* 1992;79:269-75.
556. Gale RP, Simone JV, Hoelzer D, Frei EJ. Curing leukemia. *Leukemia*. 1991;5:632-5.
557. Advisory Committee of the International Bone Marrow Transplant Registry. Report from the International Bone Marrow Transplant Registry. *Bone Marrow Transplant*. 1989;4:221-8.
558. Gale RP, Baltimore D, Greaves M. Leukemia: progress and controversies. *Leukemia*. 1991;5:1115-8.
559. Butturini A, Gale RP. Graft-versus-leukemia. *Immunol Res*. 1992;11:24-33.
560. Champlin R, Gale RP. Aplastic anemia. In: *Medicine International*. Stearn M ed. Chapter 97, Bone marrow failure. Bunche R, and Buskard, NE eds., Oxford, The Medicine Group, pp. 1-5,1992.
561. Atkinson K, Horowitz MM, Sobocinski KA, Rimm AA, Bortin MM, Gale RP. Therapy decisions in leukemia. *Bone Marrow Transplant*. 9:5-10, 1992.
652. Gale RP, Butturini A, Henon P. Is there a reason to use blood cell transplants? *Int J Cell Cloning*. 1992;10:74-8.
563. Gale RP, Winston D. Intravenous immunoglobulin in bone marrow transplantation. *Cancer*. 1991;68:1451-3.

564. Atkinson K, Horowitz MM, van Bekkum DW, Gluckman E, Gale RP, Good RA, Jacobsen N, Kolb H-J, Parkman R, Rimm AA, Ringden O, Rozman C, Zwann FE, Bortin MM. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. *Blood*. 1990;75:2459-64.
565. Gale RP, Butturini A. How do transplants cure chronic myelogenous leukemia. *Bone Marrow Transplant*. 1992;9:83-5.
566. Horowitz MM, Gale RP, Bortin MM. Allogeneic bone marrow transplantation. In: *Atlas of Organ Transplantation*. Starzl T, Shapiro R, Simmons R, eds. Pittsburgh, Gower Medical Publishing, NY, pp 11.2-11.21, 1992.
567. Gale RP, Henon P, Juttner C. Blood stem cell transplants come of age. Meeting report. *Bone Marrow Transplant*. 1992;9:151-5.
568. Gale RP. Biologic features of chronic lymphocytic leukemia. In: *5th International Workshop on Chronic Leukemia*. Polliack A, Montserrat E, eds. Chur, Hardwood Academic Publishers, pp 3-5, 1991.
569. Gale RP, Barlogie B. Multiple myeloma and chronic lymphocytic leukemia: Commonalities and differences in biology and therapy. In: *5th International Workshop on Chronic Leukemia*. Polliack A, Montserrat E, eds. Chur, Hardwood Academic Publishers, pp 27-32, 1991.
570. Gale RP, Ramberg B. Nuclear terrorism. *Croatian Med J*. 1992;33:3-5.
571. Gale RP, Butturini A. Immune therapy of human cancers. In: *Combination therapies: New and emerging uses of biologic response modifiers in cancer and infectious diseases*. Goldstein A, Garaci E, eds. New York, Plenum Press, pp 13-7, 1992.
572. Foon KA, Gale RP. Therapy of acute myelogenous leukemia. *Blood Rev*. 1992;6:15-25.
573. Mrcic M, Horowitz MM, Atkinson K, Biggs JC, Champlin RE, Ehninger G, Gajewski JL, Gale RP, Herzig RH, Good RA, Marmont AM, Masaoka T, McGlave P, Prentice HG, Rozman C, Sobocinski KA, Speck B, Bortin MM. Second HLA-identical sibling transplants for leukemia recurrence. *Bone Marrow Transplant*. 1992;9:269-75.
574. Horowitz MM, Przepiora D, Champlin RE, Gale RP, Gratwohl A, Herzig RH, Prentice HG, Rimm AA, Ringden O, Bortin MM. Should HLA-identical sibling bone marrow transplants be restricted to large center? *Blood*. 1992;79:2771-4.
575. Feinstein E, Cimino G, Gale RP, Canaani E. Initiation and progression of chronic myelogenous leukemia. *Leukemia*. 1992;6:37-43.
576. Schiller GJ, Gale RP. A critical reappraisal of gastrointestinal complications of allogeneic bone marrow transplantation. *Cell Transplant*. 1992;1:265-9.
577. Barrett AJ, Horowitz MM, Ash RC, Atkinson K, Gale RP, Goldman JM, Hensely-Downey PJ, Herzig RH, Speck B, Zwaan FE, Bortin MM. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. *Blood*. 1992;79:3067-70.
578. Montserrat E, Binet JL, Catovsky D, Dighiero G, Gale RP, Rai KR, Rozman C. Meeting Report: 5th International Workshop on chronic lymphocytic leukemia. *Leuk Res*. 1992;165:717-20.

579. Gale RP. Fetal liver transplants. *Bone Marrow Transplant.* 1992;9 (Suppl 1):118-20.
580. Gale RP, Mandelli F. Meeting report: Therapy of acute leukemia. *Haematologica.* 1992;77:103-5.
581. Gale RP, Butturini A, Horowitz M. What is the best strategy for autotransplants in cancer? *Bone Marrow Transplant.* 1992; 9:303.
582. Gale RP, Horowitz MM for the Scientific Advisory Committee of the International Bone Marrow Transplant Registry. Alternative donor transplants for leukemia. *Bone Marrow Transplant.* 1993;11(Suppl 7):66-7.
583. Bortin MM, Horowitz MM, Barrett AJ, Champlin RE, Dicke KA, Gluckman E, Kolb H-J, Marmont AM, Mrcic M, Rimm, AA, Sobocinski KA, Weiner RS, Gale RP. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980's. *J Am Med Assoc.* 1992;268:607-12.
584. Montserrat E., Gale RP, Rozman C. Bone marrow transplants for chronic lymphocytic leukemia. *Leukemia.* 1992;6:619-22.
585. Gale RP, Butturini A. What is the best strategy for bone marrow transplants in cancer. In: *High Dose Cancer Therapy: Pharmacology, Hematopoiesis and Stem Cells.* Armitage, JO, Antman KH, eds. Baltimore, Williams & Wilkins pp 124-6, 1992 .
586. Gale RP, Butturini A. Intensive therapy of chronic myelogenous leukemia. In: *High Dose Cancer Therapy: Pharmacology, Hematopoiesis and Stem Cells.* Armitage JO, Antman KH, eds. Baltimore, Williams & Wilkins, pp 619-25, 1992.
587. Naeim F, Gale RP. Bone marrow transplantation. In: *Pathology of Bone Marrow.* Naeim F, ed. New York, Igaku-Shoin Medical Publisher, pp. 343-55, 1992.
588. Gale RP, Butturini A. Transplants in AML. *Bone Marrow Transplant.* 1992;10 (Suppl 1): 25-9.
589. Feinstein E, Gale RP, Reed J, Canaani E. Expression of the wild type p53 gene induces differentiation of K562 cells, *Oncogene.* 1992;7:1853-7.
590. Gluckman E, Auerbach A, Ash RC, Biggs JC, Bortin MM, Camitta BM, Champlin RE, Friedrich W, Gale RP, Good RA, Gordon-Smith EC, Horowitz MM, Massaoka T, Ortega JJ, Pasquini R, Ramsay NKC, Rozman C, Speck B, Vowels MR. Allogeneic bone marrow transplants for Fanconi anemia: A preliminary report from the International Bone Marrow Registry. *Bone Marrow Transplant.* 1992;10 (Suppl 1): 53-7.
591. Foon KA, Gale RP. Chronic lymphocytic leukemias. In: *Principles of Hematology: Clinical and Laboratory Practice.* Bick RL, ed. Philadelphia, Mosby/Year Book, pp. 803-13, 1993.
592. Gale RP, Horowitz MM, Butturini A, Barrett AJ, Kolb HJ. What determines who develops graft-versus-host disease: the graft or the host (or both)? *Bone Marrow Transplant.* 1992;10:99-102.
593. Biggs JC, Horowitz MM, Gale RP, Ash RC, Atkinson K, Helbig W, Jacobsen N, Phillips GL, Rimm AA, Ringden O, Rozman C, Sobocinski KA, Veum JA, Bortin MM. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. *Blood.* 1992;80:1090-3.
594. Gale RP, Butturini A. Leukemia: stem cells, preleukemia and cure. *Leukemia.* 1992;6 (Suppl 1):80-5.

595. Gale RP, Butturini A. Controversies in therapy of acute lymphocytic leukemia. *Leukemia*. 1992;6 (Suppl 2): 144-7.
596. Gale RP, Butturini A. Can intensive chemotherapy cure chronic myelogenous leukemia? *Leukemia*. 1992; 6:863-5.
597. Yirmiya R, Ben-Eliyahu S, Gale RP, Shavit Y, Liebeskind JC, Taylor AN. Ethanol increases progression in rats: possible involvement of natural killer cells. *Brain Behav Immun*. 1992;6:74-86.
598. Bortin MM, Barrett AJ, Horowitz MM, Gale RP, Sobocinski K, Rimm A. Progress in allogeneic bone marrow transplantation for acute lymphoblastic leukemia in the 1980's: A report from the IBMTR. *Leukemia*. 1992;6 (Suppl 2):196-7.
599. Foon K, Gale RP. Is there a T-cell form of chronic lymphocytic leukemia? *Leukemia*. 1992;6:867-8.
600. Gale RP. Are autotransplants effective in leukemia? *Leukemia*. 1992;6 (Suppl 4): 112.
601. Surbone A, Armitage JO, Gale RP. Autotransplants in advanced non-Hodgkin lymphoma: Are they effective. *Cell Transplant* 1992;1:343-7.
602. Marin T, Butturini A, Kantarjian H, Sokol J, Mickey MR, Gale RP. Survival of children with chronic myeloid leukemia. *Am J Ped Hematol Oncol*. 1992;14:229-32.
603. Foon KA, Gale RP. Cutaneous T-cell lymphoma. In: *Principles of Hematology: Clinical and Laboratory Practice*. Bick RL, ed. Philadelphia, Mosby/Year Book, pp 803-13, 1993.
604. Kolb H, Guenther W, Duell T, Socie G, Schaffer E, Holler E, Schumm M, Horowitz M, Gale RP, Fliedner T. Cancer after bone marrow transplantation, *Bone Marrow Transplant*. 1992;10 (Suppl 1):135-8.
605. Gale RP, Butturini A. Therapeutic strategies for nuclear and radiation accidents. In: *Recent Advances in Chemotherapy: Proceedings of 17th International Conference on Chemotherapy, Munich, Futuramed*, pp 212-3, 1992.
606. Barlogie B, Gale RP. Multiple myeloma and chronic lymphocytic leukemia: Parallels and contrasts. *Am J Med*. 1992;93:443-50.
607. Schiller G, Foon K, Gale RP. Principles of leukemia treatment. In: *Leukemia*. Whittaker J, ed. Oxford, Blackwell Scientific Publications, pp 329-44, 1992.
608. Butturini A, Gale RP. Causes of leukemia. In: *Cambridge Medical Reviews: Hematological Oncology, Vol. 2*. Keating A, ed. Cambridge, Cambridge University Press. pp 103-17, 1993.
609. Ringden O, Horowitz M, Sondel P, Gale RP, Biggs JC, Champlin RE, Deeg HJ, Dicke K, Masoaka T, Powles RL, Rimm AA, Rozman C, Sobocinski KA, Speck B, Zwaan FE, Bortin MM. Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? *Blood*. 1993;81:1094-1101.
610. Schiller G, Gale RP. Is there an effective therapy for chronic graft-versus-host disease? *Bone Marrow Transplant*. 1993;11:189-92.

611. Aurer I, Sparkes R, Schiller G, Gale RP. Ph1-chromosome positive acute lymphoblastic leukemia: Is t(9;22) the initial abnormality? *Am J Hematol.* 1993;43:61-2.
612. Gale RP, Grosveld G, Canaani E, Goldman JM. Meeting report: chronic myelogenous leukemia: Biology and therapy. *Leukemia.* 1993;7:653-8.
613. Gale RP, Butturini A, Baranov A. Radiation accidents: primum non nocere. *Bone Marrow Transplant.* 1993;11:421-4.
614. Foon KA, Thiruvengadam R, Saven A, Bernstein AP, Gale RP, Genetic relatedness of lymphoid malignancies: Transformation of chronic lymphocytic leukemia as a model. *Ann Intern Med.* 1993;119:63-73.
615. Dicke, K, Hoelzer, D, Gorin, C, Lowenberg, B, Gale, RP. The role of bone marrow transplantation in adult ALL. *Eur J Cancer* 1993;4(Suppl 1):81-90.
616. Ringden O, Horowitz MM, Gale RP, Biggs JC, Gajewski J, Rimm AA, Speck B, Veum JA, de Witte T, Bortin MM. Outcome after allogeneic bone marrow transplant for leukemia in older adults. *JAMA* 1993;270:57-60.
617. Gale RP, Horowitz MM for the International Bone Marrow Transplantation Registry Predicting results of alternative donor transplants for thalassemia using a chronic myelogenous leukemia model. *Bone Marrow Transplant.* 1993;12 (Suppl 1): 82-3.
618. Bortin MM, Horowitz MM, Rowlings PA, Rimm AA, Sobocinski KA, Zhang MJ, Gale RP. 1993 progress report from the International Bone Marrow Transplant Registry. *Bone Marrow Transplant.* 1993;12:97-104.
619. Juttner C, Gale RP, Henon P, Blood stem cell transplants: Current state; future directions In: *Blood Stem Cell Transplants.* Gale RP, Juttner C, Henon P eds. Cambridge, Cambridge Univ Press, pp.167-80, 1994.
620. Gale RP, Henon P, Juttner C, Overview: Blood stem cell transplants In: *Blood Stem Cell Transplants.* Gale RP, Juttner C, Henon P eds. Cambridge, Cambridge Univ Press, pp 1-5, 1994.
621. Gale RP, Butturini A., Henon PR. Transplants of blood derived hematopoietic cells. In: *Peripheral Blood Stem Cell Autografts.* Henon PR, Wunder EW eds. Berlin, Springer-Verlag, pp 19-25, 1993.
622. Aurer I, Junbashi T, Sekine I, Tomonaga M, Gale RP. Analysis of BCR/ABL abnormalities in mRNA from 20-Year-old paraffin-embedded tissue for BCR/ABL rearrangement by polymerase chain reaction. *Acta Haematol.* 1993;90:5-8.
623. Ben-Bassat I, Bandini G, Rosti G, Gale RP. Are we curing acute myelogenous leukemia? *Leuk Res.* 1993;17:12:1071-2.
624. Gale RP, Butturini A. Recent progress in understanding chronic myelogenous leukemia. *Leukemia and Lymphoma.* 1994;11 (Suppl 1):3-5.
625. Baranov AE, Selidovkin GD, Butturini A, Gale RP. Hematopoietic recovery after acute high-dose total body radiation. *Blood.* 1994;83:596-9.

626. Storek J, Gale RP, Goldstein L. Analyzing liver dysfunction after bone marrow transplantation (review). *Transplant Immunol* 1993;1:163-71.
627. Butturini A, Gale RP. Myeloid growth factors and cancer treatment. In: *Combination Therapies 2*. Garaci E, Goldstein A, eds. Plenum Press, New York, pp. 179-87, 1993.
628. Gale RP. Cure of leukemia by bone marrow transplantation. *Bone Marrow Transplant*. 1994;Suppl. 4:S21.
629. Butturini A, Gale RP. Myeloid growth factors and cancer. In: *Hematopoietic growth factors, oncogenes and cytokines in clinical hematology. Current aspects and future directions*. Cacciola E, Diesseroth A, Guistolisi R. eds. Basel, Karger, 1993, pp 196-203.
630. Butturini A, Gale RP. Long-term bone marrow culture in Fanconi anemia with bone marrow failure. *Blood*. 1994;83:336-9.
631. Nakamura T, Alder H, Gu Y, Prasad R, Canaani O, Kamada N, Gale RP, Lange B, Crist WM, Nowell PC, Croce CM, Canaani E. Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs. *Proc Natl Acad Sci USA* 90:4631, 1993.
632. Gale RP, Horowitz MM, Ash RC, Champlin RE, Goldman JM, Rimm AA, Ringden O, Veum JA, Bortin MM. Identical-twin bone marrow transplants for leukemia. *Ann Intern Med*. 1994;120:646-52.
633. Sobocinsky KA, Horowitz MM, Rowlings PA, Zhang MJ, Nugent ML, Passweg JR, Armitage JO, Gale RP, Bortin MM. Bone marrow transplantation-1994: a report from the International Bone Marrow Transplant Registry and the North American Autologous Bone Marrow Transplant Registry. *Journal of Hematotherapy*. 1994;3:95-102.
634. Butturini A, Bernasconi S, Izzi G, Gertner J, Gale RP. Short stature, Fanconi anemia, and risk of leukemia after growth hormone therapy. *Lancet*. 1994;343:1576.
635. Gale RP, Monserrat E. Intensive therapy for chronic lymphocytic leukemia. *Bailliere's Clinical Haematology*. 1993;6: 879-885.
636. Rowlings PA, Horowitz PA, Armitage JO, Gale RP, Sobocinski KA, Zhang MJ, Bortin MM. Report from the International Bone Marrow Transplant Registry and the North American Bone Marrow Transplant Registry. In: *Clinical Transplants 1993*. Terasaki PI, Cecka JM, eds. The Regents of University of California, pp. 101-8, 1994.
637. Gale RP, Butturini A. Myeloid growth factors in cancer treatment. In: *Combination Therapies 2: biologic response modifiers in the treatment of cancer and infectious diseases*. Goldstein A, Garaci E, eds. New York, Plenum Press, pp. 179-87, 1993.
638. Sobocinski KA, Horowitz MM, Rimm AA, Gale RP, Bortin MM for the Advisory Committee of the International Bone Marrow Transplant Registry. International Bone Marrow Transplant Registry. In: *Clinical Bone Marrow Transplant*. Atkinson K, ed. Cambridge, Cambridge University Press, pp 732-40, 1994.
639. Gale RP, Butturini A, Horowitz MM. HLA-identical sibling bone marrow transplantation for acute lymphoblastic leukemia. In: *Clinical Bone Marrow Transplant*. Atkinson K, ed. Cambridge, Cambridge University Press, pp. 191-6, 1994.

640. Gale RP, Butturini A. Identical twin (syngeneic) transplantation for acute lymphocytic leukemia, acute nonlymphocytic leukemia and chronic myeloid leukemia. In: *Clinical Bone Marrow Transplant* Atkinson K, ed. Cambridge, Cambridge University Press, pp. 179-82, 1994.
641. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A, Marmont A, Masaoka T, McGlave RB, Messner H, O'Reilly RJ, Reiffers J, Rimm AA, Speck B, Veum-Stone JA, Wingard JR, Zwaan FE, Bortin MM. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase, *Blood*. 1993;82:2235-38.
642. Gale RP, Horowitz MM. Commentary: Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group. *Ann Intern Med*. 1994;120:143-58 for Abstracts of Clinical Care Guidelines, 1994.
643. Gale RP, Reiffers J, Juttner C. What's new in blood progenitor cell autotransplants. *Bone Marrow Transplant*. 1994;14:343-346.
644. Rowlings P, Gale RP, Horowitz M, Bortin M. Bone marrow transplantation for leukemia. *J of Hematotherapy*. 1994;3:235-243.
645. Gale RP, Caligaris-Cappio F, Dighiero G, Keating M, Montserrat E, Rai K for the IWCLL. IWCLL: Recent progress in chronic lymphocytic leukemia. *Leukemia*. 1994;8:1610-1614.
646. Ribas-Mundo M, Ribas Bruguera A, Gale RP. Uso clinico de los factores de crecimiento hematopoyeticos (hemtopoyetinas). *Med Clin (Barc)* 1993;100: 707-711.
647. Butturini A, Gale RP, Adler-Becher B, Verlander P, Gillio A, Auerbach A. Hematologic abnormalities in Fanconi anemia. *Blood*. 1994;84:1650-5.
648. Butturini A, Gale RP. Allogeneic bone marrow transplantation for leukemia: In: *Current Opinion in Hematology*, Goldman J, ed. Hanover, The Sheridan Press 1994;1:402-5.
649. Barrett JA, Horowitz MM, Pollock BH, Zhang MJ, Bortin MM, Buchanan GR, Camitta BM, Ochs J, Graham-Pole J, Rowlings PA, Rimm AA, Klein JP, Shuster JJ, Sobocinski KA, Gale RP. Bone marrow transplant from HLA-identical sibling as compared with chemotherapy for children with acute lymphoblastic leukemia in second remission. *N Engl J Med*. 1994;331:1253-8.
650. Gale RP, Waldmann T, Armitage J, Cavalli F. Recent progress in B- and T-cell lymphomas. *Ann Oncol*. 1994;5:689-96.
651. Foon K, Gale RP. Chronic lymphoid leukemias. In: *Blood: Principles and Practices of Hematology*. Handin RI, Lux SE, Stossel TP, eds. Philadelphia, Lippincott, pp. 791-811, 1995 .
652. Messerer D, Neiss A, Horowitz MM, Hoelzer D, Gale RP. Comparison of chemotherapy and bone marrow transplants using two independent clinical databases. *J Clin Epidemiol*. 1994;47:1119-26.
653. Butturini A, Izzi G, Benaglia G, Lloyd D, Pass B. Not all health problems seen close to Chernobyl can be attributed to radiation. (letter) *Br Med J*. 1994;309:1299-1300.
654. Gale, RP. Cord-blood cell transplantation - a real Sleeper? *N Engl J Med*. 1995;332:392-4.

655. Mugishima H, Gale RP, Rowlings PA, Horowitz MM, Marmont AM, McCann SR, Sobocinski KA, Bortin MM. Bone marrow transplantation for Diamond-Blackfan anemia. *Bone Marrow Transplant.* 1995;15:55-58.
656. Aurer I, Labar B, Nemet D, Ajdukovic R, Bogdanic V, Gale RP. High incidence of conservative RAS mutations in acute myeloid leukemia. *Acta Haematol.* 1994;92:123-5.
657. Gale RP. Bone marrow transplantation. *World Book Encyclopedia* 2:469-70, 1995.
658. Gale RP, Butturini A, Horowitz MM. HLA-identical sibling bone marrow transplants for acute lymphoblastic leukemia. *Bone Marrow Transplant.* 1995;15 (Suppl 1): 199-202.
659. Gluckman E, Auerbach A, Horowitz MM, Sobocinski KA, Ash RC, Bortin MM, Butturni A, Camitta BM, Champlin RD, Friedrich W, Good RA, Gordon-Smith EC, Harris RE, Klein JP, Ortega JJ, Pasquini R, Ramsay NKC, Speck B, Vowels MR, Zhang MJ, Gale RP. Bone marrow transplantation for Fanconi anemia. *Blood.* 1995;86:2856-62.
660. Gale RP, Butturini A. Graft-versus-leukemia in man. In: *Technical and Biological Components of Marrow Transplantation.* Buckner CD, Clift RA, eds. New York, Kluwer Academic Publishers pp. 299-314, 1995.
661. Gale RP, Butturini A. What is the best strategy for bone marrow and blood cell autotransplants in cancer? In: *High-Dose Cancer Therapy, 2nd Ed.,* Armitage JO, Antman K, eds. Baltimore, Williams & Wilkins, pp.117-19, 1995.
662. Butturini A, Gale RP. Chronic myelogenous leukemia as a model for cancer development. *Sem Oncol.* 1995;22:374-9.
663. Gale RP, Butturini A. Concepts underlying autotransplants for cancer. *Wiener Medizinische Wochenschrift* 2/3/1995, pp 25-7.
664. Gale RP, Horowitz MM, Weiner RS, Ash R, Atkinson K, Babu R, Dicke KA, Klein JP, Lowenberg B, Reiffers J, Rimm AA, Rowlings PA, Sandberg AA, Sobocinski KA, Veum-Stone J, Bortin MM. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in 1st remission. *Bone Marrow Transplant.* 1995;16: 203-8.
665. Zhang MJ, Hoelzer D, Horowitz MM, Gale RP, Messerer D, Klein JP, Löffler H, Sobocinski KA, Thiel E, Weisdorf DJ for the Acute Lymphoblastic Leukemia Working Committee. Long-term follow-up adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. *Ann Intern Med.* 1995;123:428-31.
666. Michallet M, Archimbaud E, Bandini G, Rowlings P, Deeg J, Gahrton G, Montserrat E, Rozman C, Gratwohl A, Gale RP. HLA-Identical sibling bone marrow transplants in younger patients with chronic lymphocytic leukemia. *Ann Intern Med.* 1996;124:311-5.
667. Gale RP, Butturini A. Cancer treatment in the blood bank: a growth industry? *Transfusion.* 1995;35:889-90.

668. Gale RP, Horowitz MM, Rees J, Gray RG, Oken MM, Kim KM, Zhang M-J, Ash RC, Atkinson K, Champlin RE, Dicke KA, Gajewski JL, Goldman JM, Helbig W, Henslee-Downey PJ, Hinterberger W, Jacobsen N, Keating A, Klein JP, Marmont AM, HG, Reiffers J, Rimm AA, Rowlings PA, Sobocinski KA, Speck B, Wingard JR, Bortin MM. Chemotherapy versus transplants for acute myelogenous leukemia in 2nd remission. *Leukemia*. 1996;10:13-19.
669. Gajewski JL, Phillips GA, Sobocinski MS, Armitage JO, Gale RP, Champlin RE, Gale RP, Herzig RH, Hurd DC, Jagannath S, Klein JP, Lazarus HM, McCarthy PL, Pavlovsky S, Petersen FB, Phillips GL, Rowlings PA, Russell JA, Silver SM, Vose JM, Wiernik PH, Bortin MM, Horowitz MM. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin disease. *J Clin Oncol*. 1996;14:572-8.
670. Butturini A, Arlinghaus RB, Gale RP. BCR/ABL and leukemia. *Leuk Res*. 1996;20:523-9.
671. Gale RP, Buchner T, Zhang M-J, Heinecke A, Champlin RE, Dicke KA, Gluckman E, Good RA, Gratwohl A, Herzig RH, Keating A, Klein JP, Marmont AM, Prentice HG, Rowlings PA, Sobocinski KA, Speck B, Weiner RS, Horowitz MM. HLA-identical sibling bone marrow transplants versus chemotherapy for acute myelogenous leukemia in first remission. *Leukemia*. 1996;10:1687-91.
672. Butturini A, Arlinghaus RB, Gale RP. BCR/ABL. In: *Encyclopedia of Cancer*, Bertino JR ed. Academic Press, Inc., San Diego. 1:145-8, 1996.
673. Lazarus HM, Gale RP. Blood cell and bone marrow transplants. The sixth biennial Sandoz-Keystone symposium on bone marrow transplantation. *Bone Marrow Transplant*. 1996;18:839-41.
674. Rozman C, Carreras E, Chunlin Q, Gale RP, Bortin MM, Rowlings PA, Ash RC, Champlin RE, Henselee-Doweny J, Herzig RH, Hinterberger W, Klein JP, Prentice HG, Reiffers J, Zwaan FE, Horowitz MM. Risk factors for hepatic veno-occlusive disease following bone marrow transplantation. *Bone Marrow Transplant*. 1996;17:75-80.
675. Passweg JR, Rowlings PA, Armitage JO, Gale RP, Pelz CJ, Sobocinski KA, Klein JP, Zhang M-J, Horowitz MM. Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry - North America. *Clinical Transplants*, 1995 (Cecka JM, Teraskaki PI, eds), pp 117-27, UCLA Tissue Typing Laboratory, Los Angeles, California, 1996.
676. Rowlings PA, Passweg JR, Armitage JO, Gale RP, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM. Current status of allogeneic and autologous blood and marrow transplantation. Report from the IBMTR and ABMTR - North America. In: *Yearbook of Cell and Tissue Transplantation* (Lanza RP, Chick WL, eds), Kluwer Academic Publishers, the Netherlands, 1996, pp 19-34.
677. Ribas A, Gale RP. Should people with hepatitis C virus infection receive a bone marrow transplant? *Bone Marrow Transplant*. 1997;19:97-9.
678. Wolin MJ, Gale RP. Therapy of acute myelogenous leukemia: Understanding the question, understanding the answer. *Leuk Res*. 1997;21:3-8.
679. Hinterberger W, Rowlings PA, Hinterberger-Fischer M, Gibson J, Jacobsen N, Klein JP, Kolb HJ, Stevens DA, Horowitz MM, Gale RP. Results of bone marrow transplants from genetically- identical twins in persons with aplastic anemia. *Ann Intern Med*. 1997;126:116-22.
680. Lee M, Gale RP, Yap PL. Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency. In: *Ann Rev Med* (Coggins C, Hancock EW, Levitt L, eds) . Annual Reviews Inc 1997;48:93-102.

681. Pass B, Baranov AE, Kleshchenko ED, Aldrich JE, Scallion PL, Gale RP. Collective biodosimetry as a dosimetric "gold standard": a study of three radiation accidents. *Health Phys.* 1997;72:390-6.
682. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, Horowitz MM, Witherspoon RP, Hoover RN, Sobocinski KA, Fraumeini JF, Boice JD, Schoch HG, Sale GE, Storb R, Travis WD, Kolb HJ, Gale RP, Passweg JR. Solid cancers after bone marrow transplantation. *New Engl J Med.* 1997;336:897-904.
683. Gale RP, Horowitz MM, Bortin MM for the Advisory Committee of the International Bone Marrow Transplant Registry. IBMTR analyses of results of bone marrow transplantation in acute leukemia. In: *Prognostic Factors in Acute Leukemia* (Buchner T, Hiddeman W., eds.) Berlin, Springer-Verlag, 1994, pp 681-85.
684. Passweg JR, Socie G, Hinterberger W, Bacigalupo A, Biggs JC, Camitta BM, Champlin RE, Gale RP, Gluckman E, Gordon-Smith EC, Hows JM, Klein JP, Nugent ML, Rowlings PA, Speck B, Tichelli A, Zhang MJ, Horowitz MM, Bortin MM. Bone marrow transplantation for severe aplastic anemia: Has outcome improved? *Blood.* 1997;90:858-64.
685. Antman KH, Rowlings PA, Vaughan WP, Fay JW, Fields KK, Freytes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, McCarthy PL, Pelz CJ, Saez R, Spitzer GL, Stadtmauer EA, Williams SF, Wolff S, Sobocinski KA, Armitage JO, Horowitz MM. High-dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America. *J. Clin Oncol.* 1997;15:1870-9.
686. Wolin MJ, Gale RP. IVIG in Bone Marrow Transplant. In: *Intravenous Immunoglobulins in Clinical Practice.* (Lee M, Strand V, eds.) Marcel Dekker, Inc. New York, 1997, pp 113-17.
687. Ribas A, Butturini A, Locosoulli A, Arico M, Gale RP. How important is hepatitis C virus (HCV)-Infection in people with leukemia? *Leuk Res.* 1997; 21:785-8.
688. Gale RP, Rowlings PA, Armitage JO. Autotransplant activity 1989-1994. In: *Autologous Stem Cell Transplantation: Biological and Clinical Results in Malignancies.* (Carella, A. eds), Harwood Academic Publishers, Reading, UK, 1996.
689. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, Bradley BA, Casper JT, Flomenberg N, Gajewski JL, Gluckman E, Henslee-Downey PJ, Hows JM, Jacobsen N, Kolb HJ, Lowenberg B, Masaoka T, Rowlings PA, Sondel PM, van Bekkum DW, van Rood JJ, Vowels MR, Zhang MJ, Horowitz MM. Allogeneic bone marrow transplantation for leukemia: outcome using donors other than HLA-identical siblings. *J Clin Oncol.* 1997;15:1767-77.
690. Zhang M-J, Baccharani M, Gale RP, McGlave PB, Atkinson K, Champlin RE, Dicke KA, Giral S, Gluckman E, Goldman JM, Klein JP, Herzig RH, Masaoka T, O'Reilly RJ, Rozman C, Rowlings PA, Sobocinski KA, Speck B, Zwaan FE, , Horowitz MM. Survival of patients with chronic myelogenous leukemia relapsing after bone marrow transplantation: Comparison with patients receiving conventional chemotherapy. *Br J Haematol.* 1997;99:23-9.
691. Ribas A, Ho W, Gale RP. Two people with solid cancers surviving 20-years after an auto-and twin transplant. *Bone Marrow Transplant.* 1997;20:1103-4.
692. Gale RP, Butturini A. Transplants for acute myelogenous leukemia. *Cancer Invest.* 1997;16: 66.

693. Gale RP, Hehlman R, Zhang M-J, Hasford J, Goldman JM, Heimpel H, Hochhaus A, Klein JP, Kolb H-J, McClave PB, Passweg JR, Rowlings PA, Sobocinski KA, Horowitz MM and the German CML Group. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. *Blood*. 1997;91:1810-9.
694. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Henslee-Downey J, Cahn J-Y, Calderwood S, Gradwohl A, Socie G, Abecasis MM, Passweg JR, Sobocinski KA, Zhang MJ, Horowitz MM. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. *Br J Haematol*. 1997; 97:855-64.
695. Passweg JR, Cahn J-Y, Tiberghien P, Vowels MR, Camitta BM, Gale RP, Herzig RH, Hoelzer D, Horowitz MM, Ifrah N, Klein JP, Marks D, Ramsey NKC, Rowlings PA, Weisdorf DJ, Zhang M-J, Barrett AJ. Graft-versus-leukemia effect in T-lineage and cALLa+ (B-lineage) acute lymphoblastic leukemia. *Bone Marrow Transplant*. 1998;21:153-8.
696. Passweg JR, Horowitz MM, Atkinson KA, Barrett AJ, Gale RP, Gratwohl A, Jacobsen N, Klein JP, Ljungman P, Rowlings PA, Schaefer UW, Vossen JM. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. *Bone Marrow Transplant* .1998; 21:1231-38.
697. Oh H, Gale RP, Zhang MJ, Passweg JR, Rowlings PA, Sobocinski MS, Weisdorf D, Horowitz MM. Chemotherapy versus HLA-identical sibling transplants for adults with acute lymphoblastic leukemia in first remission. *Bone Marrow Transplant*. 1998;22:253-7.
698. van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR, Chaekal O, Gale RP, Klein JP, Lazarus HM, McCarthy PL, Raemaekers JMM, Reiffers J, Phillips GL, Schattenberg AVMB, Verdonck LF, Vose JM, Hroowitz MM. Allogeneic bone marrow transplantation for low grade lymphoma. *Blood*. 1998;92:1832-6.
699. Gale RP, Park RE, Dubois R, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR. Delphi-consensus panel analysis of appropriateness of high-dose therapy and bone marrow transplants in acute lymphoblastic leukemia in 1st remission. *Leuk Res*. 1998; 22:973-81.
700. Gale RP, Park RE, Dubois R, Bierman PJ, Fisher RI, Loh KK, Peterson BA, Phillips GL, Portlock CS, Rosenblum D, Armitage JO. Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone autotransplants in diffuse large-cell lymphoma. *Leuk and Lymph*. 1998;32:139-49.
701. Mugishima H, Harada K, Chin M, Suzuki T, Takagi K, Hayakawa S, Sato K, Klein JP, Gale RP. Effects of long-term cryopreservation on hematopoietic progenitor cells in umbilical cord blood. *Bone Marrow Transplant*. 1999;23:395-6.
702. Lazarus HM, Rowlings PA, Zhang MJ, Vose Jm, Armitage JO, Bierman PJ, Gajewski JL, Gale RP, Keating A, Klein JP, Miller CB, Phillips GL, Reece DE, Sobocinski KA, Van Besien K. Autotransplants for Hodgkin disease in patients never achieving remission: a report from the autologous blood and marrow transplant registry. *J Clin Oncol*. 1999;17:534-45.
703. Saso R, Marsh J, Cevrevska L, Szer J, Gale RP, Rowlings PA, Passweg JR, Nugent ML, Horowitz MM, Gordon-Smith E. Bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. *Br J Haematol*. 1999;104:392-6.

704. Gale, RP, Park RE, Dubois RW, et al. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow autotransplants in newly diagnosed multiple myeloma. *Leuk & Lymph.* 1999;33:511-9.
705. Gale RP, Park RE, Dubois RW, et al. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission. *Leuk Res.* 1999;23:709-18.
706. Gale RP, Park RE, Dubois RW, et al. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with chronic myelogenous leukemia in chronic phase. *Leuk Res.* 1999;23:817-26.
707. McCarthy PL, Hurd DD, Rowlings PA, Murphy SC, Antman KH, Armitage JO, Cirenza E, Crump M, Doroshower J, Freytes CO, Gale RP, Kalman LA, Lazarus HM, Vaughan WP, Weinberger BB, Wieman MC, Horowitz MM. Autotransplants in thirteen men with breast cancer. *Bone Marrow Transplant.* 1999;24:365-8.
708. Rowlings PA, Williams S, Antman KH, Fields KK, Fay JW, Reed E, Pelz CJ, Klein JP, Sobocinski KA, Kennedy MJ, Freytes CO, McCarthy PL, Herzig RH, Stadtmauer EA, Lazarus HM, Pecora AL, Bitran JD, Wolff S, Gale RP, Armitage JO, Vaughan WP, Spitzer G, Horowitz MM. Factors correlated with progression-free survival after high-dose therapy and hematopoietic stem cell transplantation for metastatic breast cancer. *JAMA* 1999;14:1335-43.
709. Curtis R, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, Jaffee ES, Sale GE, Horowitz MM, Witherspoon RP, Shriner DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobocinski KA, Gale RP, Hoover RN, Fraumeni JR Jr, Deeg HJ. Risk of lymphoproliferative disorders following bone marrow transplantation: a multi-institutional study. *Blood.* 1999;94:2208-16.
710. Davies S, Ramsay NKC, Klein JP, Weisdorf DJ, Bolwell B, Cahn JY, Camitta BM, Gale RP, Giralt S, Heilman C, Heslee-Downey PJ, Herzig R, Hutchinson R, Keating A, Lazarus HM, Milone G, Neudorf S, Powles RL, Prentice HG, Schiller G, Socie G, Vowels M, Wiley J, Yeager A, Horowitz MM. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. *J Clin Oncol.* 2000;18:340-7.
711. Giralt S, Szydlo R, Goldman J, Verum-Stone J, Biggs JC, Herzig RH, Klein JP, McClave PB, Schiller G, Gale RP, Rowlings PA, Horowitz, MM. Effects of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the International Bone Marrow Registry. *Blood.* 2000;95:410-5.
712. Gale RP, Park RE, Dubois R, Bitran J, Buzdar A, Hortobagyi G, Jones S., Spitzer G, Swain S, Vaughn C, Vogel C, Martino, S. Delphi-consensus panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer. *Clin Transplant.* 2000;14:32-41.
713. Barrett AJ, Ringden O, Zhang MJ, Bashey A, Cahn JY, Cairo MS, Gale RP, Gratwohl A, Locatelli F, Martino R, Schultz KR, Tiberghien P. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. *Blood.* 2000;95:3323-7.
714. Gale RP, Cozen W, Goodman M, Wang F, Bernstein L. Decreased Chronic Lymphocytic Leukemia in Asians in Los Angeles County. *Leuk Res.* 2000;24:665-9.

715. Champlin RE, Passweg JR, Zhang MJ, Rowlings PJ, Pelz CJ, Atkinson KA, Barrett AJ, Cahn JY, Drobyski WR, Gale RP, Goldman JM, Gratwohl A, Gordon-Smith EC, Henslee-Downey J, Herzig RH, Klein JP, Marmont AM, O'Reilly RJ, Ringden O, Slavin S, Sobocinski KA, Speck B, Weiner RS, Horowitz MM. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. *Blood*. 2000;95:3996-4003.
716. Champlin RE, Schmitz N, Horowitz MM, Chapius B, Chopra R, Cornelissen JJ, Gale RP, Goldman JM, Loberiza FR, Hertenetein B, Klein J, Monterrat E, Zhang MJ, Ringden O, Tomay S, Rowlings PA, Van Hoef MEHM, Gratwohl A. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR histocompatibility and stem cell sources working committee and the European group for blood and marrow transplantation (EBMT). *Blood*. 2000;95:3702-9.
717. Tallman MS, Rowlings PA, Milione G, Zhang MJ, Perez WS, Weisdorf D, Keating A, Gale RP, Geller RB, Laughlin MJ, Lazarus HM, Luger SM, McCarthy PL, Rowe JM, Saez RA, Vowels MR, Horowitz MM. Effect of post remission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. *Blood*. 2000;96:1254-8.
718. Filipovich AH, Stone JV, Murphy SC, Ireland M, Kollman C, Pelz CJ, Casper JT, Cowan MJ, Edwards JR, Fasth A, Gale RP, Junker A, Kamani N, Loechelt BJ, Pietryga DW, Ringden O, Vowels M, Hegland J, Williams AV, Klein JP, Sobocinski KA, Rowlings PA, Horowitz MM. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. *Blood*. 2001;97:1598-1603.
719. Butturini A, Gale RP, Horowitz MM. Identical-twin hematopoietic stem cell transplantation. *Clin Bone Marrow Transplant*. Atkinson K, ed. Cambridge: Cambridge University Press, 2001.
720. Gale RP. Therapy of bone marrow failure after radiation accidents. The Criticality Accident in Tokaimura. In: *Medical Aspects of Radiation Emergency. Proceedings of the International Symposium on the criticality accident in Tokaimura*. Tsujii H, Akasaki M, eds. Chiba, National Institute of Radiological Sciences, 2001, pp 208-11.
721. Lazarus H, Loberiza F, Zhang MJ, Armitage JO, Ballen KK, Bolwell BJ, Burns LJ, Freytes CO, Gale RP, Gibson J, Herzig RH, LeMaistre CF, Marks D, Miller MJ, Milone GA, Pavlovsky S, Reece DE, Rizzon JD, van Besien K, Vose JM, Horowitz MM. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). *Bone Marrow Transplant*. 2001;27:387-96.
722. Rocha V, Wagner JE, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, Gluckman E. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. *N Engl J Med*. 2001;342:1846-54.
723. Berry DA, Broadwater G, Klein JP, Aisner J, Bitran J, Costanza M, Freytes CO, Stadtmauer E, Gale RP, Henderson IC, Lazarus HM, McCarthy PL Jr, Norton L, Parnes H, Pecora A, Perry MC, Rowlings P, Spitzer G, Horowitz MM. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of cancer and leukemia group B trials with data from the autologous blood and marrow transplant registry. *J Clin Oncol*. 2002;20:743-50.
724. van Rood JJ, Loberiza FR, Zhang MJ, Oudshoorn M, Claas F, Cairo MS, Champlin RE, Gale RP, Ringden O, Hovs JM, Horowitz MM. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. *Blood*. 2002; 99:1572-7.

725. Chiba S., Saito A, Ogawa S, Takeuchi K, Kumano K, Seo S, Suzuki T, Tanaka Y, Saito T, Izutsu K, Yuji K, Masuda S, Futami S, Nishida M, Suzuki G, Gale RP, Fukayama M. Transplantation for accidental acute high-dose total body neutron-and y-radiation exposure. *Bone Marrow Transplant.* 2002;29:935-9.
726. Litzow MR, Perez WS, Klein JP, Bolwell BJ, Camitta B, Copelan EA, Gale RP, Giralt SA, Keating A, Lazarus HM, Marks DI, McCarthy PL, Miller CB, Milone G, Prentice HG, Russell JA, Schultz KR, Trigg ME, Weisdorf DJ, Horowitz MM. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busuphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. *Br J Haematol.* 2002;119:1115-24.
727. Everman DB, Bartels CF, Yang Y, Yanamandra N, Goodman FR, Mendoza-Londono JR, Savarirayan R, White Sm, Graham JM Jr, Gale RP, Svarch E, Newman WG, Kleckers AR, Francomano CA, Govindaia V, Singh L, Morrison S, Thomas JT, Warman ML. The mutational spectrum of brachydactyly type C. *Am J Med Genet.* 2002; 112:291-6.
728. Lee S, Klein J, Barrett AJ, Ringden O, Antin JH, Cahn JY, Carabasi MH, Gale RP, Giralt S, Hale GA, Ilhan O, McCarthy PL, Socie G, Verdonck LF, Weisdorf J, Horowitz MM. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. *Blood.* 2002;100: 406-14.
729. Butturini A, Klein J, Gale RP. Modeling minimal residual disease (MRD) testing. *Leuk Res.* 2002;27: 293-300.
730. Svarch E, Fernandez J, Pons R, Gonzalez A, Warman M, Gale RP. Severe aplastic anemia in a child with brachydactyly type C. *Br J Haematol.* 2003;120: 368-9.
731. Ringden O, Barrett J, Zhang MJ, Loberiza F, Bolwell BJ, Cairo MS, Gale RP, Hale GA, Litzow MR, Martino R, Russell JA, Tiberghien P, Ispizua AU, Horowitz MM. (GV99-01). Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cells is associated with a high CD34 cell dose. *Br J Haematol.* 2003;121: 874-85.
732. Rizzo JD, Williams S, Wu JT, Pecora AL, Lazarus HM, Bolwell B, Fields KK, Gale RP, Eifenbein G, Horowitz MM, Antman KH. Syngeneic hematopoietic stem cell transplantation for women with metastatic breast cancer. *Bone Marrow Transplant.* 2003;32:151-5.
733. Bierman P, Sweetenham JW, Loberiza FR, Zhang MJ, Ballen KK, Bashey A, Bitran JD, Bolwell BJ, Burns LJ, Cairo MS, Champlin RE, Freytes CO, Gale RP, Herzig RH, Lazarus HM, Lister J, Martino R, Miller AM, Milone G, Parker AN, Schenkein DP, Schmitz N, Slavin S, Taghipour G, van Besien K, Vose JM, Horowitz MM, Goldstone A. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: A comparison with allogeneic and autologous transplantation – The lymphoma working committee of the International Bone Marrow Transplant registry and the European Group for blood and marrow transplantation. *J Clin Oncol.* 2003;20: 3744-53.
734. Vose Jm, Rizzo DJ, Tao-Wu J, Armitage Jo, Bashey A, Burns LJ, Christiansen NP, Co, Gale RP, Gibson J, Giralt SA, Herzig RH, Lemaistre CF, McCarthy PL, Nimer SD, Petersen FB, Schenkein DP, Wiernick PH, Wiley JM, Loberiza FR, Lazarus HM, van Besien K, Horowitz MM. Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission. *Biology of Blood and Marrow Transplant.* 2004;10:116-27.

735. Cutler C, Lee S, Greenberg P, Deeg HJ, Perez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo DR, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH, Horowitz MM. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low risk myelodysplasia is associated with improved outcome. *Blood*. 2004;104: 579-85.
736. Passweg JR, Walker I, Sobocinski KA, Rio B, Litzow MR, Carreras E, Szydlo R, Bolwell BJ, Ilhan O, Seiter K, Maharaj D, Pasquini R, Carabasi MH, Kolb HJ, Gale RP, Schouten HC, Cornelissen JJ, Goldman J, Gratwohl A, Montserrat E, Klein JP, Horowitz MM, Giralt S for the Chronic Leukemia Working Committee of the International Bone Marrow Transplant Registry (IBMTR). Validation and extension of the EBMT risk score for patients with chronic myeloid leukemia (CML) receiving allogeneic hematopoietic stem cell transplants. *Br J Haematol*. 2004;125:613-20.
737. Freytes CO, Loberiza FO, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, Gale RP, Horowitz MM, Klumpp TR, Martino R, McCarthy PL, Molina A, Pavlovsky S, Pecora AL, Serna DS, Tsai T, Zhang MJ, Vose JM, Lazarus HM, Van Besien K. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who relapsed after autologous stem cell transplantation for lymphoma: A report of The International Bone Marrow Transplant Registry. *Blood*. 2004;10:1182.
738. Godder K, Eapen M, Laver JH, Zhang MJ, Camitta BM, Wayne AS, Gale RP, Doyle JJ, Yu LC, Chen AR, Garvin JH, Sandler ES, Yeager AM, Edwards JR, Horowitz MM. Autologous Hematopoietic Stem cell transplantation for children with acute myeloid leukemia in first or second remission: A prognostic factor analysis. *J Clin Oncol*. 2004; 22:3798-3804.
739. Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, Tallman MS, Marks DI, Camitta BM, Champlin RE, Ringden O, Bredeson CN, Martino R, Gale RP, Cairo MS, Litzow MR, DeLima M. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. *Bone Marrow Transplant*. 2004; 34:721-7.
740. Oh H, Loberiza FR, Zhang MJ, Ringden O, Akiyama H, Asai T, Miyawaki AT, Okamoto S, Horowitz MM, Antin JH, Bashey A, Bird JM, Carabasi MH, Fay JW, Gale RP, Giller RH, Goldman JM, Hale GA, Harris RE, Henslee-Downey J, Kolb HJ, Litzow MR, McCarthy PL, Neudorf SM, Serna DS, Socie DS, Tiberghien P, Barrett AJ. Comparison of graft-vs-host-disease and survival after HLA-identical sibling bone marrow transplantation in different ethnic populations. *Blood*. 2005;105:1408-16.
741. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, Stevens C, Barker JN, Gale RP, Lazarus HM, Marks DI, van Rood JJ, Scaradavou A, Horowitz MM. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. *N Eng J Med*. 2005;351:2265-75.
742. Gale RP, Horowitz MM, Talpaz M, Scheinberg DA, Molldren J, Li Z, Baccarani M, Goldman JM, Tura S. Immune therapy of chronic myelogenous leukemia. *Leuk Res*. 2005;29:583-6.
743. Seebach JD, Stussi G, Passweg JR, Loberiza FR Jr., Gajewski JL, Keating A, Goerner M, Rowlings PA, Tiberghien P, Eifgen GJ, Gale RP, van Rood JJ, Reddy V, Gluckman E, Bolwell BJ, Klumpp TR, Horowitz MM, Ringden O, Barrett AJ, GVDH Working Committee of the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee. ABO blood group barrier in allogeneic bone marrow transplantation revisited. *Biol Blood Marrow Transplant*. 2005;11:1006-13.
744. Khoury HJ, Loberiza FR Jr., Ringden O, Barrett AJ, Bolwell BJ, Cahn JY, Champlin PE, Gale RP, Hale GA, Urbano-Ispiza A, Martino R, McCarthy PL, Tiberghien P. Impact of posttransplant G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. *Blood*. 2006;107:1712-6.

745. Tallman MS, Perez WS, Lazarus HM, Gale RP, Maziarz RT, Rowe JM, Marks DI, Cahn JY, Bashey A, Bishop MR, Christiansen N, Frankel SR, Garcia JJ, Ilhan O, Laughlin MJ, Liesveld J, Linker C, Litzow MR, Luger S, McCarthy PL, Milone GA, Pavlovsky S, Phillips GL, Russell JA, Saez RA, Schiller G, Sierra J, Weiner RS, Zander AR, Zhang MJ, Keating A, Weisdorf DJ, Horowitz MM. Pretransplant consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. *Biol Blood Marrow Transplant.* 2006;12:204-16.

746. Lazarus HM, Perez WS, Klein JP, Kollman C, Bate-Boyle B, Bredeson CN, Gale RP, Geller RP, Keating A, Litzow MR, Marks DI, Miller CB, Rizzo D Jr., Spitzer TR, Weisdorf DJ, Zhang MJ, Horowitz MM. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myelogenous leukemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. *Br J Haematol.* 2006;132:755-69.

747. Marks DI, Forman SJ, Blume KG, Perez WS, Weisdorf DJ, Keating A, Gale RP, Cairo MS, Copeland EA, Horan JT, Lazarus HM, Litzow MR, McCarthy PL, Schultz KR, Smith DD, Trigg ME, Zhang MJ, Horowitz MM. A comparison of cyclophosphamide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. *Biol Blood Marrow Transplant.* 2006;12:438-53.

748. Anagnostopoulos A, Hari PN, Perez WS, Ballen K, Bashey A, Bredeson CN, Freytes CO, Gale RP, Gertz MA, Gibson J, Goldsmith H, Lazarus HM, McCarthy PL, Reece DE, Vesole DH, Giralto SA. Autologous or allogeneic stem cell transplantation in patients with Waldenström's Macroglobulinemia. *Biol Blood Marrow Transplant.* 2006 Aug;12:845-54.

749. Hoos A, Gale RP. Immune Treatment of Chronic Myelogenous Leukemia. In: *Hematologic Malignancies: Myeloproliferative Disorders.* Melo JV, Goldman JM, eds. New York & Heidelberg, Springer-Verlag, 2007, pp. 185-200.

750. Ben Bassat I, Raanani P, Gale RP. Graft-versus-leukemia in chronic lymphocytic leukemia. *Bone Marrow Transplant.* 2007;39:441-6.

751. Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, Camitta BM, Champlin RE, Gale RP, Fuhrer M, Klein JP, Locasciulli A, Oneto R, Scahttenber AV, Socie G, Eapen M. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia: A report from the European Group for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research. *Blood.* 2007;15;110:1397-400.

752. Panepinto JA, Walters MC, Carreras J, Marsh J, Bredeson CN, Gale RP, Hale GA, Horan J, Hows JM, Klein JP, Pasquini R, Roberts I, Sullivan K, Eapan M, Ferster A. Matched related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. *Br J Haematol.* 2007; 137:479-85.

753. Lazarus HM, Stiff PJ, Carreras J, Logan BR, Akard L, Bolwell BJ, Childs RW, Gale RP, Klein JP, Lill MC, Perez WS, Stadtmauer EA, Rizzo JD. Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: A Center for International Blood and Bone Marrow Transplant Research (CIBMTR) Analysis. *Biol Blood Marrow Transplant.* 2007;13:778-89.

754. Pavletic SZ, Zhou G, Sobocinski K, Marti G, Doney K, DiPersio J, Feremas W, Foroni L, Goodman S, Prentice G, Le Maistre C, Bandini G, Ferrant A, Jacobsen N, Khouri I, Gale, RP, Wiestner A, Giralt S, Montserrat E, Chan J, Bredeson C. Genetically identical twin transplantation for chronic lymphocytic leukemia. *Leukemia*. 2007;21:2452-5.
755. Ueno, NT, Rizzo JD, Demirel T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, Bitran JD, Bolwell BJ, Elfenbein GJ, Fields KK, Freytes CO, Gale RP, Lazarus HM, Champlin RE, Stiff PJ, Niederwasser D. Allogeneic hematopoietic cell transplantation for metastatic breast cancer. *Bone Marrow Transplant*. 2007;17; 1-9.
756. Gale RP. E11 Predicted health consequences of the Chernobyl nuclear power station accident 1986-20065. *Leuk Res*. 2007;31 Suppl 2:S21-2.
757. Schlenck RF, Pasquini MC, Perez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Buchner T, Cahn JY, Cairo MS, Copeland EA, Cutler CS, Doehner H, Gale RP, Illhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCathy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A; CIBMTR Acute Leukemia Working Committee. HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first remission: collaborative study between the German AML intergroup and CIBMTR. *Biol Blood Marrow Transplant*. 2008;14;187-96.
758. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, Burns LJ, Cairo MS, Freytes CO, Goldstein SC, Hale GA, Inwards DJ, Lemaistre CF, Maharaj D, Marks DI, Schouten HC, Slavina S, Vose JM, Lazarus HM, van Besien K. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. *Biol Blood Marrow Transplant*. 2008;14:236-45.
759. Marks DI, Waleska SP, Wnsheng H, Zhang MJ, Bishop MR Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernick PH, Weisdorf DJ. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. *Blood*. 2008;112:426-34.
760. Bashey A, Perez WS, Zhang MJ, Anderson KC, Ballen K, Berenson JR, To LB, Fronseca R, Freytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pvalovsky S, Reece DE, Schiller G, Vesole DH, Hari P. Comparison of twin and autologous transplants for multiple myeloma. *Biol Blood Marrow Transplant*. 2008;14:1118-24.
761. Kumar S, Pérez WS, Zhang MJ, Ballen K, Bashey A, To LB, Bredeson CN, Cairo MS, Elfenbein GJ, Freytes CO, Gale RP, Gibson J, Kyle RA, Lacy MQ, Lazarus HM, McCarthy PL, Milone GA, Moreb JS, Pavlovsky S, Reece DE, Vesole DH, Wiernik PH, Hari P. Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. *Biol Blood Marrow Transplant*. 2008;14:1134-40.
762. Smith SM, van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, Gale RP, Hale GA, Hayes-Lattin B, Holmberg LA, Keating A, Maziarz RT, McCarthy PL, Navarro WH, Pavlovsky S, Schouten HC, Seftel M, Wiernik PH, Vose JM, Lazarus HM, Hari P. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. *Biol Blood Marrow Transplant*. 2008;14:904-12.
763. Hahn T, McCarthy PL, Zhang MJ, Wanf D, Arora M, Frangoul H, Gale RP, Horan J, Isola L, Maziarz RT, van Rood JJ, Gupta V, Halter J, Reddy V, Tiberghien P, Litzow M, Anasetti C, Pavletic S, Ringden O. Risk factors for acute graft-versus host disease after HLA-identical sibling transplants for adults with leukemia. *J Clin Oncol*. 2008;26:5728-34.

764. Lee SJ, Kukreja M, Wang T, Giralto SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, Horowitz MM, Maziarz RT. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. *Blood*. 2008;15:112:3500-7.
765. Gale RP, Bennett JM. Are myelodysplastic syndromes and acute myeloid leukemia one disease? *Leukemia Res*. 2009;33:351-4.
766. Lazaurs HM, Carreras J, Boudreau C, Loberiza FR, Jr. Armitage JO, Bolwell BJ, Freytes CO, Gale RP, Gibson J, Hale GA, Inwards DJ, LeMaistre CF, Maharaj D, Marks DI, Miller AM, Pavlovsky S, Schouten HC, van Besien K, Vose JM, Bitran JD, Khouri IF, McCarthy PL, Yu H, Rowlings, Serna DS, Horowitz MM, Rizzo JD. Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center for International Blood & Marrow Transplant Research (CIBMTR). *Biol Blood Marrow Transplant*. 2008;14:1323-33.
767. Ringden O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D, Antin JH, DiBartolomeo P, Bolwell BJ, Bredeson C, Cairo MS, Gale RP, Gupta V, Hahn T, Hale GA, Halter J, Jagasia M, Litzow MR, Locatelli F, Marks DJ, McCarthy PL, Cowan MJ, Peterdorf EW, Russell JA, Schiller GJ, Schouten H, Spellman S, Verdonck LF, Wingard JR, Horowitz MM, Arora M. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. *Blood*. 2009;13:3110-8.
768. Rahmentulla A, Gale RP. Critical care aspects of bone marrow and blood cell transplants. In: Civetta, Taylor, and Kirby's Critical Care, 4th Edition. Gabriellie A, Layon AJ, Yu M. eds. Philadelphia, Lippincott, Williams & Wilkins, 2009.
769. Gale RP, Eapen M, Logan B, Zhang MJ, Lazarus H. Comparing therapy-options: Are observational database studies and expert opinion as good (or better) than randomized trials? *Bone Marrow Transplant*. 2009; 43:435-46.
770. Devetten MP, Hari PN, Carreras J, Logan BR, van Besien K, Bredeson CN, Freytes CO, Gale RP, Gibson J, Giralto SA, Goldstein SC, Gupta V, Marks DI, Maziarz RT, Vose JM, Lazarus HM, Anderlini P. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. *Biol Blood Marrow Transplant*. 2009;15:190-17.
771. Ratanatharathorn V, Logan B, Wang D, Horowitz MM, Uberti J, Ringden O, Gale RP, Khoury HJ, Arora M, Spellman S, Cutler C, Antin J, Bornhaeuser M, Hale GA, Verdonck LF, Cairo MS, Gupta VS, Pavletic SZ. Prior rituximab correlates with less acute graft-versus-host disease in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation (PBSCT). *Br J Haematol*. 2009;145:816-24.
772. Hari PN, Zhang MJ, Roy V, Perez WS, Bashey A, To LB, Elfenbein G, Freytes CO, Gale RP, Gibson J, Kyle RA, Lazarus HM, McCarthy PL, Milone GA, Pavlovsky S, Reece DE, Schiller G, Vela-Ojeda J, Weisdorf D, Vesole D. Is the International staging system superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. *Leukemia*. 2009;23:1528-34.

773. Horan J, Carreras J, Tarima S, Camitta BM, Gale RP, Hale GA, Hinterberger W, Marsh J, Passweg JR, Walters MC, Eapen M. Risk factors affecting outcome of second HLA-matched sibling donor transplants for graft failure in severe acquired aplastic anemia. *Biol Blood Marrow Transplant.* 2009;15:626-31.
774. Mesa R, Gale RP. Hypothesis: How do JAK2-inhibitors work in myelofibrosis? *Leuk Res.* 2009;33:1156-7.
775. Tefferi A, Verstovsek A, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. *J Clin Oncol.* 2009;20;27:4563-9.
776. Weisdorf D, Nelson G, Lee SJ, Haagesnson M, Spellman S, Antin JH, Bolwel B, Cahn JY, Cervantes F, Copelan E, Gale RP. Sibling vs. unrelated donor allogeneic hemtopoietic cell transplantation for chronic myelogenous leukemia: Refined HLA-matching reveals more GVHD but not less relapse. *Biol Blood Marrow Transplant.* 2009;15:1575-1478.
777. Fenske TS, Hari PN, Carreas J, Zhang MJ, Kamble RT, Boswell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marke DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernick PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma. *Biol Blood and Marrow Transplant.* 2009;15:1455-1464.
778. Ballen FK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kroeger N, Litzow MR, Marks DI, Maziarz PH, Horowitz MM, Giralt SA, Arora M. Outcomes of transplantation for myelofibrosis. *Biol Blood and Marrow Transplant.* 2010;16:358-67.
779. Stiff PJ, Agovi MA, Antman K, Blaise D, Camitta BM, Cairo MS, Childs RW, Edwards JR, Gale RP, Hale GA, Horowitz MM, Lazarus HM, Arora M. High dose chemotherapy with blood or marrow transplant for rhabdomyosarcoma: a CIBMTR analysis. *Biol of Blood and Bone Marrow Transplant.* 2010;16:525-32.
780. Litzow MR, Tarima S, Perez WS, Bolwell BJ, Cairo MS, Camitta BM, Cutler CS, Lima MD, Dispersio JF, Gale RP, Keating A, Lazarus HM, Luger S, Marks DI, Maziarz RT, McCarthy PL, Pasquini MC, Phillips GL, Rizzo JD, Sierra J, Tallman MS, Weisdorf DJ. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. *Blood.* 2010;115:1850-7.
781. Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD, Bolwell BJ, Freytes CO, Gale RP, Goldstein SC, Halle GA, Inwards DJ, Klumpp TR, Marks DI, Maziara RT, McCarthy PL, Pavlovsky S, Rizzo JD, Shea TC, Schouten HC, Slavin S, Winter JN, van Besien K, Vose JM, Hari PN. Comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B-cell lymphoma: A report from the CIBMTR. *Biol of Blood and Marrow Transplant.* 2010;16:35-45.
782. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, Dipersio J, Keating A, Gale RP, George B, Gupta V, Hahn T, Isola L, Jagasia M, Lazarus H, Marks D, Maziarz R, Waller EK, Bredeson C, Giralt S. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. *J Clin Oncol.* 2010;10:28:1878-87.

783. Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP, Gupta V, Maharaj D, Marks DI, Pavletic SZ, Horowitz MM, Arora M. Allogenic hematopoietic cell transplant for polymphocytic leukemia. *Biol of Blood and Bone Marrow Transplant.* 2010;6:543-7.

784. Marks DI, Wang T, Perez WS, Antin JH, Copelan E, Gale RP, George B, Gupta V, Halter J, Khoury HJ, Klumpp TR, Lazarus HM, Lewis VA, McCarthy P, Rizzieri DA, Sabloff M, Szer J, Tallman MS, Weisdorf D. The outcome of full intensity and reduced intensity conditioning matched sibling or unrelated donor (URD) transplantation in adults with Philadelphia chromosome negative acute lymphoblastic leukemia (PH-ALL) in first and second complete remission (CR1 and CR2). *Blood.* 2010;116:366-74.

785. Barosi G, Magrini U, Gale RP. Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis. *Leuk Res.* 2010;34:1119-20.

786. Gupta V, Tallman MS, He W, Logan BR, Copelan E, Gale RP, Khoury HJ, Klumpp T, Koreth J, Lazarus HM, Marks DI, Martino R, Rizzieri DA, Rowe JM, Sabloff M, Waller E, Dispersio JF, Bunjes DW, Weisdorf DJ. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. *Blood.* 2010;116:1839-48.

787. Goldberg RM, Bleich D, Brunswick M, Coplan P, Dimasi J, Gale RP, Goodwin F, Horn S, Hukkelhoven M, Martin S, McGovern P, Oktem U, Pitts P, Ruano G, Rubinstein E, Sammut S, Shlaes D, Swen J, Weber M, Woosley R, Zambrowicz B. Prescription for progress: The critical path of drug development. A working paper of the 21st century FDA task force. New York, NY: Manhattan Institute for Policy Research, 2006.

788. Mesa RA, Green A, Barosi G, Verstovsek S, Vardiman J, Gale RP. MPN-Associated Myelofibrosis (MPN-MF). *Leuk Res.* 2011;35:12-3.

789. Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian J-J, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S. What are RBC-transfusion-dependence and –independence? *Leuk Res.* 2011; Jan;35: 8-11.

790. Gupta V, Eapen M, Brazauskas R, Carreras J, Aljurf M, Gale RP, Hale GA, Ilhan O, Passweg JR, Ringden O, Sabloff M, Schrezenmeier H, Socie G, Marsh JCW. Impact of age on outcomes after transplantation for acquired aplastic anemia using HLA-identical sibling donors. *Haematologica.* 2010;95:2119-25.

791. Shaw PJ, Kan F, Ahn KW, Spellman SR, Aljurf M, Burke M, Cairo MS, Chen AR, Davies SM, Frangoul H, Gajewski J, Gale RP, Godder K, Hale GA, Heemskerk MB, Horan J, Kamani N, Kasow KA, Chan KW, Lee SJ, Leung WH, Lewis VA, Miklos D, Oudshoorn M, Petersdorf EW, Ringden O, Sanders J, Schultz KR, Seber A, Setterholm M, Wall DA, Yu L, Pulsipher MA. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related or matched unrelated donors. *Blood.* 2010;116:4007-15.

792. Reece D, Vesole DH, Shrestha S, Zhang MJ, Perez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Baskey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, Lohar PV, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wierniek PH, Hari PN. Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplants: A retrospective study. *Clin Lymphoma Myeloma Leuk.* 2010;10:458-63.

793. Gale RP, Lazarus HM. How helpful are meta-analyses in determining best therapy of blood diseases? *Acta Haematol.* 2011;125:91-101. Review.
794. Cutler C, Kesselheim A, Gabardi S, Andersson BS, Carpenter P, Khoury HJ, Litzow M, Rowley SD, Lanum S, Leather H, Ya-Chen TS, Gale RP, Wingard JR, Appelbaum FR, Anasetti C. Generic Immunosuppressants in hemtopoietic cell transplantation. *Biol Blood Marrow Transplant. Biol Blood Marrow Transplant.* 2011;17:285-90.
795. Chu R, Brazauskas R, Kan F, Bashey A, Bredeson C, Camitta B, Chiang KY, Frangoul H, Gale RP, Gee A, George B, Goldman FD, Gross TG, Gupta V, Hale GA, Isola L, Ispizua AU, Lazarus H, Marsh J, Russell J, Sabloff M, Waller EK, Eapen M. Comparisons of outcomes after transplantation of G-CSF-Stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-Matched sibling donors for patients with severe aplastic anemia. *Biol Blood Marrow Transplant.* 2011;17:1018-24.
796. Sabloff M, Chandy M, Wang Z, Logan BR, Ghavamzadeh A, Li CK, Irfan SM, Bredeson CN, Cowqn MJ, Gale RP, Hale GA, Horan J, Hongeng S, Eapen M, Walters MC. HLA-matched sibling bone marrow transplantation for {beta}-thalassemia major. *Blood.* 2011;117:1745-50.
797. Barosi G, Gale RP. Bone marrow fibrosis in myeloproliferative neoplasms-associated myelofibrosis: deconstructing a myth? *Leuk Res.* 2011;35:563-5.
798. Van Etten RA, Koschmier S, Delhommeau F, Perrotti D, Holyoake T, Paranani A, Mesa R, Green A, Ibrahim A, Mughal T, Gale RP, Goldman J. The Ph – positive and Ph negative myeloproliferative neoplasms – some topical preclinical and clinical issues. *Haematologica.* 2011;96:590-601. Review.
799. Gale RP, Baranov A. If the unlikely becomes likely: Medical response to nuclear accidents. *Bulletin of the Atomic Scientists.* 2011. DOI:10.1177.
800. Pasquini MC, Wang Z, Horowitz MM, Gale RP. 2010 report from the Center for Blood and Marrow Transplant Reseach (CIBMTR): Current uses and outcomes of hematopietic cell transplants for blood and bone marrow disorders. In: Cecka JM, Terasaki PI (Eds.) *Clinical Transplants 2010.* Los Angeles, CA: Terasaki Foundation Laboratory, pp 87-105.
801. Luger SM, Ringden O, Zhang MJ, Perez WS, Bishop MR, Bornhauser M, Bredeson CN, Cairo MS, Copelan EA, Gale RP, Giralt SA, Gulbas Z, Gupta V, Hale GA, Lazarus HM, Lewis VA, Lill MC, McCarthy PL, Weisdorf DJ, Pulsipher MA. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML and MDS. *Bone Marrow Transplant.* 2012;47:203-11.
802. Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers ME, Cutler CS, Urbano-Ispizua A, Antin JH, Bolwell, BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola L, Jacobsohn DA, Jagasia M, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Gale RP, Schouten HC. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant research analysis. *Blood.* 2011;117:6714-20. Erratum in: *Blood.* 2011;118:6992.
803. Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, Freytes CO, Vogl DT, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale RP, Hari P. Trends in allogenic stem cell transplantation for multiple myeloma: a Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. *Blood.* 2011;118:1979-88.

804. Gale RP, Baranov A, Mugushima H, Oh H. Blood cell banking for workers at the Fukushima Daiichi nuclear power plant. *The Lancet*. 2011;378:483-4; author reply 484-5.
805. Gale RP, Opelz G. Commentary: does immune-suppression increase risk of developing acute myeloid leukemia? *Leukemia*. 2012;26:422-3.
806. Ringdén O, Shrestha S, da Silva GT, Zhang MJ, Dispenzieri A, Remberger M, Kamble R, Freytes CO, Gale RP, Gibson J, Gupta V, Holmberg L, Lazarus H, McCarthy P, Meehan K, Schouten H, Milone GA, Lonial S, Hari PN. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. *Bone Marrow Transplant*. 2012;47:831-7.
807. Jacobsohn DA, Arora M, Klein JP, Hassebroek A, Flowers ME, Cutler CS, Urbano-Ispizua A, Bolwell BJ, Antin JH, Boyiadzis M, Cahn JY, Cairo MS, Herzig RH, Isola LM, Klumpp TH, Lee SJ, Petersdorf EW, Santarone EW, Gale RP, Schouten HC, Spellman SR, Weisdorf DJ, Wingard JR, Horowitz MM, Pavletic SZ. Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. *Blood*. 2011;118:4472-9.
808. Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M, Gupta V, Rizzieri DA, George B, Keating A, Gale RP, Marks DI. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. *Bone Marrow Transplant*. 2012;47:810-816.
809. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizura A, Pavletic SZ, Haagenson MD, Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, Horowitz MM, Hahn T. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. *Blood*. 2012;119:296-307.
810. Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, Berenson JR, Bird JM, Dispenzieri A, Gajewski JL, Gale RP, Holmberg L, Kumar S, Kyle RA, Lazarus HM, Lonial S, Mikhael J, Milone GA, Munker R, Nath R, Saccaro S, To LB, Vogl DT, Wirk B, Hari P. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the center for International Blood and Marrow Transplant Research. *Leukemia*. 2012;26:1091-7.
811. Farag SS, Maharry K, Zhang MJ, Perez WS, George SL, Mrozek K, DiPersio J, Bunjes DW, Marcucci G, Baer MR, Cairo M, Copelan E, Cutler CS, Isola L, Lazarus HM, Litzow MR, Marks DI, Ringden O, Rizzieri DA, Soiffer R, Larson RA, Tallman MS, Bloomfield CD, Weisdorf DJ. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. *Biol Blood Marrow Transplant*. 2011;17:1796-803.
812. Hershko C, Gale RP. Is Iron-Chelation therapy useful in persons with myelodysplastic syndrome? *Open Journal of Blood Diseases*. 2011;1:3-7.
813. Hale GA, Shrestha S, Le-Rademacher J, Burns LJ, Gibson J, Inwards DJ, Freytes CO, Bolwell BJ, Hsu JW, Slavin S, Isola L, Rizzieri DA, Gale RP, Laport GG, Montoto S, Lazarus HM, Hari PN. Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: A report from the CIBMTR. *Biol Blood Marrow Transplant*. 2012;18:1036-43.e1.
814. Freytes CO, Zhang MJ, Carreras J, Burns LJ, Gale RP, Isola L, Perales MA, Seftel M, Vose JM, Miller Am, Gibson J, Gross TG, Rowlings PA, Inwards DJ, Pavlovsky S, Martino R, Marks DI, Hale GA, Smith SM, Schouten HC, Slavin S, Klumpp TH, Lazarus HM, van Besien K, Hari PN. Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplant failure. *Biol Blood Marrow Transplant*. 2012;18:1255-64.

815. Gale RP, Barosi G, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjan JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstrovsek S. RBC-transfusion guidelines update. *Leuk Res.* 2012;36:659-60.
816. Xu Z, Gale RP, Zhang Y, Qin T, Chen H, Zhang P, Zhang T, Liu L, Qu S, Xiao Z. Unique features of primary myelofibrosis in Chinese. *Blood.* 2012;119:2469-73.
817. Gale RP, Hoffman OR. Communicating radiation-related cancer-risk to the public. *Chiba Med J.* 2012;88 E:9-25.
818. Linhares YPL, Palvetic S, Gale RP. Chronic GVHD: Where are we? Where do we want to be? Will IMiDs help? *Bone Marrow Transplant.* 2013;48:203-9.
819. Tomblyn M, Chen M, Kukreja M, Aljurf MD, Al Mohareb F, Bolwell BJ, Cahn JY, Carabasi MH, Gale RP, Gress RE, Gupta V, Hale GA, Ljungman P, Maziarz RT, Storek J, Wingard JR, Young JA, Horowitz MM, Ballen KK. No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation. *Transpl Infect Dis.* 2012;14:468-78.
820. Pasquini MC, Voltarelli J, Atkins HL, Hamerschlak N, Zhong X, Ahn KW, Sullivan KM, Carrum G, Andrey J, Bredeson CN, Cairo M, Gale RP, Hahn T, Storek J, Horowitz MM, McSweeney PA, Griffin LM, Muraro PA, Pavletic SZ, Nash RA. Transplantatin for autoimmune diseases in North and South America: A report from the Center for International Blood and Marrow Transplant Research. *Biol Blood Marrow Transplant.* 2012;18:1471-8.
821. Gale RP. Markov model of CLL transplants. *Bone Marrow Transplant.* 2012;47:1145-6.
822. Gale RP. Response to: "An Unexpected mortality increase in the United States follows arrival of radioactive plume from Fukushima: Is there a correlation?" *International Journal of Health Services* 2012;42:557-9.
823. Gale RP. Communicating cancer risk from radiation exposures: nuclear accidents, total body radiation and diagnostic procedures (editorial). *Bone Marrow Transplant.* 2012;1- 2.
824. Cui R, Gale RP, Xu Z, Quin T, Fang L, Zhang H, Pan L, Zhang Y, Xiao Z. Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts. *Leuk Res.* 2012;36:1428-33.
825. Wang J, Ai X, Gale RP, Xu Z, Quin T, Fang L, Zhang H, Pan L, Hu N, Zhang Y, Xiao Z. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes. *Leuk Re.* 2013;37:305-11.
826. Gale RP. Obituary for E. Donnall Thomas (1920-2012). *Int J Hematol.* 2012;s12185-012:1219-2.
827. Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL. Autologous and allogeneic transplantation for Burkitt's lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. *Biol Blood Marrow Transplant.* 2013;19:173-9.
828. Gale RP. E. Donnall Thomas (1920-2012): Bone Marrow Transplants Pioneer and Nobel Laureate. *Transplantation.* 2012;48:1.

829. Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Michael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P. Salvage second hematopoietic cell transplantation in myeloma. *Biol Blood Marrow Transplant.* 2013;19:760-6.
830. Li B, Xu Z, Gale RP, Qin, Zhang Y, Xiao Z. Serum ferritin is an independent prognostic factor in Chinese with myelodysplastic syndromes classified as IPSS intermediate-1. *Acta Haematol.* 2013;129(4):243-50.
831. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzeri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the CIBMTR. *Biol Blood Marrow Transplant.* 2013;19:625-31.
832. Gale RP, Lazarus HM. A rose by any other name would smell as sweet, or would it? *Bone Marrow Transplant.* 2013;48:881-3.
833. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzeri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM. Impact of pretransplant conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large-B cell lymphoma and grade-III follicular lymphoma. *Biol Blood Marrow Transplant.* 2013;19(5):746-53.
834. Hale GA, Arora M, Ahn KW, He W, Camitta B, Bishop MR, Bitan M, Cairo MS, Chan K, Childs RW, Copelan E, Davies SM, Perez MA, Doyle JJ, Gale RP, Vicent MG, Horn BN, Hussein AA, Jodele S, Kamani NR, Kasow KA, Kletzel M, Lazarus HM, Lewis VA, Myers KC, Olsson R, Pulsipher M, Qayed M, Sanders JE, Shaw PJ, Soni S, Stiff PJ, Stadtmauer EA, Ueno NT, Wall DA, Grupp SA. Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. *Bone Marrow Transplant.* 2013;48:1056-64.
835. Gale RP, Lax E, Hoffman FO. On radiation and cancer risk. *The ASCO POST.* 2013;4:154-5.
836. Gale RP, Hoffman FO (2013). Radiation Risk: Communicating to the public. In: *Radiation and Risk: Expert Perspectives.* Health Physics Society: McLean, Virginia, pp 45-50.
http://hps.org/documents/radiation_and_risk.pdf.
837. Ayas M, Saber W, Davies SM, Harris RE, Hale GA, Socie G, LeRademacher J, Thakar M, Deeg HJ, Al-Seraihy A, Battiwalla M, Camitta BM, Olsson R, Bajwa RS, Bonfim CM, Pasquini R, Macmillan ML, George B, Copelan EA, Wirk B, Al Jefri A, Fasth AL, Guinan EC, Horn BN, Lewis VA, Slavin S, Stepensky P, Bierings M, Gale RP. Allogeneic Hematopoietic Cell Transplantation for Fanconi Anemia in Patients with Pretransplantation Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia. *J Clin Oncol.* 2013;31:1669-76.
838. Gale RP, Vorobiov A. First use of myeloid colony-stimulating factors in humans (Letter to the Editor) *Bone Marrow Transplant.* 2013; 2013;48:1358.

839. Foran JM, Pavletic SZ, Logarn BR, Agovi-Johnson MA, Perez WS, Bolwell BJ, Bornhauser M, Bredeson CN, Cairo MS, Camitta BM, Copelan EA, Dehn J, Gale RP, George B, Gupta V, Hale GA, Lazarus HM, Litsow MR, Maharaj D, Marks DI, Martino R, Maziarz RT, Rowe JM, Rowlings PA, Savani BM, Saboie ML, Szer J, Waller EK, Wiernik PH, Weisdorf DJ. Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myeloid leukemia: a study from the CIBMTR. *Biol Blood Marrow Transplant.* 2013;19:1102-8.
840. Shaffer BC, Modric M, Stetler-Stevenson M, Arthur DC, Steinberg SM, Liewehr DJ, Fowler DH, Gale RP, Bishop MR, Pavletic SZ. Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia. *Exp Hematol.* 2013;41:772-8.
841. Gale RP. (Letter to the Editor). *Biol Blood Marrow Transplant.* 2013;19:1271-3.
842. Gale RP, Goldman JM. Treating Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors. *Acta Haematol.* 2013;130:192-5.
843. Gale RP, Lazarus HM. (Letter to the Editor). 'Yet another rose'. *Bone Marrow Transplant.* 2013;48:1581.
844. Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, Fenaux P, Jadersten M, Hellstrom-Lindberg E, Gale RP, Beach CL, Lee SJ, Horowitz MM, Greenberg PL, Tallman MS, Dipersio JF, Nunjes D, Weisdorf DJ, Cutler C. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with De Novo myelodysplastic syndromes: An international collaborative decision analysis. *J Clin Oncol.* 2013;31:2662-70.
845. Gale RP, Lazarus HM. Are we really doing hematopoietic stem cell transplants? (Letter to the Editor). *Biol of Blood Marrow Transplant.* 2013;11:1656.
846. Jiang Q, Xu LP, Liu DH, Gale RP, Zhang MJ, Jiang B, Zhang XH, Wang Y, Chen SS, Zhao XY, Chen H, Jiang H, Chen YH, Han W, Qin YZ, Liu YR, Lv M, Huang XJ. Imatinib results in better outcomes than HLA- identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia. (Letter to the Editor). *Leukemia* 2013;27:2410-13.
847. Maziarz RT, Wang Z, Zhang MJ, Bolwell BJ, Chen AI, Fenske TS, Freytes CO, Gale RP, Gibson J, Hayes-Lattin BM, Holmberg L, Inwards DJ, Isola LM, Khoury HJ, Lewis VA, Maharaj D, Munker R, Phillips GL, Rizzieri DA, Rowlings PA, Saber W, Satwani P, Waller EK, Maloney DG, Montoto S, Laport GG, Vose JM, Lazarus HM, Hari PN. Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. *Br J Haematol.* 2013;162:648-56.
848. Smith SM, Burns LJ, van Besien K, LeRademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazars HM, Wiernick PH, Maharaj D, Laport GG, Montoto S, Hari PN. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin Lymphoma. *J Clin Oncol.* 2013;31:3100-9.
849. Gale RP. Nuclear accidents and children: special considerations for pediatric hematologists and oncologists. *Jpn J Pediatr Hematol/Oncol* 2013;50:182-185.

850. Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A, Freytes C, Vesole D, Gale RP, Anderson K, Wirk B, Savani B, Waller EK, Schouten H, Lazarus H, Meehan K, Sharma M, Kamble R, Vij R, Kumar S, Nishihori T, Kindwall-Keller T, Saber W, Hari PN. Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma. *Biol Blood Marrow Transplant.* 2013;19:1615-24.

851. Behbahan IS, Keating A, Gale RP. Concise Review: Bone Marrow Autotransplants for Liver Disease? *Stem Cells.* 2013;31:2313-29.

852. Lee SJ, Storer B, Wang H, Lazarus HM, Waller EK, Isola LM, Klumpp TR, Umejiego JB, Savani BN, Loren AW, Cairo MS, Camitta BM, Cutler CS, George B, Jean Khoury H, Marks DI, Rizzieri DA, Copelan EA, Gupta V, Liesveld JL, Litzow MR, Miller AM, Schouten HC, Gale RP, Cahn JY, Weisdorf DJ. Providing Personalized Prognostic Information for Adult Leukemia Survivors. *Biol Blood Marrow Transplant.* 2013; 19:1600-7.

853. Lazarus HM, Litzow MR, Gale RP. Improving Survival in Acute Myeloid Leukemia: pick the best subjects? *J Clin Oncol.* 2013;31:3854-6.

854. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson CN, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared to TBI. *Blood.* 2013;122:3863-70.

855. Wang J, Xu Z, Liu L, Gale RP, Cross NCP, Jones AV, Qin T, Ai X, Zhang T, Sun X, Li Q, Zhang P, Zhang Y, Xiao Z. JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms. *Leukemia.* 2013;27:1763-7.

856. Goldman JM, Gale RP. What does MRD in leukemia really mean? Goldman JM, Gale RP. What does MRD in leukemia really mean? *Leukemia.* 2014;28:1131.

857. Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, Arellano M, Artz AS, Bacher U, Cahn JY, Chen YP, Copelan EA, Drobyski WR, Gale RP, Greer JP, Gupta V, Hale GA, Kebriaei P, Pidala J, Rowe JM, Savani BN, Saber W, Vij R, Waller EK, Wiernick PH, Weisdorf DJ. Ph+ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. *Leukemia.* 2014;28:658-65.

858. Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerda AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W. Reduced intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the Center for International Blood and Marrow Transplant Research. *Biol Blood Marrow Transplant.* 2014;20:89-97.

859. Gale RP, Lazarus HM. Yet another rose? (Letter to the Editor). *Bone Marrow Transplant.* 2013;48:1581.

860. Radivoyevitch T, Jankovic GM, Tiu RV, Sauntharajah Y, Jackson RC, Hlatky LR, Gale RP, Sachs RK. Sex differences in the incidence of chronic myeloid leukemia. *Radiat Environ Biophys*. 2013; doi: 10.1007/s00411-507-4.
861. Warlick ED, Paulson K, Brazauskas R, Zhong X, Miller AM, Camitta BM, George B, Savani BN, Ustun C, Marks DI, Waller EK, Baron F, Freytes CO, Socie G, Akpek G, Schouten HC, Lazarus HM, Horwitz EM, Koreth J, Cahn JY, Bornhauser M, Seftel M, Cairo MS, Laughlin MJ, Sabloff M, Ringdén O, Gale RP, Kamble RT, Vij R, Gergis U, Mathews V, Saber W, Chen YB, Liesveld JL, Cutler CS, Ghobadi A, Uy GL, Eapen M, Weisdorf DJ, Litzow MR. Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. *Biol Blood Marrow Transplant*. 2014;20:202-8.
862. Freytes CO, Vesole DH, Lerademacher J, Zhong X, Gale RP, Kyle RA, Reece DE, Gibson J, Schouten HC, McCarthy PL, Lonial S, Krishnan AY, Dispenzieri A, Hari PN. Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation. *Bone Marrow Transplant*. 2014;49:416-21.
863. Sabloff M, Sobecks RM, Ahn KW, Zhu X, de Lima M, Brown JR, Inamoto Y, Holland HK, Aljurf MD, Laughlin MJ, Kamble RT, Hsu JW, Wirk BM, Seftel M, Lewis ID, Arora M, Alyea EP, Kalaycio ME, Cortes J, Maziarz RT, Gale RP, Saber W. Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative HLA-Identical Sibling Transplants for Chronic Lymphocytic Leukemia? *Biol Blood Marrow Transplant*. 2014;20:421-4.
864. Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, Drobyski WR, Freytes CO, Gale RP, Gasparetto CJ, Holmberg LA, Kamble RT, Krishnan AY, Kyle RA, Marks D, Nishihori T, Pasquini MC, Ramanathan M, Lonial S, Savani BN, Saber W, Sharma M, Sorrow ML, Wirk BM, Hari PN. Hematopoietic Cell Transplant Comorbidity Index is predictive of survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. *Biol Blood Marrow Transplant*. 2014;20:402-8.
865. Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN. Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation Timing and Modality. *J Clin Oncol*. 2014;32:273-81.
866. Gale, RP. Professor John M. Goldman, CML Pioneer 1938-2013. *Int J Hematol*. 2014;99:103-4.
867. Gale RP, Bloomfield CD. Geoffrey Peter Herzig, M.D., Leukemia Pioneer 1941-2013. *Leukemia* 2014;28:1177.
868. Gale RP, Bennett JM, Hoffman FO. Therapy related AML: A slip of the lip can sink a ship. *Leuk Res*. 2014;38:418-20.
869. Apperley JF, Gale RP. John Michael Goldman (1938-2013): Transplant Pioneer. *Biol Blood Marrow Transplant*. 2014;38:418-20.
870. Gale RP, Lazarus HM. Correcting 2 more myths regarding transplants for AML in second remission. *Blood*. 2014;123(5):794.

871. Apperley JF, Gale RP. Professor John M. Goldman CML Pioneer and Journal Founder 1938-2013. *Bone Marrow Transplant*. 2014 Feb;49(2):161-2. doi: 10.1038/bmt.2014.1.
872. Gale RP. Review: The BMT Data Book including Cellular Therapy, 3rd edition. R. Munker, G. Hildrebrand, H. Lazarus and K. Atkinson (eds). *Bone Marrow Transplant*. 2014;49:467.
873. Gale RP, Hochhaus A. Nicole Muller-Berat Killman 1932-2014 *Leukemia Pioneer*. *Leukemia* 2014;28:727-28.
874. Cui R, Gale RP, Zhu G, Xu Z, Qin T, Zhang Y, Huang G, Li B, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions. *Leuk Res*. 2014;38:545-50.
875. Avanzini MA, Bernardo ME, Novara F, Mantelli M, Poletto V, Villani L, Lenta E, Ingo DM, Achille V, Bonetti E, Massa M, Campanelli R, Fois G, Catarsi P, Gale RP, Moretta A, Aronica A, Maccario R, Acquafredda G, Lisini D, Zecca M, Zuffardi O, Locatelli F, Barosi G, Rosti V. Functional and genetic aberrations of in vitro cultured marrow-derived mesenchymal stromal cells of patients with classical Philadelphia-negative myeloproliferative neoplasms. *Leukemia* 2014;28:1742-5.
876. Wirk B, Fenske TS, Hamadani M, Zhang MJ, Hu ZH, Akpek G, Aljurf MD, Armand P, Ayala E, Bachanova V, Bolwell B, Cairo MS, Cashen A, Chen YB, Costa LJ, Farhan S, Freytes CO, Gajewski JL, Gibson J, Hale GA, Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, Maharaj D, Maziarz RT, Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, Sureda A, Vose JM, Waller EK, Wiernik PH, Gale RP, Burns LJ, Saber W. Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. *Biol Blood Marrow Transplant*. 2014;20:1390-8.
877. Gale RP. Professor John M. Goldman, 1938-2013: Gentleman and Scholar. *Leukemia*. 2014;28:1175-6.
878. Pasquini M, Wang Z, Horowitz MM, Gale RP. 2013 Report from the Center for International Blood and Marrow Transplant Research (CIBMTR): Current uses and outcomes of hematopoietic cell transplants for blood and marrow disorders. In: *Clinical Transplants 2013*; Terasaki Foundation Laboratory, Los Angeles, CA pp.187-97.
879. Gale RP, Wiernik PH, Lazarus HM. Should persons with acute myeloid leukemia have a transplant in first remission? *Leukemia* 2014;28:1949-52.
880. Sobecks RM, Leis JF, Gale RP, Ahn KW, Zhu X, Sabloff M, de Lima M, Brown JR, Imamoto Y, Hale GA, Aljurf MD, Kamble RT, Hsu JW, Pavletic SZ, Wirk W, Seftel MD, Lewis ID, Alyea EP, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Outcomes of HLA matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: Myeloablative vs. reduced-intensity conditioning regimens. *Biol Blood Marrow Transplant* 2014;20:1390-8.
881. Gale RP, Lazarus HM. Geoffrey Peter Herzig, MD (1941-2013): transplant pioneer. *Bone Marrow Transplant* 2014;49:597-8.
882. Li B, Xu J, Wang J, Gale RP, Xu Z, Cui Y, Yang L, Xing R, Ai X, Qin T, Zhang Y, Zhang P, Xiao Z. Calreticulin mutations in Chinese with primary myelofibrosis. *Haematologica*. 2014;99:1697-700.

883. Barosi G, Zhang MJ, Gale RP. Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it? *Leukemia*. 2014 Jul 16. doi: 10.1038/leu.2014.220. [Epub ahead of print].
884. Xing R, Li C, Gale RP, Zhang Y, Xu Z, Qin T, Li B, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z. Monosomal karyotype is an independent predictor of survival in patients with higher-risk myelodysplastic syndrome. *Am J Hematol*. 2014;89:E163-8.
885. Sharma M, Zhang MJ, Zhong X, Abidi MH, Akpek G, Bacher U, Callander NS, Dispenzieri A, Freytes CO, Fung HC, Gale RP, Gasparetto C, Gibson J, Holmberg LA, Kindwall-Keller TL, Klumpp TR, Krishnan AY, Landau HJ, Lazarus HM, Lonial S, Maiolino A, Marks DI, Mehta P, Mikhael JR, Nishihori T, Olsson R, Ramanathan M, Roy V, Savani BN, Schouten HC, Scott E, Tay J, To LB, Vesole DH, Vogl DT, Hari P. Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation. *Biol Blood Marrow Transplant*. 2014;20:1796-803.
886. Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, Hale GA, Maharaj D, Gale RP, Rowlings PA, Freytes CO, Miller AM, Vose JM, Maziarz RT, Montoto S, Maloney DG, Hari PN. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. *Bone Marrow Transplant*. 2014;49:1360-5.
887. Gale RP, Barosi G. Commentary. *Leuk Res*. 2014;38:1013-5.
888. Otegbeye F, Gale RP, Lazarus HM. Autologous GVHD? (Editorial). *Bone Marrow Transplantation* 2014;49:1349-51.
889. Pasquini M, Wang Z, Horowitz MM, Gale RP. 2013 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): Current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. *Clin Transpl*. 2013;187-97.
890. Gale RP, Rossi G. What do cytogenetic abnormalities post-autotransplant really mean? *Biol Blood Marrow Transplant*. *Biol Blood Marrow Transplant*. 2014;20:1870-1.
891. Li B, Xu J, Li C, Gale RP, Xu Z, Qin T, Zhang Y, Huang G, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z. Cytogenetic studies and their prognostic contribution in 565 Chinese patients with primary myelofibrosis. *Am J Hematol*. 2014;89:1043-6.
892. Gale RP, Hlatky L, Sachs RK, Radivoyevitch T. Why is there so much therapy-related AML and MDS and so little therapy-related CML? *Leuk Res*. 2014;38:1162-4.
893. Wang J, Xu J, Gale RP, Xu Z, Li B, Qin T, Zhang Y, Fang L, Zhang H, Pan L, Qu S, Zhang P, Xiao Z. Prognostic impact of splenomegaly on survival of Chinese with primary myelofibrosis. *Leuk Res*. 2014;38:1207-11.
894. Gale RP, Barosi G. Commentary. *Leukemia Research*. 2014;38:1013-15.
895. Gale RP. Will oncologists be the first to cure heart disease? *The Asco Post* 2014;Vol 5, Issue 15.
896. Cui Y, Li B, Gale RP, Jiang Q, Xu Z, Qin T, Zhang P, Zhang Y, Xiao Z. CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia. *J Hematol Oncol*. 2014;Oct 15;7:77.
897. Gale RP, Lazarus HM, Wiernick PH. Transplants for AML in First Remission: A great leap forward, sideways or backward? *The Asco Post* 2014;Vol 5, Issue 20.

898. Gale RP. Measurable residual disease (MRD): Much ado about nothing? *Bone Marrow Transplant.* 2015;50:163-4.

899. Bachanova V, Burns LJ, Wang T, Carreras J, Gale RP, Wiernik PH, Ballen KK, Wirk B, Munker R, Rizzieri DA, Chen YB, Gibson J, Akpek G, Costa LJ, Kamble RT, Aljurf MD, Hsu JW, Cairo MS, Schouten HC, Bacher U, Savani BN, Wingard JR, Lazarus HM, Laport GG, Montoto S, Maloney DG, Smith SM, Brunstein C, Saber W. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. *Bone Marrow Transplant.* 2015;50:197-203.

900. Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringdén OT, Savani BN, Socié G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Pérez-Simón JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhäuser M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ; Graft-vs-Host Disease Working Committee of the CIBMTR. Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. *Biol Blood Marrow Transplant.* 2015;21:266-74.

901. Vij R, Kumar S, Zhang MJ, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP, Kindwall-Keller TL, Kyle RA, Landsburg DJ, Lazarus HM, Munker R, Roy V, Sharma M, Vogl DT, Wirk B, Hari PN. Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. *Biol Blood Marrow Transplant.* 2015;21:335-41.

902. Gale RP. John Leslie Fahey 1924-2014. *Bone Marrow Transplant.* 2014;49:1453-4.

903. Li B, Gale RP, Xiao Z. Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. *J Hematol Oncol.* 2014;7:93.

904. Copelan EA, Avalos B, Ahn KW, Zhu X, Gale RP, Grunwald MR, Hamadani M, Hamilton BK, Hale GA, Marks DI, Waller EK, Savani BN, Costa LJ, Ramanathan M, Cahn JY, Khoury HJ, Weisdorf DJ, Inamoto Y, Kamble RT, Schouten HC, Wirk B, Litzow MR, Aljurf MD, van Besien KW, Ustun C, Bolwell BJ, Bredeson CN, Fasan O, Ghosh N, Horowitz MM, Arora M, Szer J, Loren AW, Alyea EP, Cortes J, Maziarz RT, Kalaycio ME, Saber W. comparison of outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. *Biol Blood Marrow Transplant.* 2015;21:552-8.

905. Arora M, Hemmer MT, Ahn KW, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RP, Inamoto Y, Weisdorf DJ, Li P, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola LM, Jacobsohn DA, Jagasia M, Klumpp TR, Petersdorf EW, Santarone S, Schouten HC, Wingard JR, Spellman SR, Pavletic SZ, Lee SJ, Horowitz MM, Flowers ME. Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort. *Biol Blood Marrow Transplant.* 2015;21:640-5.

906. Yang SM, Li JY, Gale RP, Huang XJ. The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology? *Blood Rev.* 2015;29:205-13.

907. Mahindra A, Raval G, Mehta P, Brazauskas R, Zhang MJ, Zhong X, Bird JM, Freytes CO, Hale GA, Herzig R, Holmberg LA, Kamble RT, Kumar S, Lazarus HM, Majhail NS, Marks DI, Moreb JS, Olsson R, Saber W, Savani BN, Schiller GJ, Tay J, Vogl DT, Waller EK, Wiernik PH, Wirk B, Lonial S, Krishnan AY, Dispenzieri A, Brandenburg NA, Gale RP, Hari P. New Cancers after Autotransplantations for Multiple Myeloma. *Biol Blood Marrow Transplant.* 2014;21:738-45.
908. Xia Y, Fan L, Wang L, Gale RP, Wang M, Tian T, Wu W, Yu L, Chen YY, Xu W, Li JY. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans. *Oncotarget.* 2014;6:5426-34.
909. Gale RP, Hochhaus A. Therapy of older persons with acute myeloid leukemia. *Leukemia.* 2015;29:759.
910. Gale RP, Lazaurs HM. Engraftment syndrome, the Emperor's new clothes and the artist formerly known as prince. *Bone Marrow Transplant.* 2015;50:483-4.
911. Li N, Yao QM, Gale RP, Li JL, Li LD, Zhao XS, Jiang H, Jiang Q, Jiang B, Shi HX, Chen SS, Liu KY, Huang XJ, Ruan GR. Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2^{v617F} or MPL mutations. *Leuk Res.* 2015;39:510-4.
912. Tefferi A, Hudgens S, Mesa R, Gale RP, Verstovsek S, Passamonti F, Cervantes F, Rivera C, Tencer T, Khan ZM. Use of the Functional Assessment of Cancer Therapy—anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. *Clin Ther.* 2014;36:560-6.
913. Boyladzis M, Arora M, Klein JP, Hassebroek A, Hemmer M, Urbano-Ispizua A, Antin JH, Bolwell BJ, Cahn JY, Cairo MS, Cutler CS, Flowers ME, Gale RP, Herzig R, Isola LM, Jacobsohn DA, Jagasia MH, Klumpp TR, Lee SJ, Petersdorf EW, Stantarone S, Spellman SR, Schouten HC, Verdonck LF, Wingard JR, Weisdorf DJ, Horowitz MM, Pavletic SZ. Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia. *Clin Cancer Res.* 2014;21:1-9.
914. Gale RP. RE: The Wise Men and the Elephant Meet Reverend Bayes and Professor Markov. <http://www.bloodjournal.org/content/125/5/745.e-letters>.
915. Yin J, Xie X, Zhang F, Chen Z, Hu C, Su G, Liu H, Zheng Y, He C, Shen H, Qui Q, He J, Pan Z, Gale RP, Wu D, Yin B. Low frequency of mutations in Chinese with acute myeloid leukemia: Different disease or different aetiology? *Leuk Res.* 2015;39:646-8.
916. Yao, QM, Zhou J, Gale RP, Li JL, Li LD, Li N, Chen SS, Ruan GR. A rapid, highly accurate method for qualifying CALR mutant allele burden in persons with myeloproliferative neoplasms. *Hematology.* 2015 Epub ahead of print].
917. Gale RP. Ecclesiastes strikes again! *Biol Blood Marrow Transplant.* 2015;21:1338.
918. Goyal SD, Zhang MJ, Wang HL, Akpek G, Copelan EA, Freytes C, Gale RP, Hamadani M, Inamoto Y, Kamble RT, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Reshef R, Ritchie DS, Saber W, Savani BN, Seber A, Shea TC, Tallman MS, Wirk B, Bunjes DW, Devine SM, de Lima M, Weisdorf DJ, Uy GL. Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome. *Bone Marrow Transplant.* 2015;50:1057-62.

919. Gale RP, Barosi G. Improving definitions of RBC-transfusion-dependence and –independence in myeloproliferative neoplasm-associated myelofibrosis. <http://www.bloodjournal.org/content/122/8/1395.e-letters>.
920. Barosi G, Gale RP. Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis. *Leukemia*. 2015;29:740.
921. Gale RP. Reduced-Intensity transplants, conventional transplants or chemotherapy for acute myeloid leukemia in 1st remission: who knows; ask your wife? *Leukemia*. 2015;29:1448-9.
922. Barosi G, Rosti V, Gale RP. Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis. *OncoTargets and Therapy*. 2015;8:1091–1102.
923. Cui Y, Tong H, Du X, Li B, Gale RP, Qin T, Liu J, Xu Z, Zhang Y, Huang G, Jin J, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z. Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia. *Experimental Hematology & Oncology*. 2015;4:14.
924. Saramipoor Behbahan I, Keating A, Gale RP. Bone Marrow Therapies for Chronic Heart Disease. *Stem Cells*. 2015;33:3212-27.
925. Gale RP, Eapen M. Who is the best alternative allotransplant donor? *Bone Marrow Transplant*. 2015;50 Suppl 2:S40-2.
926. Inamoto Y, Flowers ME, Wang T, Urbano-Ispizua A, Hemmer MT, Cutler CS, Couriel DR, Alousi AM, Antin JH, Gale RP, Gupta V, Hamilton BK, Kharfan-Dabaja MA, Marks DI, Ringdén OT, Socié G, Solh MM, Akpek G, Cairo MS, Chao NJ, Hayashi RJ, Nishihori. Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. T, Reshef R, Saad A, Shah A, Teshima T, Tallman MS, Wirk B, Spellman SR, Arora M, Martin PJ. Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. *Biol Blood Marrow Transplant*. 2015;21:1776-82.
927. Tonorezos ES, Stillwell EE, Calloway JJ, Glew T, Wessler JD, Rebolledo BJ, Pham A, Steingart RM, Lazarus H, Gale RP, Jakubowski AA, Schaffer WL. Arrhythmias in the setting of hematopoietic cell transplants. *Bone Marrow Transplant*. 2015;50:1212-6.
928. Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R, Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, William BM, Wirk B, Maloney DG, Smith SM, Sureda AM, Carreras J, Hamadani M; for Center for International Blood and Marrow Transplant Research Lymphoma Working Committee. Impact of Pretransplantation ¹⁸F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. *Biol Blood Marrow Transplant*. 2015;21:1605-11.
929. Gale RP, Bennett JM, Hoffman FO. Therapy-related AML and MDS: Who really has it? *The Hematologist*. *ASH News and Reports*. 2015;12:1,5.
930. Urbano-Ispizua A, Pavletic SZ, Flowers ME, Klein JP, Zhang MJ, Carreras J, Montoto S, Perales MA, Aljurf MD, Akpek G, Bredeson CN, Costa LJ, Dandoy C, Freytes CO, Fung HC, Gale RP, Gibson J, Hamadani M, Hayashi RJ, Inamoto Y, Inwards DJ, Lazarus HM, Maloney DG, Martino R, Munker R, Nishihori T, Olsson RF, Rizzieri DA, Reshef R, Saad A, Savani BN, Schouten HC, Smith SM, Socié G, Wirk B, Yu LC, Saber W. The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. *Biol Blood Marrow Transplant*. 2015;21:1746-53.

931. Ayas M, Eapen M, Le-Rademacher J, Carreras J, Abdel-Azim H, Alter BP, Anderlini P, Battiwalla M, Bierings M, Buchbinder DK, Bonfim C, Camitta BM, Fasth AL, Gale RP, Lee MA, Lund TC, Myers KC, Olsson RF, Page KM, Prestidge TD, Radhi M, Shah AJ, Schultz KR, Wirk B, Wagner JE, Deeg HJ. Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. *Biol Blood Marrow Transplant.* 2015;21:1790-5.
932. Lowenberg B, Gale RP. Dirk W. Van Bekkum: Transplant Pioneer (1925-2015). *Biol Blood Marrow Transplant.* 2015;21:1701-2.
933. Satwani P, Ahn KW, Carreras J, Abdel-Azim H, Cairo MS, Cashen A, Chen AI, Cohen JB, Costa LJ, Dandoy C, Fenske TS, Freytes CO, Ganguly S, Gale RP, Ghosh N, Hertzberg MS, Hayashi RJ, Kamble RT, Kanate AS, Keating A, Kharfan-Dabaja MA, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Prestidge TD, Rolon JM, Savani BN, Vose JM, Wood WA, Inwards DJ, Bachanova V, Smith SM, Maloney DG, Sureda A, Hamadani M. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. *Bone Marrow Transplant.* 2015;50:1416-23.
934. Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavina S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. *Biol Blood Marrow Transplant.* 2016;51:58-66.
935. Uy GL, Costa LJ, Hari PN, Zhang MJ, Huang JX, Anderson KC, Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz MA, Gibson J, Hamadani M, Lazarus HM, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T, Olsson RF, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer EA, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D'Souza A. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. *Bone Marrow Transplant.* 2015;50:1513-8.
936. Halahleh K, Gale RP, Nagler A. Isochromosome X in Myelodysplastic Syndrome. *Acta Haematol.* 2016;135:37-8.
937. Pasquini MC, Zhang MJ, Medeiros BC, Armand P, Hu ZH, Nishihori T, Aljurf MD, Akpek G, Cahn JY, Cairo MS, Cerny J, Copelan EA, Deol A, Freytes CO, Gale RP, Ganguly S, George B, Gupta V, Hale GA, Kamble RT, Klumpp TR, Lazarus HM, Luger SM, Liesveld JL, Litzow MR, Marks DI, Martino R, Norkin M, Olsson RF, Oran B, Pawarode A, Pulsipher MA, Ramanathana M, Reshef R, Saad AA, Saber W, Savani BN, Schouten HC, Ringdén O, Tallman MS, Uy GL, Wood WA Jr, Wirk B, Pérez WS, Batiwala M, Weisdorf DJ. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. *Biol Blood Marrow Transplant.* 2016;22:248-57.
938. Gale RP, Apperly J. Transmission of CML or of t(9; 22) and BCR/ABL? They are not the same. *Bone Marrow Transplant.* 2015;50:1528.
939. Farina M, Rossi G, Bellotti D, Marchina E, Gale RP. Is Having Clonal Cytogenetic Abnormalities the Same as Having Leukaemia? *Acta Haematologica.* 2016;135:39-42.

940. D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huan J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Gale RP, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau, HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A Center for International Blood and Marrow Transplantation Research Study. *J Clin Oncol* 2015;doi10.1200/jco.2015.62.4015.
941. Gale RP. Early and late graft-failure after transplants. Commentary. *Bone Marrow Transplant.* 2016;51:182-3.
942. Gale RP, Hoffman FO. Does low-dose radiation cause leukemia? *ASCO Post* 2015;Vol. 6, Issue 21. <http://www.ascopost.com/issues/november-25,-2015/does-low-dose-radiation-cause-leukemia.aspx>.
943. Radivoyevitch T, Sachs RK, Gale RP, Molenaar RJ, Brenner DJ, Hill BT, Kalaycio ME, Carraway HE, Mukherjee S, Sekeres MA, Maciejewski JP. Defining AML and MDS second cancer risk dynamics after diagnosis of first cancers treated or not with radiation. *Leukemia.* 2016;30:285-94.
944. Lowenberg B, Gale RP. Dick W. van Bekkum, 1925-2015. *Transplantation.* 2015;99:2442-3.
945. Gale RP, Lowenberg B. Dirk W. van Bekkum: a pioneer in haematology, transplantation and radiobiology (1925-2015). *Leukemia.* 2015;29:2275-6.
946. Pusic I, Retting MP, DiPersio JF, Bauer S, McFarland K, Gale RP, Pavletic SZ. Phase-1/2 study of pomalidomide in chronic GvHD. *Bone Marrow Transplant.* 2015;51:612-4.
947. Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, Fenske TS, Freytes C, Gale RP, Ganguly S, Hertzberg M, Klychnikov E, Lazarus HM, Olsson R, Perlaes MA, Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolanos-Meade J, Hamadani M. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched related donors. *Blood.* 2016;30:521-5.
948. Estey E, Othus M, Lee Sj, Appelbaum FR, Gale RP. New drug approvals in acute myeloid leukemia: what's the best end point. *Leukemia.* 2015;doi:10.1038/leu.2015.262.
949. Tao H, Ma X, Su G, Yin J, Xie X, Hu C, Chen Z, Tan D, Xu Z, Zheng Y, Liu H, He C, Gale RP, Chen Z, Wu D, Yin B. BCL 11A expression in acute myeloid leukemia. *Leuk Res.* 2016;41:71-5.
950. Lazarus HM, Gale RP, et al. (eds) (2016) *Hematopoietic Cell Transplants: Concepts, Controversies and Future Directions.* Cambridge University Press, United Kingdom. Comes in October 2016. ISBN 9781316606698.
951. Hoelzer D, Gale RP. Prof. Theodor M. Fliedner (1 October 1929 – 9 November 2015): Haematopoietic stem cell and radiation biology and pioneer. *Leukemia.* 2016;30:765-6.
952. Gale RP. How do haematopoietic cell transplants cure leukaemias? *Rev Hematol Méx.* 2015;16:237-8.

953. Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, Te Boekhorst PA, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. *J Clin Oncol*. 2016;10:151-9.
954. Liang JH, Gao R, Xia Y, Gale RP, Chen RZ, Yang YQ, Wang L, Qu XY, Qiu HR, Cao L, Hong M, Wang R, Wang Y, Fan L, Chen YY, Hu ZB, Li JY, Xu W. Prognostic impact of Epstein-Barr Virus (EBV)-DNA copy number at diagnosis in chronic lymphocytic leukemia. *Oncotarget*. 2016;7:2143-42
955. Gale RP. Statistics and the Great Persky. *Biol Blood Marrow Transplant*. 2016;22:589-91.
956. Radivoyevitch T, Sachs RK, Gale RP, Smith MR, Hill BT. Ionizing radiation exposures in treatments of solid neoplasms are not associated with subsequent increased risk of chronic lymphocytic leukemia. *Leuk Res*. 2016;43:9-12.
957. Sanchorawala V, Gale RP. David C Seldin, MD, Ph.D.: scientist, clinician, teacher, gentleman, 1957-2015. *Bone Marrow Transplant*. 2016;51:323.
958. Gale RP, Hoelzer D. Professor Theodor Fliedner and the atomic hematologists. *The Hematologist, ASH News and Reports*. 2016;13:1-5.
959. Barosi G, Klersy C, Villani L, Bonetti E, Catarsi P, Poletto V, Campanelli R, Impera S, Latagliata R, Viarengo G, Carolei A, Massa M, Musso M, Crescimanno A, Gale RP, Rosti V. $JAK2^{V617F}$ allele burden $\geq 50\%$ is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy. *Leukemia*. 15 March 2016;30:1772-5.
960. Harada M, Gale RP. Commentary: How do haematopoietic cell transplants cure leukaemia? *Int J Hematol*. 2016;103:396-8.
961. Gale RP, Seber A, Bonfim C, Pasquini M. Haematopoietic cell transplants in Latin America. *Bone Marrow Transplant*. 2016; 51:898-905.
962. Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Staib P, Beelen D, Serve H, Schliemann C, Stelljes M, Balleisen L, Maschmeyer G, Grüneisen A, Eimermacher H, Giagounidis A, Rasche H, Hehlmann R, Lengfelder E, Thiel E, Reichle A, Aul C, Ludwig WD, Kern W, Haferlach T, Köpcke W, Görlich D, Sauerland MC, Heinecke A, Wörmann BJ, Hiddemann W, Büchner T. Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia. *Leukemia*. 2016;30:1230-6.
963. Munker R, Brazauskas R, Wang HL, de Lima M, Khoury HJ, Gale RP, Maziarz RT, Sandmaier BM, Weisdorf D, Saber W; Center for International Blood and Marrow Transplant Research. Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia. *Biol Blood Marrow Transplant*. 2016;22:1024-9.

964. Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Azim H, Malone A, Olsson R, Hamadani M, Daly A, Bacher U, Wirk BM, Kamble RT, Gale RP, Wood WA, Hale G, Wiernik PH, Hashmi SK, Mark D, Ustun C, Munker R, Savani BN, Alyea E, Popat U, Sobecks R, Kalaycio M, Maziarz R, Hijjiya N, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. *Biol Blood Marrow Transplant.* 2016;22:1056-64.
965. Büchner T, Krug UO, Gale RP, Heinecke A, Sauerland MC, Haferlach C, Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL, Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L, Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke W, Hehlmann R, Wörmann BJ, Berdel WE, Hiddemann W. Age, not therapy-intensity, determines outcomes of adults with acute myeloid leukaemia. *Leukemia.* 2016;30:1781-4.
966. Hoelzer D, Gale RP. Theodor M Fliedner (1 October 1929 – 9 November 2015), transplant pioneer. *Bone Marrow Transplant.* 2016;51:471-2.
967. Harada M, Gale RP. How do transplants cure leukemia? *HemOnc.* 2016, March 25. [Epub ahead of print].
968. Gale RP, Opelz G. In Memoriam: Paul I. Terasaki – September 10, 1929 to January 25, 2016. *Biol Blood and Marrow Transplant.* 2016;22:777-8.
969. Li B, Xu Z, Li Y, Gale RP, Song Z, Ai X, Qin T, Zhang Y, Zhang P, Huand G, Xiao Z. The different prognostic impact of type-1 or type-1 like and type-2 or type-2 like CALR mutations in patients with primary myelofibrosis. *Am J Hematol.* 2016;91:E320-1.
970. Gale RP, Opelz G. Paul Ichiro Terasaki September 10, 1929 to January 25, 2016: Transplant Pioneer. *Transplantation.* 2016,100:968-9.
971. Gale RP, Opelz G. Paul I Terasaki (10 September, 1929 – 25 January, 2016). *Bone Marrow Transplant.* 2016;51:621-2.
972. Yin J, Zhang F, Tao H, Ma X, Su G, Xie X, Xu Z, Zheng Y, Liu H, He C, Mao ZJ, Wang Z, Chang W, Gale RP, Wu D, Yin B. BCL11A expression in acute phase chronic myeloid leukemia. *Leuk Res.* 2016;47:88-92.
973. Gale RP, Pusic I. Transplants for MDS and quality-of-life. But whose quality of life? *Bone Marrow Transplant.* 2016;51:1066-8.
974. Qin YZ, Wang Y, Zhu HH, Gale RP, Zhang MJ, Jiang Q, Jiang H, Xu LP, Chen H, Zhang XH, Liu YR, Lai YY, Jian B, Liu KY, Huang XJ. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. *Chin J Cancer.* 2016;35:46.
975. Kiladjian JJ, Gale RP. Is there consensus on consensus? *Leukemia.* 2016;30:1229.
976. Barosi G, Gale RP. How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis? *Leukemia.* 2016;30:1453-5.
977. Jiang Q, Gale RP. Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myelogenous leukemia in China. *J Cancer Res Clin Oncol.* 2016;142:1549-55.

978. Jiang Q, Liu ZC, Zhang SX, Gale RP. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. *J Cancer Res Clin Oncol*. 2016;142:1539-47.
979. Yao QM, Liu KY, Gale RP, Jiang B, Liu YR, Jiang Q, Jiang H, Zhang XH, Zhang MJ, Chen SS, Huand XJ, Xu LP, Ruan GR. Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia. *BMC Cancer*. 2016;16:269.
980. Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone AK, Valcárcel D, Grunwald MR, Bacher U, Hamilton B, Kharfan-Dabaja MA, Saad A, Cutler C, Warlick E, Reshef R, Wirk BM, Sabloff M, Fasan O, Gerds A, Marks D, Olsson R, Wood WA, Costa LJ, Miller AM, Cortes J, Daly A, Kindwall-Keller TL, Kamble R, Rizzieri DA, Cahn JY, Gale RP, William B, Litzow M, Wiernik PH, Liesveld J, Savani BN, Vij R, Ustun C, Copelan E, Popat U, Kalaycio M, Maziarz R, Alyea E, Sobecks R, Pavletic S, Tallman M, Saber W. Scoring system prognostic outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. *J Clin Oncol*. 2016;34:1864-71.
981. Gale RP, Zhang MJ. What is the *P*-value anyway? *Bone Marrow Transplant*. 2016;51:1439-40.
982. Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, Battiwalla M, Bornhauser M, Chan YS, Carmitta B, Chen YB, Cutler CS, Gale RP, Ganguly S, Hamadani M, Inamoto Y, Jagasia M, Kamble R, Koreth J, Lazarus HM, Liesveld J, Litzow MR, Marks DI, Nishihori T, Olsson RF, Reshef R, Rowe JM, Saad AA, Sabloff M, Schouten HC, Shea TC, Soifeer RJ, Uy GL, Waller EK, Wiernik PH, Wirk B, Woolfrey AE, Bunjes D, Devine S, de Lima M, Sandmaier BM, Weisdorf D, Khoury HJ, Saber W. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. *Cancer*. 2016;122:3005-14
983. Gale RP. Thirty year of Bone Marrow Transplantation. *Bone Marrow Transplant*. 2016;11:1411-12.
984. Gale RP, Fuchs EJ. Is there really a specific graft-versus-leukaemia effect? *Bone Marrow Transplant*. 2016;11:1413-15.
985. Gale RP, Hoelzer D. The age of the atomic hematologist/oncologists. *ASCO Post*. 2016: July10.
986. Prasad V, Gale RP. Precision medicine in acute myeloid leukemia: Hope, hype or both? *Leuk Res*. 2006;48:73-7.
987. Othus M, Estey E, Gale RP. Correspondence to: Assessment of minimal residual disease in standard-risk AML. *N Engl J Med*. 2016;375:6.
988. Gale RP. 30 years after Chernobyl: lessons learned. *The Cancer Letter*. April 27, 2016. (Editorial): http://cancerletter.com/articles/20160422_3/.
989. Nakao S, Gale RP. Are mild/moderate acquired idiopathic aplastic anaemia and low-risk myelodysplastic syndrome one or two diseases or both and how should it/they be treated? *Leukemia*. 2016;11:2127-30.
990. Gale RP, Hochaus A, Zhang MJ. What is the (p-) value of the p-value? *Leukemia*. 2016;30:1965-7.
991. Qiu ZY, Fan L, Wang R, Gale RP, Liang HJ, Wang M, Wang L, Wu YJ, Qiao C, Chen YY, Xu W, Qian J, Li JY. Methotrexate therapy of T-cell large granular lymphocytic leukemia impact of STAT3 mutation. *Oncotarget*. 2016;7:61419-25.

992. Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA. Associations between gender, disease features and symptom burden in the MPN population: An analysis by the MPN QOL International Working Group. *Haematologica*. 2016;102:85-93.
993. Massa M, Campanelli R, Fois G, Villani L, Bonetti E, Catarsi P, Poletto V, Viarengo G, De Amici M, Rosti V, Gale RP, Barosi G. Reduced frequency of circulating CD4+CD25brightCD127lowFOXP3+ regulatory T-cells in primary myelofibrosis. *Blood*. 2016;128:1660-2.
994. Gale RP. Prof. Thomas Buchner (22 September 1934-5 August 2016). A career devoted to research in acute myeloid leukemia. *Leuk Res*. 2016;49:113-14.
995. Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, Ribrag V, Schiller G, Vannucchi AM, Zhou D, Reiser D, Zhong J, Gale RP. A randomized study of pomalidomide vs. placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion-dependence. *Leukemia*. 2016;31:896-902.
996. Medeiros BC, Gale RP. Why do subjects on clinical trials discontinue therapy? Do we really know? *Leukemia Res*. 2016;51:19-21.
997. Cui Y, Tong H, Du X, Li B, Gale RP, Qin T, Liu J, Xu Z, Zhang Y, Huang G, Jin J, Fang L, Zhang H, Pan L, Hu N, Qu S, Xiao Z. TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia. *Stem Cell Investig*. 2016;3:50.
998. Gale, RP. Recent progress and concepts in pancreatic cancer. *The ASCO Post*. 2016;7:1.
999. Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. *Bone Marrow Transplant*. 2016;52:400-8.
1000. Ge Z, Gu Y, Han Q, Zhao G, Li M, Li J, Chen B, Sun T, Dovat S, Gale RP, Song C. Targeting High Dynamins-2 (DNM2) Expression by Restoring Ikaros Function in Acute Lymphoblastic Leukemia. *Sci Rep*. 2016;6:38004.
1001. Yin J, Zhang F, Tao H, Ma X, Su G, Xie X, Xu Z, Zheng Y, Liu H, He C, Mao ZJ, Wang Z, Chang W, Gale RP, Wu D, Yin B. Corrigendum to "BCL11A expression in acute phase chronic myeloid leukemia" [*Leuk. Res*. 47 (2016) 88-92]. *Leuk Res*. 2017;52:67.
1002. Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. *Biol Blood Marrow Transplant*. 2016;23:269-77.

1003. Estey E, Gale RP. Acute myeloid leukemia and the chosen people. *Leukemia*. 2016;39:269-71.
1004. Madeiros BC, Gale RP. Why do subjects on clinical trials discontinue therapy? Do we really know? *Leuk Res*. 2016;51:19-21.
1005. Sanz J, Gale RP. One or two umbilical cord blood cell units? *Caveat emptor*. *Bone Marrow Transplant*. 2017;52:341-3.
1006. Jaimovich G, Martinez Rolon J, Baldomero H, Rivas M, Hanesman I, Bouzas L, Bonfim C, Palma J, Kardus-Urueta A, Ubidia D, Bujan-Boza W, Gonzalez-Ramella O, Ruiz-Argüelles G, Gomez-Almaguer D, Espino G, Fanilla E, Gonzalez D, Carrasco A, Galeano S, Borelli G, Hernandez-Gimenez M, Pasquini M, Kodera Y, Gratwohl A, Gratwohl M, Nuñez J, Szer J, Gale RP, Niederwieser D, Seber A. Latin America: the next region for haematopoietic transplant progress. *Bone Marrow Transplant*. 2017;52:671-7.
1007. Liang JH, Ding CY, Gale RP, Wang L, Xu J, Qu XY, Fan L, Li TL, Li JY, Xu W. Prognostic value of whole-body SUVmax of nodal and extra-nodal lesions detected by 18F-FDG PET/CT in extra-nodal NK/T-cell lymphoma. *Oncotarget*. 2017;8:1737-1743.
1008. Michelis FV, Gupta V, Zhang MJ, Wang HL, Aljurf M, Bacher U, Beitinjaneh A, Chen YB, DeFilipp Z, Gale RP, Kebriaei P, Kharfan-Dabaja M, Lazarus HM, Nishihori T, Olsson RF, Oran B, Rashidi A, Rizzieri DA, Tallman MS, de Lima M, Khoury HJ, Sandmaier BM, Weisdorf D, Saber W; Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research, a research collaboration between the National Marrow Donor Program/Be the Match Registry and the Medical College of Wisconsin. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. *Cancer*. 2017 Jan 24. doi: 10.1002/cncr.30567. [Epub ahead of print]
1009. Alikian M, Gale RP, Apperley JF, Foroni L. Molecular technique for the personalized management of patients with chronic myeloid leukaemia. *Biomol Detect Qualif*. 2017;11:4-20.
1010. Gale RP, Bennett JM, Hoffman FO. Who has therapy-related AML. *Mediterr J Hematol Infect Dis* 2017;9:e2017025 <http://dx.doi.org/10.4084/MJHID.2017.025>.
1011. Prasad V, Gale RP. What precisely is precision oncology and will it work? *ASCO Post*. 2017; <http://www.ascopost.com/issues/january-25-2017/what-precisely-is-precision-oncology-and-will-it-work>
1012. Jiang Q, Wang HB, Yu L, Gale RP. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy. *J Cancer Res Clin Oncol*. 2017 Mar 1. doi: 10.1007/s00432-017-2353-2. [Epub ahead of print].
1013. Sanz J, Gale RP. One of two umbilical cord blood cell units? *Caveat emptor*. *Bone Marrow Transplant*. 2017;52:341-3.
1014. Gale RP, Opelz G. Is there immune surveillance against chronic myeloid leukemia? Possibly, but not much. *Leuk Res*. 2017;57:109-11. <http://dx.doi.org/10.1016/j.leukres.2017.03.003>.
1015. Estey E, Gale RP. How good are we at predicting the fate of someone with acute myeloid leukemia? *Leukemia*. 2017; doi 10.1038/leu.2017.56.

1016. Wang SJ, Wang PZ, Gale RP, Qin YZ, Liu YR, Lai YY, Jiang H, Jiang Q, Zhang XH, Jiang B, XU LP, Huang XJ, Liu KY, Ruan GR. Cysteine and Glycine-rich protein 2 (CSPR2) transcript levels correlate with leukemia relapse-free survival in adults with B-cell acute lymphoblastic leukemia and normal cytogenetics. *Oncotarget*. 2017; www.impactjournals.com/oncotarget. Advance publication.
1017. Alikian M, Gale RP, Apperley JF, Foroni L. Molecular techniques for the personal management of patients with chronic myeloid leukaemia. *Biomolecular Detection and Quantification*. 2017;11:4-20.
1018. Li D, Gale RP, Liu Y, Lei B, Diao D, Zhang M. 5'-Triphosphate siRNA targeting MDR1 reverses multi-drug resistance and activates RIG-I-induced immune-stimulatory and apoptotic effects against human myeloid leukaemia cells. *Leuk Res*. 2017;58:23-30.
1019. Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GS, Walter RB. Measurable residual disease testing in acute myeloid leukaemia. *Leukemia*. 2017;31:1482-1490.
1020. Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfane-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoemans H, Schouten HC, Socie G, Storek J, Verdonck L, Vij R, Wood WA, Yu L, Martino R, Carabasi M, Dandoy C, Gergis U, Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz KR, Wirk BM, Spellman S, Arora M, Pidale J. Improved survival after acute graft vs host diagnosis in the modern era. *Haematologica*. 2017 Mar 16. *Haematol*.2016.156356.
1021. Gerds AT, Whoo Ahn K, Hu Zh, Abdel-Azim H, Akpek G, Aljurf M, Ballen KK, Beitinjaneh A, Bacher U, Cahn JY, Chhabra S, Cutler C, Daly A, DeFilipp Z, Gale RP, Gergis U, Grunwald MR, Hale GA, Hamilton BK, Jagasia M, Kamble RT, Kindwall-Keller T, Nishihori T, Olsson RF, Ramanathan M, Saad AA, Solh M, Ustun C, Valcarcel D, Warlick E, Wirk GM, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W. Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. *Biol Blood Marrow Transplant*. 2017 Mar doi:10.1016/j.bbmt.2017.03.014. Epub ahead of print.
1022. Cheng YC, Shi Y, Zhang MJ, Brazauskas R, Hemmer MT, Biship MR, Nieto Y, Stadtmauer E, Ayash L, Gale RP, Lazarus HM, Holmberg L, Lill M, Olsson RF, Wirk BM, Arora M, Hari P, Ueno N. Long-term outcome of inflammatory breast cancer compared to non-inflammatory breast cancer in the setting of high-dose chemotherapy with autologous hematopoietic cell transplantation. *J of Cancer*. 2017;8:1009-17.
1023. Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. *Leukemia*. 2017; 1-14. MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma. *Blood Cancer J*. 2017;7:doi: 10.1038/bcj.2017.61.
1024. Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Barriwala M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hasmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzeri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorrow ML, Szer J, Wirk BM, Wood VA, Artz A. Increasing use of allogeneic hematopoietic cell transplantation in patients age 79 years and older in the United States. *Blood*. 2017;doi: 20.1182/blood-2107-03-772368.
1025. Barosi G, Massa M, Campanelli R, Fois G, Catarsi P, Viagrenco G, Villani L, Poletto V, Bosoni T, Magini U, Gale RP, Rosti V. Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. *Leuk Res*.2017; doi:10.1016/j.leukeres.2017.06.004.

1026. Krug U, Gale RP, Berdel WE, Muller-Tidow C, Stelljes M, Metzeler K, Sauerland MC, Hiddeman W, Buchner T. Therapy of older persons with acute myeloid leukaemia. *Leuk Res.* 2017;doi:10.1016/j.leukres.2017.05.020.
1027. Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. *Leukemia.* 2017;doi: 10.1038/leu.2017.187.
1028. Claudiani S, Apperley J, Gale RP, Clark R, Szydlo R, Deplano S, Palanciawandar R, Khorashad J, Foroni L, Milojkovic D. E14a BCR-ABL1 transcript is associated with higher rate of treatment-free remission in persons with chronic myeloid leukemia after stopping tyrosine kinase-inhibitor-therapy. *Hematologica.* 2017;doi:10.3324/haematol.2017.168740.
1029. Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, Angel-Diaz M, Gale RP, Ganguly S, Girnius SK, Hashmi S, Pawarode A, Vesole DH, Wiernik PH, Wirk BM, Marks DI, Nishihori T, Olsson RF, Usmani SZ, Mark TM, Nieto YL, D'Souza A. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. *Cancer.* 2017;doi:10.1002/cncr.30747.
1030. Jaimovich G, Rolon JM, Baldomero H, Rivas H, Hanesman I, Bouzas L, Bonfirm C, Palma J, Kardus-Urueta A, Ubidia D, Bujan-Boza W, Gonzalez-Ramella O, Ruiz-Arguelles G, Gomez-Almaguer D, Espino G, Fanilla E, Gonzalez D, Carrasco A, Galeano S, Borelli G, Hernandez-Gimenez M, Pasquini M, Kodera Y, Gratwohl A, Gratwohl M, Nunez J, Szer J, Gale RP, Niederwieser D, Seber A. Latin America: the next region for haematopoietic transplant progress. *Bone Marrow Transplant.* 2017;doi:10.1038/bmt.2017.48.
1031. Li B, Gale RP, Xu Z, Qin T, Song Z, Zhang P, Bai J, Zhang L, Zhang Y, Liu J, Huang G, Xiao Z. Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis. *J Hematol Oncol.* 2017;10:99.
1032. Vrooman LM, Millard HR, Brazauskas R, Majhail NS, Battiwalla M, Flowers ME, Savani BN, Akpek G, Aljurf M, Bajwa R, Baker KS, Beitinjaneh A, Bitan M, Buchbinder D, Chow E, Dandoy C, Dietz AC, Diller L, Gale RP, Hashmi SK, Hayashi RJ, Hematti P, Kamble RT, Kascow KA, Kletzel M, Lazarus HM, Malone AK, Marks DI, O'Brien TA, Olsson RF, Ringden O, Seo S, Steinberg A, Yu LC, Warwick A, Shaw B, Duncan C. Survival and late effects after allogeneic hematopoietic cell transplantation for hematologic malignancy at less than three years of age. *Biol Blood Marrow Transplant.* 2017;pii: S-1083-8791(17)30426.
1033. Kandelwal P, Millard HR, Thiel E, Abdel-Azim H, Abraham AA, Auletta JJ, Boulard F, Brown VI, Camitta BM, Chan KW, Chaudhury S, Cowan MJ, Angel-Diaz M, Gadalla SM, Gale RP, Hale G, Kasow KA, Keating AK, Kitko CL, MacMillan ML, Olsson RF, Page KM, Seber A, Smith AR, Warwick AB, Wink B, Mehta PA. Hematopoietic stem cell transplantation activity in pediatric cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report. *Biol Blood Marrow Transplant.* 2017; doi:10.1016/j.jbbmt.2017.04.018.
1034. Gale RP, McCann S. A brief history of hematopoietic cell transplantation. In: *Hematopoietic Cell Transplants: Concepts, Controversies and Future Direction.* Lazarus HM, Gale RP, Keating A, Bacigalupo A, Munker R, Atkinson K, Abutalib S (eds). Cambridge, UK, Cambridge Univ Press, 2017; pp. 1-7.
1035. Pasquini MC, Gale RP. Autologous hematopoietic cell transplants for autoimmune diseases: therapeutic rationale and limitations. In: *Hematopoietic Cell Transplants: Concepts, Controversies and Future Direction.* Lazarus HM, Gale RP, Keating A, Bacigalupo A, Munker R, Atkinson K, Abutalib S (eds). Cambridge, UK, Cambridge Univ Press, 2017; pp. 531-4.

1036. Xiong J, Wang L, Fei XC, Zheng Z, Zhao Y, Wang CF, Li B, Chen SJ, Janin A, Gale RP, Zhao WL. MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma. *Blood Cancer J.* 2017;7:doi 10.1038/bcj.2017.61.
1037. Gale RP, Opelz G. In reponse to stopping imatinib in CML (letter for the Editor). *The Haematologist*, August 21, 2017. <http://www.hematology.org/Thehematologist/Letters/7657.aspx>
1038. Gale RP. Johannes Joseph van Rood, Transplant Pioneer (April 7, 1926 to July 21, 2017). *Biol Blood Marrow Transplant.* 2017;23:1601.
1039. Fibbe W, Gale RP. Johannes Joseph van Rood, Pioneer in immune genetics (7 April 1926-21 July 2017). *Leukemia.* 2017;doi: 10.1038/leu.2017.278.
1040. Malogolowkin MH, Hemmer MT, Le-Rademacher J, Hale GA, Metha PA, Smith AR, Kitko C, Abraham A, Abdel-Azim H, Dandoy C, Angel Diaz M, Gale RP, Guilcher G, Hayashi R, Jodele S, Kasow KA, MacMillian ML, Thakar M, Wirk BM, Woolfrey A, Thiel EL. Outcomes following autologous hematopoietic stem cell transplant for patients with relapsed Wilms' tumor: a CIBMTR retrospective analysis. *Bone Marrow Transplant.* 2017;52:1549-55.
1041. Jiang Q, Wang H, Yu L, Gale RP. Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia. *J Cancer Res Clin Oncol.* 2017 Sep 11. doi: 10.1007/s00432-017-2517-0. [Epub ahead of print]
1042. Mahindra A, Hari P, Fraser R, Fei M, Huang J, Berdeja J, Callander N, Costa L, Diaz MA, Freytes C, Gale RP, Girnius S, Holmberg L, Kharfan-Dabaja M, Kumar S, Kyle R, Lazarus H, Lee C, Maiolino A, Moreb J, Nishihori T, Pawarode A, Saad A, Savani BN, Schriber J, William B, Wirk BM, Krishnan A, Nieto Y, D'Souza A. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. *Bone Marrow Transplant.* 2017 Sep 18. doi: 10.1038/bmt.2017.198. [Epub ahead of print]
1043. Kelly DL, Buchbinder D, Duarte RF, Auletta JJ, Bhatt N, Byrne M, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick A, Wirk BM, Yi J, Battiwalla M, Flowers ME, Savani B, Shaw BE. Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review From the Late Effects and Quality of Life Working Committee of the CIBMTR and Complications and Quality of Life Working Party of the EBMT. *Biol Blood Marrow Transplant.* 2017 Sep 19. pii: S1083-8791(17)30698-5. doi: 10.1016/j.bbmt.2017.09.004. [Epub ahead of print] Review.
1044. Ueda M, Berger M, Gale RP, Lazarus HM. Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. *Blood Reviews.* 2017; <http://dx.doi.org/10.1016/j.bire.2017.09.003>.
1045. Fibbe W, Gale RP. Johannes Joseph van Rood: pioneer in immuno-genetics (7 April 1926 – 21 July 2017). *Bone Marrow Transplant.* 2017;doi:10:1038/bmt.2017.221.
1046. Gale RP. Medical and policy considerations for nuclear and radiation accidents, incidents and terrorism. *Curr Opin Hematol.* 2017;24:496-501.

1047. Madeiros BC, McCaul K, Kambhampati S, Pollyea DA, Kumar R, Silverman LR, Kew A, Saini L, Beach CL, Vij R, Wang X, Zhong J, Gale RP. Randomized study of continuous high-dose lenalidomide, sequential azacitine and lenalidomide or azacitine in persons \geq 65 years with newly-diagnosed acute myeloid leukemia. *Hematologica*. 2017. Doi:10.3324/hematol.2017.172353.
1048. Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjan JJ, Zhang P, Gale RP, Mesa RA, Geyer HL. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. *Leuk Res*. 2017;63:34-40.
1049. Qayed M, Wang T, Hemmer MT, Spellman S, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Aljurf M, Ayas M, Bitan M, Cairo M, Choi SW, Dandoy C, Delgado D, Gale RP, Hale G, Frangoul H, Kamble RT, Kharfan-Dabaja M, Lehman L, Levine J, MacMillan M, Marks DI, Nishihori T, Olsson RF, Hematti P, Ringden O, Saad A, Satwani P, Savani BN, Schultz KR, Seo S, Shenoy S, Waller EK, Yu L, Horowitz MM, Horan J. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. *Biol Blood Marrow Transplant*. 2017;doi 10.106/j.bbmt.2017.11.004 [Epub ahead of print].
1050. Bejanyan N, Zhang MJ, Wang HL, Lazaryan A, de Lima M, Marks DI, Sandmaier BM, Bachanova V, Rowe J, Tallman M, Kebriaei P, Kharfan-Dabaja M, Gale RP, Lazarus HM, Ustun C, Copelan E, Hamilton BK, Schiller G, Hogan W, Hashmi S, Seftel M, Kanakry C, Olsson RF, Martino R, Saber W, Khoury HJ, Weisdorf DJ. Pre-Transplant Consolidation is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. *Biol Blood Marrow Transplant*. 2017;doi: 10.1016/j.bbmt.2017.12.784.
1051. Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI; Acute Leukemia Committee of the CIBMTR. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. *Biol Blood Marrow Transplant*. 2017;doi: 10.1016/j.bbmt.2017.11.025.
1052. Kempin S, Finger PT, Gale RP, Rescigno J, Rubin J, Choi W, Fisher R, Aizman A, Genis I, Malamud SC, Moslehi R. A cluster of vitreoretinal lymphoma in New York with possible link to the Chernobyl nuclear disaster. *Leuk Lymphoma*. 2017; doi:10.1080/10428194.2017.10403025.
1053. Buchbinder D, Kelly DL, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Gabriel M, Mahindra A, Norkin M, Schoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick AB, Wirk BM, Yi J, Battiwalla M, Flowers MDE, Savani B, Shaw BE. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. *Bone Marrow Transplant*. 2018 Jan 17. doi: 10.1038/s41409-017-0055-7. [Epub ahead of print].

1054. Medeiros BC, McCaul K, Kambhampati S, Pollyea DA, Kumar R, Silverman LR, Kew A, Saini L, Beach CL, Vij R, Wang X, Zhong J, Gale RP. Randomized study of continuous high-dose lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed myeloid leukemia. *Haematologica*. 2018;103:101-6.
1055. Jiang Q, Yu L, Gale RP. Patients and hematologists concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia. *J Canc Res Clin Oncol*. 2018;doi 10.1007/s00432-018-2594 [Epub ahead of print].
1056. Mughal RI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE, Barbui T, Hehlman R, Mauro M, Saussele S, Radich JP, Van Etten RA, Saglio G, Verstovsek S, Gale RP, Abdel-Wahab O. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. *Leuk Res*. 2018;67:67-74.
1057. Gale RP, Hochhaus A. Therapy-free remission in chronic myeloid leukemia: possible mechanism. *Expert Rev Hematol*. 2018; doi 10.1080/17474086.2018.1442213. [Epub ahead of print].
1058. Gale RP, Ruiz-Arguelles G. The big freeze may be over: a contracting universe for cryopreservation? *Bone Marrow Transplant*. 2018;doi 10.1038/s41409-018-0119-3.
1059. Xin X, Ding Y, Yang Y, Fu X, Zhou J, McKee CM, Muschel RJ, Gale RP, Apperley JF, Xu D. Protease nexin-1 prevents growth of human B cell lymphoma via inhibition of sonic hedgehog signaling. *Blood Cancer J*. 2018;doi 10:1038/s41408-018-0063-x.
1060. Barosi G, Gale RP. Is there expert consensus on expert consensus? *Bone Marrow Transplant*. 2018;doi 10.1038/s41409-018-0128-2.
1061. Ruiz-Arguelles G, Gale RP. Autotransplantations without cryopreservation. *J Glob Oncol*. 2018;4:1.
1062. Gale RP. Standardizing haematopoietic cell transplants in China. *J of Hematology & Oncology*. 2018;11:34.
1063. Heidel FH, Gale RP, Hochhaus A. Managing myeloproliferative neoplasms evidence based on ELN treatment recommendations 2018. *Leukemia*. 2018;doi: 10.1038/s413745-018-0079.
1064. Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hermatti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, O'Brien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Veneris MR. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. *Bone Marrow Transplant*. 2018;doi 10.1038/s41409-018-0100-1.
1065. Kardus-Urueta A, Gale RP, Gutierrez-Aguirre CH, Herrera-Rojas MA, Murieta-Alvarez I, Perez-Fontalvo R, Ruiz-Delgado GJ, Ruiz-Rojas G, Jaimovich G, Feldman L, Labastida-Mercado N, Endara A, Castro M, Galindo-Beccerra S, Cardona-Molina MA, Gomex-Almaguer D, Ruiz-Arguelles GJ. Freezing the graft is not necessary for autotransplant for plasma cell myeloma and lymphomas. *Bone Marrow Transplant*. 2018;doi:10.1038/s41409-017-0047-7.

1066. Gale RP, Armitage JO. Are we prepared for nuclear terrorism? *N Engl J Med.* 2018;378:1246-54.
1067. Ueda M, Berger M, Gale RP, Lazarus HM. Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. *Blood Reviews.* 2017;doi.org/10.1016/j.bire.2017.09.003.
1068. Gale RP, Hochhaus A. Therapy-free remission in chronic myeloid leukemia: possible mechanism. *Expert Rev Hematol.* 2018;11:269-72.
1069. Gale RP. Introducing Prof. Shaun McCann, Bone Marrow Transplantation's new sommelier. *Bone Marrow Transplant.* <https://10.1038/s41409-018-0129-1>.
1070. Zhang M, Yin J, He Q, Zhang F, Huang H, Wu B, Wang X, Liu H, Yin H, Zeng Y, Gale RP, Wu D, Yin B. Chinese and Europeans with acute myeloid leukemia have discordant mutation topographies. *Leuk Res.* 2018 Apr 22;70:8-12. doi: 10.1016/j.leukres.2018.04.009.
1071. Halahleh K, Ma'koseh M, Abu-Jazar H, Yaser S, Howar H, Al-Rawashdeh M, Tbakhi A, Najjar R, Hussein N, Al-Rimawi D, Gale RP, Sarhan M. High-dose chemotherapy and autotransplants for plasma cell myeloma in Jordan. *Bone Marrow Transplant.* 2018 May 8. doi: 10.1038/s41409-018-0201-x
1072. Buchbinder D, Kelly DL, Duarte RF, Auletta JJ, Bhatt N, Byrne M, DeFilipp Z, Garbriel M, Mahindra A, Norkin M, Shoemans H, Shah AJ, Ahmed I, Atsuta Y, Basak GW, Beattie S, Bhella S, Bredeson C, Bunin N, Dalal J, Daly A, Gajewski J, Gale RP, Galvin J, Hamadani M, Hayashi RJ, Adekola K, Law J, Lee CJ, Liesveld J, Malone AK, Nagler A, Naik S, Nishihori T, Parsons SK, Scherwath A, Schofield HL, Soiffer R, Szer J, Twist I, Warwick AB, Wirk BM, Yi J, Battiwalla M, Flowers MDE, Savai B, Shaw BE. Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. *Bone Marrow Transplant.* 2018;53:535-55.
1073. Li J, Huang XF, Cai QQ, Wang C, Cai H, Zhao H, Zhang L, Cao XX, Gale RP, Zhou DB. A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. *Am J Hematol.* 2018;93:803-9.
1074. Qin S, Fan L, Liang J, Gale RP, Miao Y, Wu Y, Wang R, Yang H, Wu W, Xia Y, Wu J, Zhu H, Wang L, Xu W, Li J. Definition of disease-progression risk stratification in untreated chronic lymphocytic leukemia using combined clinical molecular and virological variables. *Hematological Onc.* 2018;1-7.
1075. Gale RP. Letter to the Editor. *CTT Journal.* 2018;7:69.
1076. Halahleh K, Gale RP. Cancer Care in the Palestinian territories. *Lance Oncol.* 2018;19:e359-64.
1077. Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molennar RJ, Barriwalla M, Savani BN, Flowers MED, Cooke KR, Hamilton BK, Kalaycio M, Maciejewski JP, Ahmed I, Akpek G, Bajel A, Buchbinder D, Chan JY, D'Souza A, Daly A, DeFilipp Z, Ganguly S, Hamadani M, Hayshi RJ, Hematti P, Inamoto Y, Khera N, Kindwell-Keller T, Landau H, Lazarus H, Majhail NS, Marks DI, Olsson RF, Seo S, Steinberg A, William BM, Wink B, Yared JA, Aljurf M, Abidi MH, Allewell H, Beitinjaneh A, Cook R, Cornell RF, Fay JW, Hale G, Chakrabarty JH, Jodele S., Kasow KA, Mahindra A, Malone AK, Popat U, Rizzo JD, Schouten HC, Warwick AB, Wood WA, Sekeres MA, Litzow MR, Gale RP, Hashmi SK. Risk of acute myeloid leukemia and myelodysplastic syndrome after auto transplant for lymphomas and plasma cell myeloma. *Leuk Res.* 2018; 74:130-36.

1078. Gale RP. He/onc response crucial to radiation exposure incident. *HemOnc today*. 2018;19:1,16.
1079. Gale RP, Lo-Coco F. Prof. Franco Mandelli: Leukaemia therapy pioneer. *Bone Marrow Transplant*. 2018;53:1375-6.
1080. Gale RP. Therapy for immunoglobulin D Plasma cell myeloma. *Acta Hematol*. 2018;139:193-194.
1081. Gale RP. Study limitations in HLA-Mismatched microtransplant in older patients newly diagnosed with acute myeloid leukemia. *JAMA Oncol*. 2018;4:891.
1082. Kumar AJ, Kim S, Hemmer AT, Arora M, Spellman SR, Pidala JA, Couriel DR, Alousi AM, Alijurf MD, Cahn JY, Cairo MS, Cutler CS, Farhan S, Gergis U, Hale GA, Hashmi Sk, Inamoto Y, Kamble RT, Kharfan-Dabaja MA, MacMillan ML, Marks DI, Nakasone H, Norkin M, Qayed M, Rindgen O, Schouten HC, Schultz KR, Solh MM, Teshima T, Urbano-Ispizua A, Verdonck LF, Gale RP, Hamilton BK, Majhail NS, Loren AW. Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. *Blood Adv*. 2018;2:1022-31.
1083. Liang JH, Gao R, Dai JC, Gale RP, Li W, Fan L, Hu ZB, Xu W, Li JY. The prognostic role of HBV infection in chronic lymphocytic leukemia. *J Cancer Res Clin Oncol*. 2018;144:1309-15.
1084. Harris AC, Boelens JJ, Ahn KW, Fei M, Abraham A, Artz A, Dvorak C, Frangoul H, Freytes C, Gale RP, Hong S, Lazarus HM, Loren A, Mineishi S, Nishihori T, O'Brien T, Williams K, Pasquini MC, Levine JE. *Blood Adv*. 2018;2:1198-1206.
1085. Estey EH, Gale RP, Sekeres MA. New drugs in AML: uses and abuses. *Leukemia*. 2018; 32:1479-81.
1086. Barbui T, Passamonti F, Accorsi P, Pane F, Vannuchi AM, Velati C, Gale RP, Tura S, Barosi G. Evidence-and consensus-based recommendations for phlebotomy in polycythemia vera. *Leukemia*. 2018;21:2077-81.
1087. Scott EC, Hari P, Kumar S, Fraser R, Davila O, Shah N, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Geris U, Cerny J, Kyle RA, Kindwaller-Keller LC, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A. Staging systems for newly diagnosed myeloma patients undergoing autologous hematopoietic cell transplantation: The revised international staging system shows the most differentiation between groups. *Biol Blood Marrow Transplant*. 2018;24:2443-9.
1088. Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Alijurf MD, MacMillan ML, Litzow MR, Solh MM, Quayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK. Comparative analysis of calcineurin inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of graft-versus-host disease after reduced-intensity conditioning allogeneic transplantation. *Biol Blood Marrow Transplant*. 2019;25:73-85.

1089. Yang S, Gale RP, Shi H, Liu Y, Lai Y, Lu J, Huang X. Is there an epidemic of chronic lymphocytic leukaemia (CLL) in China? *Leuk Res.* 2018;73:16-20.
1090. Barosi G, Passamonti F, Accorsi P, Pane F, Vannucchi AM, Velati C, Gale RP, Tura S, Barbui T. Response to “Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions” by Heidel, et al. *Leukemia.* 2018;32:2727-28.
1091. Norkin M, Shaw BE, Barauskas R, Tecca HR, Leather HL, Gea-Banacloche J, Kamble R, DeFilipp Z, Jacobsohn DA, Ringden O, Inamoto Y, Kasow K, Buchbinder D, Shaw P, Hematti P, Schears R, Badawy SM, Lazarus HM, Bhatt N, Horn Bm, Chhabra S, Page K, Hamilton B, Hildebrandt GC, Yared JA, Agrawal V, Beitinjaneh A, Majhail N, Kindwall-Keller T, Olsson RF, Shoemans H, Gale RP, Ganguly S, Ahmed I, Schouten HC, Liesveld J, Khera N, Steinberg A, Shah AJ, Solh M, Marks DI, Rybka W, Alijurf M, Dietz AC, Gergis U, George B, Seo S, Flowers MED, Battiwalla M, Savani BN, Riches ML, Winard JR. Characteristics of late fatal infections after allogeneic hematopoietic cell transplant. *Biol Blood Marrow Transplant.* 2018;25:362-8.
1092. Alousi A, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Pidala J, Anderlini PN, Boyiadzis M, Bredeson CN, Cahn JY, Cairo MS, Gadalla SM, Hashmi SK, Gale RP, Kanda J, Kamble RT, Kharfam-Dajaba MA, Litzow MR, Rindgen O, Saad AA, Schultz KR, Verdonck LF, Waller EK, Yared JA, Holtan SG, Weisdorf DJ. Peripheral blood versus bone marrow from unrelated donors: bone marrow allografts have improved long-term overall and greaft-versus-host disease, relapse-free survival. *Biol Blood Marrow Transplant.* 2018;25:270-8.
1093. Gale RP, Halaleh K. Cancer care in the Palestinian territoried. *ASCO Post.* October 25, 2018.
1094. Amadori S, Arcese W, Avvisati G, Gale RP, Lo-Coco F. Prof. Mandelli Leukaemia Visionary. May 12, 1931-July 15, 2018. *Leukemia;* 2019;33:285-6.
1095. Radivoyevitch T, Jorgensen TN, Lindner DJ, Maciejewski JP, Miyazaki Y, Gale RP. Chronic myeloid leukemia: two mysteries (Letter to the Editor). *Leuk Res.* 2019;79:3-5.
1096. Gale RP, Zhang MJ. Statistical analyses of clinical trials in haematopoietic cell transplantation or why there is a strong correlation between people drowning after falling out of a fishing boat and marriage rate in Kentucky. *Bone Marrow Transplant.* 2019;doi.org/10.1038/s41409-019-0431-6.
1097. Zheng C, Dai R, Gale RP, Zhang MJ. Causal interference in randomized clinical trials. *Bone Marrow Transplant.* 2019;doi:10.1038/s41409-018-0424-x.
1098. Parikh SH, Satwani P, Ahn KW, Sahr NA, Fretham C, Abraham AA, Agrawal V, Auletta JJ, Abdel-Azin H, Copelan E, Diaz MA, Dvorak CC, Fragoul HA, Freytes CO, Gadalla SM, Gale RP, George B, Gergis U, Hashmi S, Hematti P, Hildebrandt GC, Keating AK, Lazarus HM, Myers KC, Olsson RF, Prestidge T, Rotz SJ, Savani BN, Sherek EB, Williams KM, Work B, Pasquinni MC, Loren AW. Survival trends in infants undergoing allogeneic hematopoietic cell transplant. *JAMA Pediatr.* 2019;doi:10.1001/jamaediatrics.2019.0081.
1099. Barosi G, Gale RP. Response to the commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma”. *Leukemia.* 2019;33:1301-2.
1100. Shi Z, Li B, Huang H, Qin T, Xu Z, Zhang H, Fang L, Pan L, Hu N, Qu S, Huang G, Gale RP, Xiao Z. Prognostic impact of red blood cell distribution width in myelodysplastic syndromes. *Br J Hematol.* 2019;doi:10.1111/bjh.15830.

1101. Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz MA, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hildebrandt GC, Holmberg L, Kample RT, Kapoor P, Lazarus H, Lee C, Murthy HS, Naik S, Nishihori T, Saad A, Savani BN, Seo S, Warwick A, Work B, Yared JA, Nieto Y, Hari P. Autologous hematopoietic cell transplantation for male germ cell tumors: improved outcomes over 3 decades. *Biol Blood Marrow Transplant.* 2019;25:1099-1106.
1102. Abidi MZ, Hari P, Chen M, Kim S, Battiwala M, Dahl PB, Diaz MA, Gale RP, Ganguly S, Gergis U, Green J, Hildebrandt G, Hill JA, Komanduri K, Lazarus H, Marks D, Nishihori T, Olsson R, Seo S, Ustun C, Yared J, Yin D, Wingard J, Wink BM, Auletta J, Lindemans C, Riches M. Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. *Bone Marrow Transplant.* 2019;doi:10.1038/s41409-019-0457-9.
1103. Estey E, Othus M, Gale RP. New study-designs to address the clinical complexity of acute myelogenous leukemia. *Leukemia.* 2019;doi:10.1038/s41375-018-0363-y.
1104. Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakai B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. Revised international staging system in predictive for early relapse (<24 months) after autologous transplantation for newly diagnosed multiple myeloma. *Biol Blood Marrow Transplant.* 2019;25:683-88.
1105. Hourigan CS, Gale RP, Walter RB. Refining AML outcome prediction. *Leukemia.*2019;33:283-4.
1106. Inamoto Y, Petricek I, Burns L, Chhabra S, DeFilipp Z, Hermatti P, Rovo A, Schears R, Shah A, Agrawal V, Al-Khinji A, Ahmed I, Ali A, Alijurf M, Alkhateeb H, Beitinjaneh A, Bhatt N, Buchbinder D, Byrne M, Collander N, Fahnehjelm k, Farhadfar N, Gale RP, Ganguly S, Hildebrandt GC, Horn E, Jakubowski A, Kamble RT, Law J, Lee C, Nathan S, Penak O, Pngali R, Prasad P, Pulanic D, Rotz S, Shreenivas A, Steinberg A, Tabbara K, Tichelli A, Work B, Yared J, Basak GW, Battiwalla M, Duarte R, Savani BM, Flowers MED, Shaw BE, Valdes-Sanz N. Non-GVHD ocular complications after hematopoietic cell transplantation: Expert review from the late effects and quality of life working committee of the CIBMTR and Transplant Complications Working Party of the EBMT. *Bone Marrow Transplant.*2019; 54:648-61.
1107. Brunstein CG, Pasquini MC, Kim S, Fei M, Adeloka K, Ahmed I, Alijurf M, Agrawal V, Auletta JJ, Battiwalla M, Bejanyan N, Bubalo J, Cerny J, Chee L, Ciurea SO, Freytes C, Gadallia SM, Gale RP, Ganguly S, Hashimi SK, Hematti P, Hildebrandt G, Holmberg LA, Lahoud OB, Landau H, Lazarus HM, de Lima M, Mathews V, Maziarz R, Nishihori T, Norkin M, Olsson R, Reshef R, Rotz S, Savani B, Schouten HC, Seo S, Wirk BM, Yared J, Mineishi S, Rogosheske J, Perales MA. Effects of conditioning regimen dose reduction in obese patients undergoing autologous hematopoietic cell transplantation. *Biol Blood Marrow Transplant.* 2019;25:480-87.
1108. Jiang M, Chen H, Lai S, Wang R, Qiu Y, Ye F, Fei L, Sun H, Xu Y, Jiang X, Zhou Z, Zhang T, Li Y, Xie J, Fang Q, Gale RP, Han X, Huang H, Guo G. Maintenance of human haematopoietic stem and progenitor cells in vitro using a chemical cocktail. *Cell Discov.* 2018;4:59.
1109. Chhabra S, Ahun KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalycio ME, Popat U, Sobecks RM, Saber W. Myeloablative vs. reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. *Blood Adv.* 2018;2:2922-36.

1110. Saglio G, Fava C, Gale RP. Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia? *Haematol.* 2018;doi:10.3324.
1111. Gale RP, Gomez-Cruz GB, Olivares-Gazca JC, Leon-Pena AA, Gomez-Almaguer D, Gomez-de-Leon A, Gonzales-Lopez EE, Ruiz-Arguelles A, Soto-Vega E, Munoz-Perez MJ, Ruiz-Delgado GJ, Ruiz-Arguelles GJ. Determine safety of outpatient chemotherapy and autotransplants using refrigerated, non-frozen grafts in persons with multiple sclerosis. *Clin Transplant.* 2019 Apr 20:e13567. doi: 10.1111/ctr.13567.
1112. Ntelipoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydlo R, Alikian M, Foong HE, Nilakopoulou Z, Loaiza S, Khorashad JS, Milojkovic D, Perrotti D, Gale RP, Foroni L, Apperley JE. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second generation tyrosine kinase inhibitors. *Haematologica.* 2019; haematol.2018.200220;doi:10.3324/haematol.2018.200220.
1113. Houshmand M, Simonetti G, Circosta P, Gaidano V, Cignetti A, Mantinelli G, Saglio G, Gale RP. Chronic myeloid leukemia stem cells. *Leukemia.* 2019; <https://doi.org/10.1038/s41375-019-0490-0>.
1114. Gale RP. Chernobyl, the HBO miniseries: Fact and fiction (part I). *The Cancer Letter.* 2019;20:19-21.
1115. Halaleh K, Sarban M, Gale RP, Hashem H, Khattab E, Da'na W, Ma'koseh M, Abu Shanab M, Yousef M, Khalil L, Hussein N, Sharma S, Abujazar H, Rihani R, Tbaki A, Al Abadi A. Hematopoietic cell transplants in Jordan: different indications from the US and EU. *Bone Marrow Transplant.* 2019; <https://doi.org/10.1038/s41409-019-0578-1>.
1116. Gale RP. Chernobyl, the HBO miniseries: Fact and fiction (part II). *The Cancer Letter.* 2019;21:13-16.
1117. Gale RP. Chernobyl, the HBO miniseries: Fact and fiction (part III). *The Cancer Letter.* 2019;24:23-6.
1118. Gale RP. Chernobyl, the HBO miniseries: Fact and fiction (part IV). *The Cancer Letter.* 2019;
1119. Rashidi A, Hamadani M, Zhang MJ, Wang HL, Abdel-Azim H, Aljurf M, Assal A, Bajel A, Bashey A, Battiwalla M, Beitinjaneh AM, Bejanyan N, Bhatt VR, Bolaños-Meade J, Byrne M, Cahn JY, Cairo M, Ciurea S, Copelan E, Cutler C, Daly A, Diaz MA, Farhadfar N, Gale RP, Ganguly S, Grunwald MR, Hahn T, Hashmi S, Hildebrandt GC, Holland HK, Hossain N, Kanakry CG, Kharfan-Dabaja MA, Khera N, Koc Y, Lazarus HM, Lee JW, Maertens J, Martino R, McGuirk J, Munker R, Murthy HS, Nakamura R, Nathan S, Nishihori T, Palmisiano N, Patel S, Pidala J, Olin R, Olsson RF, Oran B, Ringden O, Rizzieri D, Rowe J, Savoie ML, Schultz KR, Seo S, Shaffer BC, Singh A, Solh M, Stockerl-Goldstein K, Verdonck LF, Wagner J, Waller EK, De Lima M, Sandmaier BM, Litzow M, Weisdorf D, Romee R, Saber W. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. *Blood Adv.* 2019 Jun 25;3(12):1826-1836. Doi: 10.1182/bloodadvances.2019000050.
1120. Pan B, Wang D, Li L, Shang L, Xia F, Zhang F, Zhang Y, Gale RP, Xu M, Li Z, Xu K. Interleukin-22 accelerates thymus regeneration via Stat3/Mcl-1 and decreases chronic graft-versus-host disease in mice after allotransplants. *Biol Blood Marrow Transplant.* 2019 Jun 10. pii: S1083-8791(19)30366-0. doi: 10.1016/j.bbmt.2019.06.002.


1121. Hamilton BK, Liu Y, Hemmer MT, Majhail N, Ringden O, Kim D, Costa L, Stuart R, Alousi A, Pidala JA, Couriel DR, Aljurf M, Antin JH, Bredeson C, Cahn JY, Cairo M, Choi SW, Dandoy C, Gale RP, Gergis U, Hematti P, Inamoto Y, Kamble RT, MacMillan M, Marks DI, Nemecek E, Nishihori T, Saad A, Savani BN, Schriber J, Seo S, Socié G, Teshima T, Verdonck LF, Waller EK, Wirk M, Spellman SR, Arora M, Chhabra S. Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2019 May 31. pii: S1083-8791(19)30330-1. doi: 10.1016/j.bbmt.2019.05.019. [Epub ahead of print]
1122. Houshmand M, Simonetti G, Circosta P, Gaidano V, Cignetti A, Martinelli G, Saglio G, Gale RP. Chronic myeloid leukemia stem cells. *Leukemia*. 2019;33:1543-56.
1123. Hansrivijit P, Gale RP, Barrett J, Ciurea SO. Cellular therapy for acute myeloid Leukemia - Current status and future prospects. *Blood Rev*. 2019 May 11. pii: S0268-960X(18)30123-1. doi: 10.1016/j.blre.2019.05.002. [Epub ahead of print] Review.
1124. El Fakih R, Hashmi SK, Ciurea SO, Luznik L, Gale RP, Aljurf M. Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application. *Bone Marrow Transplant*. 2019 May 14. doi: 10.1038/s41409-019-0547-8. [Epub ahead of print] Review.
1125. Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, Aljurf M, Beitinjaneh AM, Bhatt VR, Buchbinder D, Byrne M, Cahn JY, Cairo M, Castillo P, Chhabra S, Diaz MA, Farhan S, Floisand Y, Frangoul HA, Gadalla SM, Gajewski J, Gale RP, Gandhi M, Gergis U, Hamilton BK, Hematti P, Hildebrandt GC, Kamble RT, Kanate AS, Khandelwal P, Lazaryn A, MacMillan M, Marks DI, Martino R, Mehta PA, Nishihori T, Olsson RF, Patel SS, Qayed M, Rangarajan HG, Reshef R, Ringden O, Savani BN, Schouten HC, Schultz KR, Seo S, Shaffer BC, Solh M, Teshima T, Urbano-Ispizua A, Verdonck LF, Vij R, Waller EK, William B, Wirk B, Yared JA, Yu LC, Arora M, Hashmi S. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2019 May 11. pii: S1083-8791(19)30291-5. doi: 10.1016/j.bbmt.2019.05.007. [Epub ahead of print]
1126. Nteliopoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydlo R, Alikian M, Foong HE, Nikolakopoulou Z, Loaiza S, Khorashad JS, Milojkovic D, Perrotti D, Gale RP, Foroni L, Apperley JF. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second generation tyrosine kinase inhibitors. *Haematologica*. 2019 May 9. pii: haematol.2018.200220. doi: 10.3324/haematol.2018.200220. [Epub ahead of print]
1127. Shi Z, Qin T, Xu Z, Li B, Huang H, Zhang H, Fang L, Pan L, Hu N, Qu S, Huang G, Gale RP, Xiao Z. Leuk Lymphoma. 2019 May 6:1-3. doi: 10.1080/10428194.2019.1607324. [Epub ahead of print]
1128. Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. *Blood Adv*. 2019 May 14;3(9):1441-1449. doi: 10.1182/bloodadvances.2018030171.
1129. Hu ZH, Gale RP, Zhang MJ. Direct adjusted survival and cumulative curves for observational studies. *Bone Marrow Transplant*. 2019;May 17:10.1038/s41409-019-0552-y.

1130. Shi Z, Li B, Huang H, Qin T Xu Z, Zhang H, Fang L, Pan L, Hu N, Qu S, Huang G, Gale RP, Xiao Z. Prognostic impact of red blood cell distribution width in myelodysplastic syndromes. *Br J Haematol.* 2019;186:352-55.
1131. Gale RP. Immune therapy of sarcomas in Russia: Another Sputnik? *Haematopoiesis Immunology.* 2019: 55-60.
1132. Gale RP, Nathan DG. Physicians and the threat of nuclear war. *ASCO POST.* July 25, 2019; 82-3.
1133. Gale RP. Another Puebla milestone? *Revista de Hematologia.* 2019;20:164-6.

BOOKS

1. Immunology of Bone Marrow Transplantation. Gale RP, Opelz G, eds. New York. Grune and Stratton, 1977.
2. Biology of Bone Marrow Transplantation. Gale RP, Fox CR, eds. New York, Academic Press, 1980.
3. Fetal Liver Transplantation: Current Concepts and Future Directions. Lucarelli G, Fliedner T, Gale RP, eds. Amsterdam, Excerpta Medica, 1980.
4. Recent Advances in Bone Marrow Transplantation. Gale RP, ed. New York, Alan R. Liss, 1983.
5. Leukemia: Recent Advances in Biology and Treatment. Gale RP, Golde DW, eds. New York, Alan R. Liss, 1985.
6. Fetal Liver Transplantation: Progress in Clinical and Biological Research, Volume 193. Gale RP, Touraine J-L, Lucarelli G, eds. New York, Alan R. Liss, 1985.
7. Leukemia Therapy. Gale, RP, ed. Blackwell Scientific, Oxford, 1986.
8. Cellular Immunotherapy of Cancer. Truitt RL, Bortin MM, Gale RP, eds. New York, Alan R. Liss, 1987.
9. Progress in Bone Marrow Transplantation. Gale RP, Champlin RE, eds. New York, Alan R. Liss, 1987.
10. Chronic Lymphocytic Leukemia: Recent Progress and Future Direction. Gale RP, Rai K, eds. New York, Alan R. Liss, 1987.
11. Recent Advances in Leukemia and Lymphoma. Gale RP, Golde DW, eds. New York, Alan R. Liss, 1987.
12. Fetal Liver Transplantation. Touraine J-L, Gale RP, Kochupillai V, eds. Amsterdam, Martinus Nijhoff, 1987.
13. Hematopoiesis: Effects of Chemotherapy and Radiation. Testa NG, Gale RP, eds. New York, Marcel Dekker, 1988.
14. Final Warning: The Legacy of Chernobyl. Gale RP, Hauser T. New York, Warner, Books, 1988.
15. Bone Marrow Transplantation: Current Controversies. Gale RP, Champlin RE, eds. New York, Alan R. Liss, 1989.
16. Advances and Controversies in Thalassemia Therapy: Bone Marrow Transplantation and Other Approaches. Buckner G, Gale RP, Lucarelli G, eds. New York, Alan R. Liss, 1989.
17. Acute Lymphoblastic Leukemia: Current Controversies. Gale RP, Hoelzer D (eds). New York, Wiley-Liss, 1990.

18. Acute Myelogenous Leukemia: Progress and Controversies. Gale RP, ed. New York, Wiley-Liss, 1990.
19. New Strategies in Bone Marrow Transplantation. Champlin RE, Gale RP, eds. New York, Wiley-Liss, 1990.
20. Blood Stem Cell Transplants. Gale RP, Juttner, CA, Henon P. eds. Cambridge, Cambridge Univ Press, 1994.
21. Radiation What It Is, What You Need To Know. Gale RP, Lax E. New York, Knopf, 2013.
22. Hematopoietic Cell Transplants: Concepts, Controversies and Future Direction. Lazarus HM, Gale RP, Keating A, Bacigalupo A, Munker R, Atkinson K, Abutalib S. eds. Cambridge, Cambridge Univ Press, 2017.



COMMENTARIES, MEDIA

1. Gale RP. The lessons of Chernobyl. Los Angeles Times, May 29, 1986.
2. Gale RP, Hammer A. Out of tragedy, an opportunity. Los Angeles Times, April 26, 1987.
3. Hammer A, Gale RP. The lessons of Chernobyl: One year later. New York Times, April 26, 1987.
4. Gale RP. Guidebook to Armageddon. New York Times Book Review, July 19, 1987.
5. Hauser T. Interview: Dr. Robert Peter Gale. Penthouse, August 1988, pp. 65-148.
6. Gale RP. Chernobyl lets us weigh the nuclear risks. Toronto Star, August 15, 1988.
7. Gale RP. Armenia. Lancet. 1989;1:38.
8. Gale RP. New victims of the nuclear arms race. Lancet. 1990;2:363.
9. Gale RP. USSR: Follow-up after Chernobyl. Lancet. 1990;2:401.
10. Gale RP. The man who didn't know "No." USA Today, December 14, 1990.
11. Gale RP. Armand Hammer. Preventive medicine: Thinking big. Lancet, 1990.
12. Gale RP. A view from space: Why are we at war.

13. Gale RP. Dear Beppe. Airone, 1990.
14. Gale RP. Nuclear war in the Middle East Jewish Journal, 1991.
15. Gale RP. Il tropianto di medolo. Leadership Medica, December 1990.
16. Gale RP. Le nuove vittime del flusso di armi nucleari. Chemist, Novemeber 1990.
17. Gale RP. Contaminated, betrayed, can America trust again? Los Angeles Times, April 24, 1991.
18. Gale RP. Chernobyl's fallout: Consider the numbers. International Herald Tribune, April 27/28, 1991.
19. Gale RP. Our energy debate can't run on emotion. Los Angeles Times, May 5, 1989.
20. Gale RP. Viewpoint from United States of America: Myths and Legend. What about reality? Pravda, April 26, 1991.
21. Gale RP. Nuclear terrorism.
22. Gale RP, Ramberg B. Russia and nuclear terrorism.
23. Gale RP. The US should recognize Croatia now.
24. Gale RP. War in Yugoslavia: Civilian hospitals as military targets. Lancet 339:48,1992.
25. Gale RP. Ten years after disaster, some positive results. Los Angeles Times, April 26, 1996.
26. Gale RP. Fukushima not a repeat of Chernobyl: A doctor's analysis of nuclear accidents. The Cancer Letter, April 1 2011.
27. Gale RP. Assessing Fukushima, one year later. Los Angeles Times, March 11, 2012.
28. Gale RP. Cancer from Fukushima? Is Sushi Eating Over? The Cancer Letter, March 16, 2012.
29. Gale RP. Nuclear Accidents, Letter to the Editor. New York Times, January 3, 2013.
30. Gale RP, Lax E, Hoffman FO. Thoughts on overusing radiation in medicine and redeeming that whole body scan coupon. The Cancer Letter, March 1, 2013.
31. Gale RP, Lax E. Fukushima radiation proves less deadly than feared. Bloomberg News on line, March 10, 2013.
32. Gale RP, Hoffman FO. http://www.smithsonianmag.com/smart-news/how-bombings-hiroshima-and-nagasaki-still-inform-health-today-180956185/?utm_source=smithsoniandaily&no-is.
33. Gale RP: TV Interview, April 4, 2016: <http://www.euronews.com/2016/04/26/the-medical-response-in-the-aftermath-of-the-chernobyl-disaster/>
34. ASCO Post, June 3, 2016: http://www.ascopost.com/issues/june-10-2016-supplement/international-authority-on-radiation-effects-robert-peter-gale-md-phd-has-pushed-scientific-boundaries-in-search-of-answers/?utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=5489250

35. ASH Clinical News, June 22, 2016: Pulling back the curtain. <http://ashclinicalnews.org/robert-p-gale-md-phd/>
36. Forbes (on line), June 11, 2019: Top UCLA doctor denounces HBO's "Chernobyl as wrong and "dangerous". <https://www.forbes.com/sites/michaelshellenberger/2019/06/11/top-ucla-doctor-denounces-depiction-of-radiation-in-hbos-chernobyl-as-wrong-and-dangerous/#583df9e21e07>